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2 Introduction
2.1 Historical Perspectives and Epidemiology
Hypertrophic cardiomyopathy (HCM) is the single most common cause of sudden death in
otherwise healthy young people, found in approximately half of such cases.1"4 It is a genetic
disease occurring in approximately 1 in 500-1,000 of the general population.5,6 The myopathy is
often undiagnosed and asymptomatic cases are often unrecognised. Usually, HCM develops
with progressive asymmetric LV hypertrophy (LVH) during the period of rapid body growth of
adolescence, but it may be present in childhood or even before birth. Progressive hypertrophy
after age 20 is uncommon, but initial diagnosis even in old age is not. The hypertrophy
predominantly involves the LV, and is often more marked than in any other cardiac disease. It
represents hypertrophy and hyperplasia of several cell types, including cardiac myocytes,
fibroblasts, and smooth muscle cells, along with excessive collagen and matrix deposition.7,8
The normal parallel arrangement of myocytes is often disturbed (fibre disarray).
The first descriptions of Hypertrophic Cardiomyopathy HCM) are often attributed to Teare in
the late 1950s.9,10 In the half century following, what was considered an unusual or rare single
clinical entity associated with a dire prognosis is increasingly understood as a group of
myocardial diseases with surprisingly heterogeneous genetic causes and phenotypic
expressions with a benign outcome as the more common clinical course.
a PubMed search for 'hypertrophic and cardiomyopathy' yields nearly 16,000 hits, with 3181
in the last 5 years(June 2009); to date, the most active research interests have included
(1) The development of therapies for the relief of outflow obstruction.
(2) The beginning of an understanding of the genetic basis of hereditary left ventricular
hypertrophy.
(3) The development of cardiac imaging techniques to serve diagnostic and prognostic needs.
(4) The development of strategies identifying and addressing risks of sudden death.
Further advances in therapy are likely to require both further development in these areas, but
will also include:
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(1). a more thorough understanding of the pathophysiology of the symptomatic patient with
unobstructed HCM. This includes an improvement in detecting and managing 'diastolic failure',
myocardial ischaemia and myocardial fibrosis.
(2). Unravelling of the cellular processes leading from mutation to disease and of the powerful
factors that modify disease expression. Novel pharmacological therapies may follow.
(3). Randomised clinical trials to evaluate existing and future clinical practice. Few randomised
trials interrogate the value of contemporary clinical practice.
2.2 Definitions of Hypertrophic Cardiomyopathy
HCM is currently diagnosed on the basis of morphologic abnormalities, requiring the
demonstration of a criterion magnitude of left ventricular hypertrophy (LVH) unexplained by an
identified hemodynamic, metabolic, infiltrative or endocrine cause of LVH.1,3,4,11 Limitations to
the utility of these definitions includes the many patients with LVH (who may have a variant of
HCM), scenarios where LVH accompanies cardiovascular conditions also associated with LVH
(hypertension and athletic training in particular), and when a genetic abnormality associated
with familial HCM is identified in individuals without LVH. Some sarcomeric mutations
associated with symptoms and/or risks of sudden death are associated with minimal or no LVH
in some but not others from the same families.12,13
2.2.1 Classifications of Hypertrophic Cardiomyopathy
Heterogeneity is a striking feature of HCM, and is evident from morphologic, clinical, prognostic
and molecular perspectives. For example, any sarcomeric mutation associated with HCM
identified thus far can result in a variety of disease phenotypes or no detectable disease at all.
Similarly, exhaustive mutation detection in, say, patients with obstructive HCM will detect
several different and often novel mutations, or will fail to find any mutations at all. Clinical,
translational and basic research, as well as clinical practice needs valid and precise definitions
of disease; this heterogeneity defies a single disease classification scheme. Morphologic,
physiologic, prognostic, mutation-specific, gene specific and molecular-functional classification
systems have been suggested; their existence describes attempts to provide a single unified
classification scheme that satisfies clinical needs (in developing symptomatic, prognostic and
screening strategies) and the need to understand mechanism of disease. Notably, despite these
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efforts, clinical phenotypes remain disconnected from the causes of HCM; powerful and
unidentified factors modify the end result of mutant gene expression.14,15
2.2.1.1 Morphological Classification
Early investigators determined that LVH varied in magnitude and its distribution in the LV.16,17
Asymmetric septal hypertrophy (ASH) describes the most commonly observed distribution of
hypertrophy in the LV septum. Approximately one quarter of ASH distribution HCM patients
develop a dynamic LV outflow tract obstruction as a consequence of systolic anterior
movement (SAM) of the mitral valve leaflets towards the basal septum to cause obstructive
HCM.18 More unusual morphologic variants include mid-cavity obstructive HCM, apical (or
Japanese) HCM and dilated-phase or 'burnt-out' HCM (Figure 1 and Figure 2). Finally, cardiac
magnetic resonance imaging's 'killer application' promises to be tissue characterisation. The
detection of myocardial scarring by delayed enhancement following gadolinium enhancement
may prove both diagnostically and prognostically powerful.
Figure 1: Morphological Variants in Hypertrophic Cardiomyopathy.
A: Idealized figures illustrating distributions of LVH seen in HCM. In addition to 'classical' variants (1-4), imaging may
demonstrate normal LV wall thickness, and sarcomeric mutations may also present as a dilated cardiomyopathy,
either with an intervening hypertrophic stage19, or as end stage ' burnt-out' hypertrophic disease.20 22
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Figure 2: Cardiac Morphology and Tissue Characterisation: Magnetic Resonance Imaging
Morphology and patterns of hyperenhancement (delayed gadolinium enhancement, DGE) demonstrated by cardiac
magnetic resonance imaging. A, B, C: Asymmetric septal hypertrophy (ASH) with 4-chamber views demonstrating
cardiac morphology at end diastole (A), end systole (B) and delayed enhancement (C). SAM with septal contact
(arrow) results in LVOTO and mitral regurgitation. Delayed enhancement is seen in the basal septum (double
arrows). A unilateral pleural effusion and collapse of the left lung is also seen. D, E, F: Reversed ASH in 4-chamber (D)
and basal short axis (E) views. There is extensive patchy DGE in the basal anterolateral segment. G, H, I: The
uncommon apical variant of HCM. 4-Chamber views demonstrate distal LVH and small end-diastolic cavitary volumes
(D) and the systolic obliteration of the distal two-thirds of the LV cavity. DGE is extensive, and was demonstrated in
all LV segments (I). Images courtesy of the London Chest CMR unit (M. Westwood, C. Davies, A Mathur)
2.2.1.2 Pathophysiological Classification
The physiologic abnormalities and symptoms associated with HCM show a surprising
degree of infidelity to the morphology. Arrhythmia risk, abnormal myocardial
relaxation/compliance, and ischaemia are demonstrated in patients with severe/mild LVH,
unobstructed/obstructed, high/low risk and in symptomatic/asymptomatic patients. These
features do not have a simple relationship with any morphologic or genetic feature of HCM.
Furthermore, physiologic disturbances appear to contribute to the evolution of the clinical
expression of disease more so, and often in the absence of, demonstrable changes in LV
morphology.
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For example, an individual who is asymptomatic in his 20's may develop exertional limitations
in his 40's, despite minimal or no changes in cardiac morphology. Ischaemic, obstructive,
restrictive, arrhythmic, systolic and chronotropic abnormalities are not mutually exclusive, and
may progress and interact in the absence of obvious changes in LVH. Difficulties in taking
objective measurements of the parameters other than gross morphology and flow velocities,
and the lack of rational therapies render physiologic classification of largely theoretical interest.
Nonetheless, we increasingly speak of restrictive or diastolic failure FICM, dilated phase HCM,
ischaemic HCM, HCM with associated atrial myopathy, and are keenly pursuing ways to more
accurately identify pro-arrhythmic HCM.23 The potential for therapy tailored to abnormal
physiology such as using renin-angiotensin-aldosterone system (RAAS) modulation for
restrictive HCM, or defibrillator therapy for pro-arrhythmic HCM provide powerful motivation
for the further development of a disease understanding and classification on a physiological
basis.
2.2.1.3 Genetic Classification
The genomics revolution has failed to make substantial contributions to the clinical
management of HCM.24 Despite the tremendous advances in the identification of mutant
genetic causes of HCM, genetic classifications have thus far proven to be of quite limited
practical significance. Our ability to associate natural history with a defined mutation has at
least three major limitations: (1) A genetic cause for HCM is currently not found in
approximately 40% of proband patients25,26 ; (2) the large number and rarity of most individual
mutations 25"28; and (3) the high degree of infidelity between genotype and phenotype, even
within a single pedigree, a feature of the disease that attests to the power of undefined
modifying influences.14,15 Nonetheless, although a single HCM causing mutation does not
dictate the cardiac phenotype, or even cause the disease in many individuals, it does appear to
influence clinical phenotype.
For a few of the many mutations thus far detected that have been extensively studied in many
affected individuals from different families, several clinical features are more prominent than
expected. This includes sudden death risk, atrial fibrillation, mid cavity disease and LVH with
accessory pathways and conduction disease.29 33
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2.2.1.4 Molecular classifications
Classifications based on the gene affected rather than on the precise mutation, or on the gene
products likely role (for example considering all actin mutations together, or all actin, troponin
or tropomyosin mutations as thin filament mutations, or all sarcomeric mutations versus non
sarcomeric HCM) has also not proven useful. Thus beta myosin or 'thick-filament' HCM does
not appear to be appreciably different from 'thin-filament' HCM. 14,34 Over the next few years,
we are likely to see more non-sarcomeric genes implicated in HCM, and comparisons between
sarcomeric and non-sarcomeric HCM will be made.35
2.2.1.5 Molecular or Motor Function Classification:
The development of a classification scheme that is derived from a mechanistic understanding
of the molecular dysfunction that results from mutant protein expression remains an important
and attractive goal of cardiomyopathy research. It stands to reason that as the functional
consequences of a mutation are necessary for the development of HCM, some dimension of
the phenotypic severity will correspond to the severity of the molecular disability.
Mutations in sarcomeric genes are the commonest causes of HCM, accounting for 50-60% of
cases in tertiary referral populations. For the many dozen mutations in these genes that are
known to cause HCM, there is a very limited understanding of the functional consequences of
mutant protein expression and how this may lead to the HCM phenotype. The design and
validation of assays of molecular/contractile function (for example Vactin, ATPase activity and
pCa50) may yet contribute towards a more thorough understanding and classification
system.36"40 At present, no studies convincingly associate bench-top assays of mutant protein
function with any 'assay' of clinical outcome. Some researchers have been tempted to talk in
terms of 'gain of function' mutations causing LVH and DCM resulting from 'loss of function'
mutations41, however parameters of in-vitro acto-myosin interaction bear no relation to the
resulting phenotype.37
An alternative perspective is that the development of LVH in HCM is the output value of an
equation where sarcomeric dysfunction is a necessary, but not sufficient, input variable. Quite
apart from its property as a necessary variable, a mutation also has an unrelated further
property influencing, but not dictating, other phenotypic characteristics. These characteristics
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include LVH distribution 33'42,sudden death risk12,31,43,44 and atrial myopathy. 29 The non-
sarcomeric input variables that are responsible for variable penetrance and phenotypic
heterogeneity are not defined but must be reasonably (genetically) polymorphic to account for
the dramatic disease heterogeneity encountered in individuals with identical mutations. A
better understanding of the cardiomyocyte's hypertrophic circuitry and of the genetic
polymorphisms in the components of this circuitry is important for a more complete
mechanistic understanding of HCM's aetiology. The hypertrophic circuit may also provide
insights into other myopathic processes such as due to hypertensive heart disease, LV













Figure 3: The Hypertrophic Circuit of a Cardiomyocyte.
The concept of a cellular circuit effecting altered transcription leading to cardiac hypertrophy may help in the
understanding of why similar phenotypes may result from different hypertrophic stimuli, and why the same stimulus
can lead to different phenotypes. The final phenotype depends on the nature(s) of the hypertrophic stimulus, as well
as the component circuitry - which will have genetically determined differences between individuals.
2.2.1.6 Clinical Classification
A pragmatic clinical approach, based purely on the indications for available
interventional strategies, is concerned with the division of HCM into symptomatic and
asymptomatic disease, into obstructive and non-obstructive HCM, and into categories of
estimated risk of sudden death from arrhythmia or stroke. In these schemes, morphologic
features (for example the LVH magnitude, left atrial involvement, LV dilatation), clinical
variables (prior clinical events, family history and results of routine cardiac testing such as
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exercise testing), and occasionally the precise genetic cause (for example the detection of a
'malignant' mutation) are helpful in predicting clinical outcome. The approach is based on the
few clinical interventions currently available (Figure 4). The scheme is critically dependent on
the accuracy of the HCM diagnosis; does a hypertensive patient with asymmetric or symmetric
LVH require a defibrillator if he/she has risk factors?
Figure 4: Management of Symptoms and Risks of Sudden Death in HCM.
This decision making therapeutic cascade considers prognostic and symptomatic indications for intervention. At
present, the presence of LVOTO is only considered important in symptomatic HCM. *LVOTO is an independent risk
factor for poor prognosis, and future indications for either ICD therapy or ASA might consider one or both of these
interventions in asymptomatic individuals with obstruction.
ABPR = Abnormal Blood Pressure Response to exercise; LVH = LV Hypertrophy; NSVT = Non Sustained Ventricular
Tachycardia; LVOTO = LV outflow tract obstruction. Adapted from Mohiddin and Knight. Alcohol Septal Ablation.45
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2.3 Genetics
2.3.1 Genetic Basis of the Familial Hypertrophic Cardiomyopathies
Since the earliest description of HCM, its genetic basis has been appreciated. 46 In
common with many other hereditary diseases, research in the last 2 decades has brought
significant advances in the understanding of its molecular basis, and has revealed an
unexpected degree of heterogeneity.26"28,47
Most cases of HCM are inherited as an autosomal dominant disease. Hence, half of the parents,
siblings, and children are at risk of inheriting the disease mutation. However, fewer than half
actually develop HCM, as the disease penetrance (number of subjects with HCM / number of
subjects with disease mutation x 100) is often much lower than 100%.37,48 The ability of HCM
to 'skip' one or more generations in some families complicates most stepwise strategies when
screening for familial disease.48 Truly sporadic HCM, proven by the demonstration of the
absence of an identified disease mutation in both parents, is uncommon.
Most of the molecular defects identified to date are missense mutations (single base-pair
substitution) changing the identity of an evolutionarily-conserved amino acid in one of several
genes that encode contractile proteins of the sarcomere (Table l).49 In as many as 10% of
probands, HCM is associated with double (homozygous or double heterozygous) disease
causing mutations.26,27'37'38'50,51 To date, studies comprehensively sequencing all sarcomeric
genes in HCM cohorts detect mutations in only about half. It is likely that non-sarcomeric genes
account for a considerable fraction of all HCM cohorts; these are now being detected.35 LVH is
also feature of several multi-system hereditary conditions diseases (Table 1).
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Gene/Disease # Mutations Features
Sarcomeric HCM
Beta myosin heavy chain >190
Cardiac Myosin Binding Protein C >140
Alpha Tropomyosin >10
Cardiac Troponin T >20
Cardiac Troponin I >10
Alpha Cardiac Actin >7
Essential Light Chain of Myosin 5
Regulatory Light Chain of Myosin 10
Titin 1
Non-Sarcomeric HCM
PRKAG2, subunit of AMPK >5
Myosin VI (unconventional myosin) 1
Muscle LIM protein gene 3
Component of Multi-System Syndrome
McLeod syndrome (XK) >15
Friedreich's ataxia (FRDA) >15
Leopard Syndrome (PTPN11) 2
Mitochondrial DNA deletions see t;
(e.g. MELAS, MERFF, Kearns-Sayre)
Commonest cause of HCM, variable
disease penetrance and phenotype
Second commonest cause of HCM
Mild LVH and high risk of sudden death
in some pedigrees




Glycogen granules, A-V bypass tracts,




Expanded trinucleotide repeat and
missense mutations
Biventricular outflow obstruction
2 LVH, LV systolic dysfunction,
Alpha-B Crystallin myopathy (CRYAB) 1 Skeletal myopathy, lens opacities
Table 1. Genetic Heterogeneity In HCM.
Adapted from Fananapazir and Mohiddin in Hypertrophic Cardiomyopathy, Conn's Current Therapy, 2005,49 LVH, LV
hypertrophy; A-V, atrio-ventricular; WPW, Wolff-Parkinson-White syndrome
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2.3.1.1 Sarcomeric Hypertrophic Cardiomyopathy
Up to half HCM cases result from the dominant-negative effects of a mutant protein
component of the sarcomere, the highly organized contractile unit of cardiac and skeletal
muscle.52 At least nine different genes are implicated, including those encoding beta myosin
heavy chain, cardiac actin, myosin binding protein C, alpha tropomyosin, the troponins, titin
and the light chains of myosin.25,26,41 Most are missense mutations, permitting the synthesis of
a full-size sarcomeric protein with a substitute amino acid at one or another position.
These were the first detected causes, and HCM has been described as a disease of the
sarcomere. One conventional hypothesis is that LVH develops to compensate for the abnormal
sarcomeric contractility that results from the incorporation of 'poison peptides' into the
contractile assembly.41 Thus, increasing contractile unit number, and reducing cavity sizes and
wall tension accommodate impaired contractility (Figure 5). At present, more than 400
mutations in these nine genes have been causally associated with HCM.
(http://Renetics.med.harvard.edu/seidman/cg3/index.html)
"I've got it. Onur , * strange feeling
tikr we*«e iu*t hrrn going m urUrt."
Figure 5. Compensatory Theory of Hypertrophy.
More weak rowers needed; myocytes incorporating mutant gene product may need to be larger with more
numerous 'weaker' sarcomeres to compensate for their relative contractile impairment. (Larson, Farside)
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A myocyte is composed of sarcomeres arranged in series and in parallel. In turn, each
sarcomere, the basic force-generating element of muscle, consists of a thick filament arranged
in parallel to a thin filament. The thin filament is anchored to a dense transverse band known
as the Z-line. Interaction between the filaments results in their relative motion, shortening the
sarcomere and creating a contractile force that acts at the Z-line to cause contraction of the
entire muscle cell. In molecular terms, the thick filament is composed principally of the
polymerised tails of numerous beta-myosin heavy chains, which are intertwined in pairs, while
the thin filament consists chiefly of polymerised actin, which forms from actin monomers in a
fashion resembling two stacks of coins gradually twisting around each other.
Interaction between myosin and actin is the molecular basis of contraction. Each beta-myosin
has a head hinged to its long tail; in pairs, the heads extend away from the heavy chain,
oriented toward the thin filament, and are therefore referred to as cross-bridges. Each head
can bind actin and the intracellular fuel ATP; the head also comprises two other proteins, the
essential and regulatory light chains of myosin that are thought to provide a modulating
influence on head function. The myosin-binding site on actin is in the groove between the
"stacks of coins." In the resting state, the site is occupied by alpha-tropomyosin, which inhibits
actin-myosin interaction. Three other proteins, troponins C, I, and T, are also components of
the thin filament. The muscle cell's electrical depolarisation results in calcium influx. Binding of
calcium to troponin C then induces a conformational change in alpha-tropomyosin, exposing
the myosin-binding site on filamentous actin.
The beta-myosin head can now bind to actin; the head also hydrolyses its bound ATP, which
dissociates, causing a conformational change in the head—a change that exerts directional
force on the thin filament. On binding the next ATP, the head dissociates and beta-myosin
returns to its former conformation. If ATP and calcium remain available, the process can
continue, with progressive translocation of the thin filament relative to the thick filament.
It seems likely that in one way or other, all sarcomeric gene mutations associated with HCM
impair the function of the sarcomere as a molecular motor. This view is supported by several
vitro assays of mutant protein or myocyte function.36"40,53"57 For example, in the translocation
test, myosin is bound by its tail to a glass slide, leaving the head free to interact with
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filamentous actin. For several different sarcomeric mutations, translocation velocity is altered.
In some cases, such as the alpha-tropomyosin mutation Val95Ala,12 the velocity is depressed,
but for two essential-light-chain mutations, the velocity is increased.33 This type of evidence,
now obtained for several mutations in several genes, provides evidence that different
mutations have distinctive functional consequences. The infidelity between precise molecular
defect and final phenotype becomes all the more perplexing.
Several cardiac sarcomeric genes—beta-myosin heavy chain, the essential and regulatory light
chains, and alpha-tropomyosin—are also expressed in skeletal muscle. In some beta-myosin
mutations, a skeletal myopathy develops that resembles central core disease, in which
mitochondria are absent from the core of many slow muscle fibres.58 Light-chain mutations
have been associated with a skeletal myopathy involving ragged red fibres similar to those seen
in mitochondrial myopathies.33
2.3.1.2 Non-Sarcomeric Hypertrophic Cardiomyopathy
As many as half the HCM patients do not have a sarcomeric mutation despite most having a
cardiac phenotype indistinguishable from that in patients with a sarcomeric mutation. Similarly
indistinguishable from HCM can be the LVH in certain multisystem hereditary disorders; for
example in Leopard syndrome59, Friedreich's ataxia60 and in Neuroacanthocytosis.61,62
Transgenic studies also indicate that non-sarcomeric molecular lesions can cause cardiac
hypertrophy.63
Mutations affecting energy production in the myocyte are an increasingly recognized aetiology
of HCM. Mutations in PRKAG2, a gene that encodes a regulatory subunit of cyclic AMP
dependent kinase (AMPK), are associated with a cardiomyopathy syndrome characterized by
HCM that progresses to LV dysfunction, atrio-ventricular bypass tracts, atrial fibrillation, and
bradycardia from heart block and sinus node disease.30 AMPK is activated by increases in AMP
relative to ATP and is thought to act as an energy charge sensor.64 Activated AMPK increases
ATP production, inhibits non-essential cellular processes, and alters gene expression.
Mutations in nuclear and mitochondrial genes encoding mitochondrial proteins have also been
associated with HCM (table 1). Expanded trinucleotide repeats and missense (mainly null)
mutations in the FRDA gene encoding fraxatin, a nuclear encoded mitochondrial protein,
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results in Friedreich's ataxia.60 Up to 75% of patients have LVH similar to that in HCM.65 The
absence of fraxatin may lead to abnormal iron metabolism and oxidative damage to
mitochondria.55 Mutations affecting nuclear and mitochondrion-encoded components of the
electron transport system and beta-oxidation have been associated with a variety of
cardiomyopathic states (Table 2).57
Myocellular Ca2+ concentrations are tightly regulated. Increases in intracellular Ca2+ initiate
sarcomeric contraction, and its rapid removal leads to relaxation. Ca2+ dependent signalling in
myocytes also mediates the hypertrophic gene response to a variety of hypertrophic
stimuli.53,58 To date, no abnormalities in Ca2+ regulatory genes have been reported as certain
causes of human HCM. However, a multitude of transgenic models have shown that
abnormalities in several of these genes are sufficient to produce hypertrophic cardiomyopathy.
69-71
Syndrome Gene Affected/Gene Product Phenotype
Friedreich's ataxia FRDA/frataxin-nuclear encoded mitochondrial LVH, LVD, HB
protein
Kearns-Sayre mtDNA deletions/mitochondrial proteins LVH, LVD,HB
ME LAS mtDNA deletions/mitochondrial proteins LVH, LVD,HB
MERFF mtDNA deletions/mitochondrial proteins LVH, LVD,HB
Myotonic dystrophy-1 DMPK/ Myotonic dystrophy protein kinase HB, VT
Myotonic dystrophy -2 ZNF9/Zinc finger protein HB, VT
Duchenne muscular dystrophy DMD/dystrophin - cytoskeletal protein LVD
Becker muscular dystrophy DMD/dystrophin (allelic with Duchenne) LVD*
Limb-girdle muscular dystrophy** Several - at least 15 different AD and AR variants HB, LVD
Emery Dreifuss -X linked STA/Emerin- nuclear membrane protein HB, LVD
Emery Dreifuss - AD & AR LMNA***/Lamins A and C- nuclear membrane HB, LVD
proteins
Desmin related myopathies Several include desmin, alpha-B crystallin LVH, LVD, HB,
RCM
Table 2: Cardiac Involvement in Selected Hereditary Neurological Syndromes
* less severe than Duchenne muscular dystrophy; ** Some variants, such as those associated with mutations in the
sarcoglycan genes, are associated with LV dilatation and dysfunction; *** LNMA mutations also associated with
limb-girdle muscular dystrophy type IB, Charcot Marie Tooth disease type 2B-1, and can also result in a dilated
cardiomyopathy, often with conduction abnormalities in the absence of skeletal muscle weakness.. MtDNA -
mitochondrial DNA; LVH- LV hypertrophy; LVD-LV dilatation and systolic dysfunction; HB-heart block; RCM-restrictive
cardiomyopathy; AD-autosomal dominant; AR-autosomal recessive.
Adapted from Mohiddin and Fananapazir, in Neuroacanthocytosis Syndromes.72
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2.3.2 Genetic Basis of the Dilated Cardiomyopathies
Dilated cardiomyopathy (DCM) is characterized by left ventricular dilatation and systolic
dysfunction, and patients are at risk of death from congestive cardiac failure, cardiac
arrhythmias and thromboembolic complications. Pathologic changes include myocyte atrophy
and death and myocardial fibrosis.
In most cases, the cause of DCM is never determined. It has been estimated that DCM
is familial (FDC) in approximately one-third of cases and transmission may be autosomal
dominant or recessive, or X-linked.73-75 DCM may be an important and life threatening
complication of several neuromuscular (and metabolic) diseases such as the muscular
dystrophies, mitochondrial syndromes and myotonic dystrophy (table 2).67,75
In addition to the relatively low likelihood of a case of DCM being genetically determined,
screening strategies are also complicated by a more variable age-related penetrance than is the
case for HCM, and because inheritance patterns other than autosomal dominant are more
likely. However, it is important to consider FDC in all patients with DCM unless there is strong
evidence that an alternative cause is responsible. Early, preferably pre-clinical diagnosis of
family members at risk may allow prognostically beneficial therapy proven to prevent
progressive systolic impairment and death from heart failure.
Products of genes associated with FDC include those localized to the cytoskeletal, nuclear
envelope, sarcomere and mitochondrion; still others are implicated by transgenic studies. It has
been suggested that FDC results from abnormalities in propagation of contractile force
generated by the sarcomere to the extracellular matrix.41 Non-familial DCM, such as resulting
from ischaemic heart disease, viral myocarditis, alcohol abuse, vitamin deficiency,
chemotherapy and haemacromatosis, are characterized by diffuse myocardial damage and cell
death.77"80 In FDC, it is likely that cell damage and death result from a variety of insults such as
from sarcomeric contraction improperly constrained by the cytoskeleton and cellular
'ischaemia' resulting from energy deficit.
2.4 Clinical Features of Hypertrophic Cardiomyopathy
HCM is occasionally detected in-utero or in infancy. However, the disease usually develops
during the period of rapid body growth in puberty. Significant increases in LV wall thickness
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after the age of 18 years are unusual. Occasionally, HCM is diagnosed for the first time in the
elderly, although in most cases it is thought that the LV hypertrophy has been present for
decades. Late-onset HCM, proven with serial cardiac imaging is unusual;81 late diagnosis or late-
onset of symptoms are not synonymous with true late-onset cardiac hypertrophy. Age-related
penetrance defines most stepwise or cascade family screening strategies.
2.4.1 Clinical Assessment
History: Some patients with severe LV hypertrophy may be asymptomatic, but complaints of
chest discomfort, dyspnoea, palpitations, fatigue, presyncope, and syncope are common.
Symptoms are frequently induced by postural changes or by exertion, dehydration, arrhythmia,
after large meals and vasodilating drugs. The construction of a family pedigree and
identification of any family members with cardiovascular histories (including sudden death and
stroke) is useful.
Clinical Examination: Examination may be normal, and must not be solely relied upon when
screening at-risk family members. Patients with obstructive HCM may have a bifid arterial pulse
and there is often a prominent LV apical impulse. Auscultation may reveal an added third or
fourth heart sound, and in patients with obstruction, a harsh systolic murmur at mid-sternum
radiates to the axilla, increases in intensity on assuming an upright posture and becomes
fainter with squatting. In a few, there may be signs right heart failure. Electrocardiography
(ECG) and echocardiography (echo) are the principal diagnostic tools.
Electrocardiography: The 12-lead electrocardiogram is highly variable and may be normal. The
most common finding is voltage criteria for LV hypertrophy with 'strain' pattern and changes
frequently precede echocardiographically detectable LV hypertrophy.
Cardiac Imaging: Two-dimensional echo is the primary method for diagnosing HCM and the
usual diagnostic criteria require the demonstration of LV wall thickness of greater than 13 mm
(usually asymmetric hypertrophy of the septum) in the absence of another cause for cardiac
hypertrophy. In athletes or patients with hypertension, wall thickness should exceed 15 mm.82
Echocardiography also; establishes the severity and distribution of left and right ventricular
hypertrophy; demonstrates the presence or absence of LV obstruction and its site and severity
(LV outflow tract or intra-LV cavity), and the presence or absence of mitral valve regurgitation
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and aberrant papillary muscles; provides estimates of LV systolic function, pulmonary arterial
pressure, and the severity of left atrial enlargement.
In addition to providing a more accurate definition of regional cardiac wall thickness, LV mass
and systolic function, cardiac magnetic resonance imaging (CMR) allows the detection of
regional myocardial scarring through imaging of delayed enhancement (DGE) following
intravenous infusion of the contrast agent gadolinium. DGE may prove an important prognostic
feature of HCM.
Exercise Testing: With adequate precautions treadmill exercise testing is safe and objectively
assesses exercise tolerance. Exercise-induced arrhythmia and a hypotensive blood pressure
response may identify patients at increased risk for sudden death.83 The use of metabolic
exercise testing is largely confined to research indications and will often demonstrate markedly
impaired exercise capacity even in individuals that report few or no symptoms.
Ambulatory electrocardiographic monitoring: Holter monitoring detects non-sustained
ventricular tachycardia in approximately one quarter of HCM patients or even more in some
cohorts84 NSVT is recognized as a principal risk factor for sudden death; in common with all
other risk factors used in primary prevention of sudden death algorithms, NSVT has poor
positive predictive accuracy.85,86 Holter monitoring may also detect other important
arrhythmias, notably atrial fibrillation (AF). Most expert opinions on HCM will consider warfarin
anticoagulation after a single episode of paroxysmal AF is detected.1
Myocardial perfusion imaging: Stress induced myocardial perfusion defects, typically with
myocardial scintigraphy or cardiac MRI are present in up to two thirds of patients.82,87,88 Assays
of coronary sinus lactate concentrations during rapid pacing have demonstrated that perfusion
defects truly represent myocardial ischaemia.89 Perfusion defects may be subendocardial and
circumferential, resulting in an apparent LV cavity dilatation during stress myocardial
scintigraphy. Fixed defects at scintigraphy probably represent large areas of myocardial
scarring. CMR first-pass perfusion imaging (gadolinium) combined with high spatial resolution
cardiac imaging and tissue characterization is preferred when available. The clinical and
research utility of CMR perfusion imaging in HCM has yet to be fully evaluated.82
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Cardiac catheterisation: Right and left heart catheterisation provides measures of cardiac
output, ventricular filling pressures and LV pressure gradients under basal conditions and
following provocation. These hemodynamic indices are valuable for guiding symptomatic
therapy and for assessing the efficacy of therapeutic interventions and research outcomes.
Coronary artery angiography excludes congenital and acquired coronary disease and assesses
the suitability of septal arteries for alcohol septal ablation (see management).
Electrophysiological studies: Standard electrophysiology (EP) protocols often provide evidence
of sinus node, atrioventricular node, and His-Purkinje disease, and may induce atrial or
ventricular arrhythmias. EP abnormalities are more frequently demonstrated in sudden death
(SD) survivors,90 but the validity of EP in SD primary prevention in adult patients is unproven;
few centres now perform EP studies routinely.91 EP provoked ventricular arrhythmias may play
a small role in assessing children at high risk of SD.92
Genetic testing: An early hope was that mutation-specific natural histories would provide an
ability to predict clinical events. This has proven to be the case for only a handful of specific
mutations, with most capable of causing any of the HCM phenotypes. Additionally, genetic
testing remains time and resource expensive, and will identify mutations in only 50-60% of
patients. Nonetheless, the clinical utility of genetic diagnoses lies in the ability to make a
preclinical diagnosis. Identifying children at risk of developing disease - and those not - allows
lifestyle and professional choices to be made early, may assist SD prevention and focuses
clinical resource
2.4.2 Risks of Sudden Death, Stroke and Heart Failure
Several studies have identified that HCM is the commonest cause of SD in the young, usually
defined as death occurring within 24 hours of the onset of symptoms in individuals under the
age of 45 years. 93 95 Estimated risks of SD have varied widely, a phenomenon at least partly
due to the provenance of the cohort of patients studied. The annual mortality in tertiary
centre cohorts is greater than that in studies of 'community based' patients. An annual risk for
death in relatively unselected HCM patients is likely to be 0.5-1% per year, rising to 2% or even
higher in certain groups, such as children with HCM.20,96"102 Few studies adequately
differentiate cause of sudden death - these include SD assumed secondary to ventricular
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arrhythmia, heart failure related death (with arrhythmia as a frequent terminal event), and
stroke. In a retrospective analysis of data from a cohort of 368 HCM patients, a summation of
risk factors identified patients at higher risks of SD. In this study the presence of one risk factor
was associated with an annual death risk of 1.2%, two with 3%, and three with 10.7% .9S
This and other studies do not specifically address stroke and congestive heart failure related
causes of death. Similarly, there are no trials examining efficacy of intervention intended to
improve prognosis (implantable cardioverter-defibrillators (ICD), anticoagulation or heart
failure medication). In current risk assessment strategies, the risk factors are added; however,
the importance of each risk factor cannot be equal. Certainly, each on its own has a low
positive predictive value. Their relative importance, non-binary status and any important
synergistic interactions remain unexamined. For example a patient with recurrent syncope and
a family history of multiple sudden deaths would receive the same risk estimate as a patient
with an abnormal exercise blood pressure response and a single episode of syncope. The
sizeable fraction of patients in the retrospective ICD cohort studies (discussed below) with only
one risk factor yet who receive appropriate shocks attests to the importance of the clinical
experience. Additionally, more recently identified risk factors (Table 3) will need to be
incorporated into prognostic assessments. Several difficulties are evident; (i) their
independence from and interaction with other RFs are not known, (ii) their relative
contributions are to arrhythmia, stroke or heart failure death risk are unknown, (iii) the risk
reduction benefit from specific interventions, for example treatment of LV outflow obstruction
or avoidance of physical exertion, is also unknown.
Finally, the patient's age has considerable bearing on risk assessment. Sudden death is
commonest in the second and third decade of life, and uncommon prior to age 14 years.
Children and young adults with FICM are thought to be at the highest risks of SD, but the risk
factors that predict SD in the young are likely to be different than those that predict death in
older adults.92 Younger adults with risk factors have more cumulative risk than older adults
with the same risk profile; additionally older adults have survived despite the estimated risk.
Unpublished data from children aged <20 suggests that many of the risk factors used for adults
will not identify high risk children.92 Instead, of a number of candidate risk factors, only septal
wall thickness and electrophysiological studies were independent predictors of SD in
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multivariate analysis. Children with inducible VT and ST > 20 mm had a five-year SD rate of
25%; without inducible VT and ST > 20 mm the five-year event rate was 8%. (Table 4).92
Established Risk Factors Candidate Risk Factors
Cardiac arrestv Atrial fibrillation
Sustained VTv Left atrial enlargement
Non-sustained VT* Myocardial ischaemia
Family history of premature SD* DGE imaging
Unexplained syncope* 'Malignant' mutation




Table 3: Conventional and Candidate Risk Factors for Predicting Premature Death in HCM.
v ICD indicated for secondary prevention; * Risk factors used in summation to risk stratify for the purposes of
primary prevention ICD implantation.98 Environmental refers to common situations that may increase risk, for
example hypertension, competitive sports, recreational drug taking. VT, ventricular tachycardia; DGE, delayed
gadolinium enhancement; LVOTO, LV outflow obstruction. Modified from Maron et al.1
Septal thickness < 20mm Septal thickness > 20mm
EPS negative 0% (0%, 0%), N=45 8% (0%, 17%), N=50
EPS positive 0% (0%, 0%), N=7 25% (5%, 41%), N=26
Table 4: Predicting SD events in EICM patients less than 20 years old.
The table shows 5 year probabilities (95% confidence interval)(N= number of patients in each stratum).92
2.4.2.1 Ventricular Arrhythmia
A consensus document prepared for the AHA, ACC and ESC1 unequivocally recommends ICD
implantation for secondary prevention of arrhythmic SD - i.e. after failed SD, syncope or
haemodynamic compromise with documented spontaneous ventricular arrhythmia. ICD
implantation is considered a class 2a indication (level of evidence C) in HCM patients with one
or more 'major' risk factor for SD. In other words, the guidance states that while many experts
would favour ICD implantation at this level of perceived risk, some would not (see table for
interpretation of guidance). In large part, this is because there are no prospective studies
examining either accuracy of risk prediction or success of intervention. A single risk factor
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probably confers approximately 1% annual risk of death (inclusive of arrhythmic, stroke, heart
failure). The low event rate, ICD implantation costs/morbidity and the absence of trial evidence
have led most centres to consider a threshold of 2 risk-factors more reasonable.
Strategies for the prevention of arrhythmic SD have not been tested prospectively.
Retrospective studies describe a high intervention rate in patients receiving ICDs for primary
prevention.103"105 These studies also detail a relatively high rate of ICD complications, in part
reflecting the challenges of ICD therapy in active young individuals (about one quarter receive
inappropriate shocks). Additionally, the risk factor profiles of those patients receiving
appropriate ICD discharges were no different from those not receiving shocks. Furthermore, in
one study, one third of the patients shocked appropriately had only a single risk factor.103 Our
ability to risk stratify remains severely limited.
2.4.2.2 Thrombo-Embolic Events
Stroke risks in HCM increase with advancing age.105 In large part, this is thought to reflect an
increased frequency of atrial fibrillation occurring as part of a progressive left atrial myopathy
(increased LA size, decreased LA systolic function). Approximately 2% of HCM patients per year
develop AF, and they have sizeable stroke risks (OR of 17.7 compared with HCM without AF).107
Significant left atrial enlargement (>50 mm) developing without evidence of AF is
considered a sufficient indication for anticoagulation in some centres. The rationale for this is
that the atrial myopathy often includes severe impairment of LA contractile and capacitance
function which may predispose to stroke, as well as the high likelihood that undetected PAF is
present (or will shortly develop) in such patients.
2.4.2.3 Systolic Left Ventricular Failure
While symptoms associated with congestive heart failure are common and multifactorial in
HCM, the development of progressive LV systolic impairment and LV dilatation is rather less
common. Estimates are that approximately 10 % of patients enter a well defined burnt-out
phase of the disease, sometime termed end-stage (ES) disease.20"22 Many more patients
develop more subtle degrees of systolic impairment; after all, the basic molecular fault in most
cases is an abnormal component of the contractile apparatus.
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Outpatient review with regular cardiac imaging is indicated; patients with ES disease
have increase risks of adverse events, including mortality/transplant rates of approximately
10% per annum.21,22 No reliable method of predicting those patients at greatest risk of
developing ES disease has been developed. It has been suggested that left atrial dilatation may
be an early sign of the development of end-stage (ES) disease. 108 Patients with ES disease
invariably have myocardial scarring detectable at DGE imaging. Even though DGE imaging is
positive in two thirds of all HCM patients, serial CMR imaging with detailed assessment of LV
volumes and quantification of DGE has a potential role in the detection of early ES disease.
109,110
Patients with dilating phase HCM are usually considered suitable for consideration of all the
prognostic pharmacological and device modalities indicated for systolic heart failure. The
efficacy of any of these interventions in this group of patients has not been demonstrated, but
is assumed to be similar to that in the cohorts examined in the large heart failure trials.
2.4.3 Obstruction and Mitral Regurgitation
In one quarter of HCM patients, almost exclusively where the LVH has an ASH distribution,
mitral-septal contact in systole can result in a dynamic LV outflow tract obstruction (LVOTO).
This systolic anterior motion of the mitral valve (SAM) also interrupts leaflet coaptation
producing a variable degree of mitral regurgitation (MR). Echocardiography with Doppler best
demonstrates and quantifies all these abnormalities. Obstructive HCM is often associated with
symptoms, particularly on effort. LVOTO is also associated with a poorer prognosis.111"113
In symptomatic individuals, pharmacological treatment with beta blockade, verapamil or
disopyramide (alone or in combination) may reduce measured outflow gradients. Invasive
reduction of LVOTO is indicated if symptoms in patients with LVOTO resulting from SAM persist
despite maximum pharmacological treatment (see figure 4 in section 1.2). The premise of all
LVOTO therapies is that outflow obstruction and MR contribute to symptoms; the relatively
poor correlation between both LVOTO magnitude and MR with symptom status probably
reflects the additional and variable importance of myocardial ischaemia, impaired LV filling,
small stroke volumes and arrhythmias.
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The determinants of SAM are uncertain; is there a 'pull' or 'push' force on the mitral
apparatus?114 The conventional understanding is that the anterior leaflet is pulled towards the
LVOTO as the result of the Venturi effect produced as systolic flow accelerates across the
convexity of the ventricular surface of the anterior mitral leaflet. 115A negative pressure pulls
the anterior leaflet away from the posterior leaflet and towards the septum. Alternatively, as
the result of distorted LV geometry, the systolic effort pushes the mitral leaflets towards the
LVOT.116 The uncertainty regarding mechanisms resulting in SAM contributes to the vigorous
debate concerning the preferred invasive treatment modality. Following the initial description
of alcohol septal ablation (ASA) in 1995,117,118 it has gained rapid acceptance and is now the
most commonly chosen treatment option for LVOTO reduction. More ASA procedures than
operations have been performed despite the passage of more than 40 years since surgical LV
septal myectomy (LVM) was developed.1,119
The debate concerning the relative merits of ASA and LVM is not informed by any randomised
studies. The only randomised trials addressing drug-refractory symptomatic LVOTO treatment
options examine dual chamber (DDD) pacing. DDD, ASA and LVMM, have all been subject to
the contrary opinions of enthusiasts and detractors. A fourth option, mitral valve replacement,
is considered only in the presence of other indications for mitral valve replacement.120
2.4.3.1 Surgical Myectomy
In the 1960's, a surgical approach to resect the sub-aortic ventricular septum through
the retracted aortic valve at aortotomy was developed.119 The Morrow procedure or LVM is still
considered the 'Gold Standard' treatment by several influential opinions. 1,121 Modern surgical
results, as reported by the few centres with significant experience, are impressive, with low
operative mortality, substantial symptom improvement, increased exercise tolerance, and
perhaps an improved prognosis.121124 While few doubt the potential benefits of LVM, its
designation as 'Gold Standard' is not supported by randomised trial data or contemporary real-
world practice. Additionally, published results are from the few centres with considerable
experience where complication rates are low. These include aortic incompetence, heart block,
ventricular septal defects, and all the complications of open-heart surgery. Surgical techniques
are undoubtedly superior when more complex anatomic problems are to be addressed, for
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example if the subvalvar apparatus is abnormal or there is co-existing mid-cavity
obstruction.125,126
2.4.3.2 Pacemaker Therapy
Pacing therapy (DDD) with right ventricular pre-excitation reduces LVOTO acutely and
chronically.127,128 This effect is likely to be the result of (paradoxical) septal movement away
from the direction of SAM, but reductions in cardiac output may also contribute. Apical RV lead
placement and carefully chosen paced A-V intervals are important for successful therapy.
Uniquely in HCM research, pacing has been examined in prospective placebo controlled
randomised trials. M-PATHY was a cross-over study where 3 months of active pacing were
compared with placebo pacing.129 No benefits of active pacing were demonstrated over an
apparently large placebo effect.
The hemodynamic and symptomatic benefits of pacing are reported to be progressive
throughout the first 6 months following implantation and persist after cessation of pacing.130
Potential bias from crossover treatment effects and type 2 error due to the abbreviated
duration of therapy may have contributed to a failure to demonstrate treatment benefit and
the large placebo effects. Significant hemodynamic and symptomatic improvement after DDD
pacing were demonstrated in the larger randomised double-blinded PIC study.131
Potential adverse effects on LV systolic and diastolic function of chronic RV pacing132,133,
equivocal trial data and the development of ASA have resulted in the relegation of pacing to a
poor third choice. Nonetheless, pacemaker has low complication rates compared with ASA and
LVMM. The rate of ICD implantation in HCM patients is increasing and almost all are dual
chamber systems to minimize inappropriate shocks. A therapeutic trial of pacing therapy in ICD
patients with symptomatic LVOTO may prove reasonable before ASA or LVM. Furthermore,
pacing-ICD therapy will increase the safety of both ASA and LVM.
2.4.3.3 Non-surgical Septal Reduction
ASA's rapid acceptance has undoubtedly been influenced by the convictions of proponents and
a greater willingness of patients for less invasive procedures. In the non-randomised and
uncontrolled studies now available, ASA substantially reduces LVOT gradient, improves
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symptoms, increases exercise tolerance and leads to desirable changes in cardiac anatomy and
physiology. These include reduced LV filling pressure, abolition or attenuation of MR, smaller
LA size, and reduction in LVH.134 Early concerns regarding arrhythmogenicity of the 'infarct' scar
are not supported by data, but the potential for long-term complications cannot be
dismissed.135 The major complication in contemporary ASA cohorts remains complete heart
block, and permanent pacing is required in approximately 10% of treated patients. However, it
should be noted that despite ASA's comparative youth, the number of patient treatment years
must now exceed that of LVM. ASA has evolved such that its procedural mortality and efficacy
are similar to that of LVM.134
2.4.3.4 Additional Indications for Invasive Therapy
Provoked LVOTO: LVOTO worsens if end diastolic LV volumes are reduced (postural change,
dehydration, vasodilatation, post-prandially etc) or if inotropy is increased (after ventricular
extrasystoles, exertion). A systolic murmur apparent on standing from a squat is strongly
suggestive of provoked LVOTO, as are symptoms of postural presyncope and an intolerance of
extrasystoles. Labile LVOTO may be missed if echocardiographic or invasive studies do not
include techniques to provoke SAM. Most studies (LVM, DDD and ASA) include patients with
provokable LVOTO, and symptomatic benefits are demonstrated.
The Valsalva manoeuvre and exercise can be used to demonstrate provokable LVOTO, though
Valsalva detects fewer patients with provoked LVOTO than exercise will.136 Pharmacological
agents include amyl nitrate, sublingual glycerin trinitrate and intravenous isoproterenol.
Dobutamine is not recommended as it can provoke LVOTO in normal hearts.137 The
Brokenborough effect following ventricular extrasystoles can demonstrate provokable LVOTO
in the catheter laboratory, either through the irritant effects of manipulating a catheter in the
ventricle, or by paced extrasystoles. This latter technique is particularly useful during ASA
where temporary pacing can introduce identically timed extrasystoles every few cardiac cycles.
Mitral Valve Abnormalities and Mid-Cavity Obstruction: Benign structural abnormalities of the
mitral valve are common in HCM.138 More important abnormalities include anomalous
insertions of the papillary muscles/chordae onto the mitral leaflets or septum, and
displacement of the papillary muscles.138,139 Surgery is strongly favoured if significant structural
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mitral abnormalities co-exist with SAM, but the MR of uncomplicated SAM should be abolished
or improve following successful ASA.
Pronounced papillary muscle hypertrophy may result in the uncommon and poorly
understood mid-cavity (mid-ventricular) variant.140,141 Mid-cavity obstruction can co-exist with
LVOTO, or can become apparent after successful LVOTO treatment.125 Potential adverse
consequences include reduced contribution of the distal LV segment reduction to cardiac
output, effects of elevated afterload on the distal LV segment (including metabolic
consequences, reduction of myocardial perfusion pressures, aneurysm formation) and any
(poorly defined) consequences of muscle contracting onto muscle.
Sustained monomorphic VT is uncommon in HCM, but when present is frequently associated
with a distal LV aneurysm resulting from mid-cavity obstruction, (personal observation) The
detection of monomorphic VT should prompt a search for apical abnormalities that may not be
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Figure 6. Echocardiographic and Angiographic Findings in Mid-Cavity Obstructive HCM.
This patient, was referred for alcohol septal ablation. Doppler studies were interpreted as demonstrating an outflow
gradient of approximately 70 mmHg (A). A more careful examination of Doppler signals reveals that the high velocity
signal is in early diastole (arrow), and that the systolic outflow velocity is normal (double arrow). The location and
timing in the cardiac cycle of this high velocity Doppler signal (arrow) are demonstrated in a 4-Chamber view (B) and
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in colour M-Mode (C). The presence of an apical aneurysm, undetected by echocardiography, is demonstrated on
the LV angiograms (D-G). In systolic frames (D and F), it can be seen that the apical and the proximal LV are
disconnected by mid-ventricular obliteration. In early diastole (E and G) and with relief of the mid ventricular
obstruction, the high pressure apical cavity empties into the relaxing proximal LV generating the high Doppler
velocities. From Mohiddin and Knight, Alcohol Septal Ablation in the Oxford Textbook of Interventional Cardiology.45
Several groups report that pacing142, ASA143 and surgery 140 can reduce mid-cavity
gradients. However, although mid-cavity disease is often associated with drug-refractory
symptoms, it is not understood why symptoms develop or if gradient reduction improves
these.
Asymptomatic LVOTO: A fundamental understanding in general cardiology is that mitral
regurgitation and aortic stenosis are associated with increased risks of heart failure and sudden
death, even in asymptomatic patients. Are LVOTO and MR in obstructive HCM independently
associated with worse prognosis? Retrospective studies report that LVOTO is independently
associated with greater risks of death.111113 These reports include important differences
concerning mode of death (heart-failure or arrhythmic), the importance of LVOTO as a binary
or continuous risk factor, and the significance of symptom status.
Maron et al.111 analysed records from 1101 patients followed for a mean of 6.3 years. Patients
with LVOTO (resting gradient>30 mmHg) had a relative risk (RR) of death of 1.6, but risk did not
increase with increments of LVOTO above 30 mmHg. Death was most often related to heart
failure or stroke rather than from arrhythmic SD. In half as many patients followed for 4.5
years, Autore et al report that LVOTO predicted cardiovascular death best in asymptomatic
patients (RR 2.4). In patients with functional class III or IV symptoms, but not LVOTO were
powerful predictor (RR 7.9).112 After a median follow up of 5.1 years, Elliott et al. also report
reduced survival in patients with LVOTO.113 They detect an incremental risk, with an RR for all
cause death and transplantation of 1.24 per 20 mmHg of LVOTO. A very low SD risk in the least
symptomatic leads the authors to conclude that septal reduction therapy in the asymptomatic
is not indicated for the prevention of SD.
At present, the desire to relieve symptoms is the only indication for invasive LVOTO
reduction. Long-term consequences on cardiac structure and function of chronic LVOTO and
MR may include progressive atrial enlargement and atrial fibrillation, pulmonary hypertension
and LV systolic impairment. Furthermore, LVOTO reduction leads to modest LVH regression
36
remote from the ablated myocardium, suggesting that some of the LVH develops in response
to afterload, in addition to the 'primary' hypertrophy.144 Future approaches to LVOTO may
include prognostic indications and treatment protocols may resemble those for the
management of asymptomatic and symptomatic structural valve disease.
Finally, it must be remembered that FICM is a complex syndrome where several mechanisms
are responsible for symptoms. A patient with successful LVOTO reduction still has HCM, and
remains subject to other contributors to symptom limitation, disease progression and SD risk.
2.4.4 Diastolic Function - Atrioventricular Coupling
In HCM, clinical practice is largely based on a relatively limited understanding of the
physiology of the disease process; in an almost complete absence of randomised trial data,
dynamic outflow obstruction is often managed invasively, defibrillators are used when sudden
death risk is deemed high, and symptoms of heart failure are treated with negative inotropes
and diuretics. While there is an accumulation of clinical evidence that they are effective
treatments, mechanisms underlying heart failure-related symptomatology in HCM are less well
understood and symptomatic patients are difficult to treat.23
Abnormalities of LV filling are thought to be a major cause of exercise intolerance in
many patients, particularly those without LVOTO. Abnormalities affecting LV relaxation, LV
compliance and atrial function all contribute to sub-optimal diastolic performance, and
elevated LV filling pressures or limited preload reserve may result in exercise limitation. LV
filling can be referred to as atrio-ventricular (A-V) coupling to emphasize the importance of
both atrial and ventricular properties. Limitations in methods available for assessing these
properties inhibit our ability to assess patients and to develop intervention strategies.23
2.4.4.1 Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
The management approach to the symptomatic HCM patient with LVOTO assumes that
obstruction makes a significant contribution to the development of symptoms. LVOTO
reduction is often very successful in symptom improvement, but successful LVOTO treatment
may still be associated with significant residual symptoms.121,145 For the symptomatic HCM
patient without LVOTO, therapeutic options are few and often unsatisfactory.
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Clinical investigations in the symptomatic non-obstructive patient often detect evidence of
ischaemia, abnormal diastolic indices, systolic abnormalities, atrial enlargement, myocardial
scarring at MRI and atrial/ventricular arrhythmias. No individual or profile of abnormality
reliably distinguishes symptomatic from asymptomatic patients, or correlates sufficiently well
with measured exercise limitation. However, abnormal LV filling is thought to make major
contributions to heart failure symptoms and exercise intolerance in such patients. In the study
of 'Diastolic Failure', HCM can be regarded as a 'super' model.23 LV filling is a complex and
interactive process determined by preload, afterload, systolic events, and the passive and
active properties of the cardiac chambers and vascular structures. Though it is easy to
demonstrate abnormal LV filling in HCM cohorts, the specific determinants of the diastolic
abnormalities and their clinical importance have been difficult to characterize. AS LV filling
depends on several interacting cardiac properties, a comprehensive description of diastole,
'diastolic profiling', will include several parameters.
Definitions of Diastole: The definition and temporal limits of diastole can be described in
cellular or hemodynamic terms. 146151 Following peak LV force generation during early systole,
energy-dependent sequestration of calcium into the sarcoplasmic reticulum leads to rapid
dissociation of actin-myosin fibril cross-links and the beginning of 'cellular' diastole. As a result,
rapid LV pressure decline results in aortic valve closure; 'haemodynamic' diastole begins shortly
after 'cellular' diastole. A period of isovolumic relaxation follows until atrial pressure exceeds
LV pressure and the mitral valve opens. Early rapid filling occurs until atrio-ventricular pressure
equilibration again develops (diastasis) and there is little or no flow across the valve. The
passive capacitance and intra-cavitary pressure in the left atrium and pulmonary veins and as
well as LV relaxation velocity, LV restoring forces (a suction effect as the LV 'springs' from end
systolic toward equilibrium volume) and compliance all influence early LV filling.
If sinus rhythm is present, late diastolic atrial contraction causes a second LV filling phase,
providing the final stretch to myocardial fibres and thereby increasing LV stroke volume via the
Frank-Starling mechanism. This phase of LV filling is dependent on the interaction of atrial
systolic force (itself dependent on atrial preload and atrial inotropy) and the LV's passive
pressure-volume characteristics (compliance). Cellular diastole is terminated by energy
dependent actin-myosin cross-linking and cycling after intracellular calcium is again increased
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effecting excitation-contraction coupling. The mitral valve closes as LV pressure rises to exceed
LA pressure and diastole, as defined haemodynamically, comes to an end.
Preload Reserve: Preload reserve refers to the heart's capacity to increase cardiac output
through increasing cardiac filling (Starling relationship). In the resting HCM heart, LV volumes
are typically small, frequently with near obliteration of end systolic cavity volume suggesting
further decreases in end-systolic volume can make only minimal contributions to an increased
stroke volume. As such, increasing ventricular end diastolic volume and reliance on preload
reserve is probably more important for increasing cardiac output than in a normal heart.
Apparently 'normal' age-related decreases in LV compliance and atrial elastance are described
in normal hearts152 159 and may have much greater consequences in an ageing HCM heart
dependent for increased cardiac output on preload reserve. Several cellular, histological, and
anatomic/chamber abnormalities have been well described and can, theoretically, impair atrio¬
ventricular coupling (Table 5).
Functional Abnormality Potential consequence for LV Filling
Myocellular Sarcomeric impairment I.V and LA systolic impairment
Prolonged myocyte relaxationDelayed calcium
, • 58,56,160-164
sequestration
Myocardial Fibrosis'65"'67 Reduced compliance
Dysynchronous contraction and relaxation
Impaired contraction and relaxation
Reduced end systolic size, reduced compliance
reduced compliance
smaller atrial kick'
passive LV filling impaired, Elevated pulmonary venous
pressures
Dysynchronous contraction and relaxation
Abbreviated LV filling
Loss of atrial kick, abbreviated LV filling
Disarray7'68
Ischaemia8"
LV Architecture Small volumes
Increased wall thickness'69 171





Table 5: Contributions to Impaired Atrio-Ventricular Coupling and LV filling in HCM.
Adapted from Mohiddin and McKenna. in Diastolic Heart Failure.23
2.4.4.2 Clinical Significance of Diastolic Abnormalities in HCM
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Small LV volumes, abnormal relaxation kinetics, reduced chamber compliance, atrial systolic
abnormalities and Myocellular dysfunction are features of HCM that may restrict preload
reserve, resulting in elevated pulmonary venous pressures and/or inadequate cardiac output.
Tolerance of exertion, particularly as diastole is abbreviated by increased heart rates, may be
severely compromised by restrictions in LV filling.
In HCM patients, resting abnormalities in LV diastolic filling parameters were documented
decades ago.156,175"192 Much of the earlier work, while documenting perturbations in LV
relaxation and compensatory augmentation of atrial emptying failed to either analyse or to
demonstrate a strong relationship (or any relationship) between selected parameters of LV
filling and functional capacity or exercise performance. Most studies utilize echocardiographic,
nuclear or catheter data to assess diastole. Several limitations are evident in these studies; (1)
there is no Gold Standard measure that assesses all major components of LV filling in diastole;
(2) the demonstration of elevated LV filling pressures does not necessarily identify the failing
component(s) of diastole; (3) it is unclear which pressure measurement best represents LV
filling (e.g. mean PAWP, mLAP, post-a/pre-a LVEDP); (4) many measurements are load (pre-
and after-) load dependent (5) resting measurements of LV filling cannot assess non-constant
(e.g. inotrope/load dependent LV relaxation and atrial contractility) and non linear (e.g. LV
compliance) variables; (6) inclusion of obstructed and non-obstructed patients may confound
the results as symptoms/exercise limitation in these patients may have different causes, and
the presence of obstruction/mitral regurgitation may invalidate the diastolic assay under
investigation; (7) in some of the studies, inclusion of a high percentage of asymptomatic
patients limits the power of a study to associate the measured diastolic parameter with
functional impairment.
2.4.4.2.1 Invasive Hemodynamic Studies
Chan et al compared PAWP, cardiac index (CI) and blood pressure (BP) after diuresis and
infusion of fluid volume in 13 HCM patients.193 In the HCM patients and normal controls, all
three indices were higher in the resting upright state after fluid infusion. At peak upright
exercise testing, PAWP was also significantly higher in patients when fluid replete compared to
the same patients after diuresis, but CI and BP were similar. Thus, as a higher PAWP in the
volume replete was not associated with greater exercising CI, the authors concluded that
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stroke volume was insensitive to preload. In this study, the mean PAWP at peak exercise was
25 mmHg, similar to that seen in exercising heart failure patients194 and compared to only
approximately 10 mmHg in normal volunteers.195 LV volumes were not measured.
Frenneaux et al.196 and Lele at al.188 reported results of invasive (Swann-Ganz) exercise testing.
Subjects were relatively young (mean 34 years) and mildly symptomatic or asymptomatic as
most (87%) were in New York Heart Association (NYHA) functional class I or II, and several had
LVOTO. Cardiac index increased by 340%, but did not correlate with PCWP. Patients did,
however, demonstrate large changes in mean PCWP; 5±6 mmHg at rest increasing to 24±11
mmHg at peak exercise. An analysis of their data shows a poor relationship between exercise
induced augmentation of stroke volume and increases in PAWP (R2= 0.05, my own calculations,
from published data tables 188). Thus, PAWP increases to levels associated with pulmonary
oedema and there is no simple relationship between PAWP and cardiac output. Similar findings
are reported by Kitzman et al. in a mixed group of patients with LVH;197 stroke volume did not
increase despite significant increases in preload - again, as measured by mean PAWP.
LVEDP is the appropriate measure on the pressure-volume plot that describes the Starling
relationship. The apparent paradox whereby changes in stroke volume and filling pressures
appear unrelated may be explained by poor validity of mean PAWP as surrogate measure for
LVEDP; the correlation between mean PAWP and LVEDP is poorest in patients with
Lvh 172 198 199 Mean PAWP may better reflect pulmonary venous hydrostatic pressures and
therefore assess exercise limitation by dyspnoea rather than by limited cardiac output.
Simultaneous LV volume/pressure measurements and those of LA function would more
completely assess LV filling than any single pressure measurement. As yet, no studies compare
pressure/volume characteristics with symptom status or functional parameters.
2.4.4.2.2 Echocardiographic Studies
Echocardiography can estimate chamber volumes, relaxation properties, and more
recently Doppler derived measurements are being used to estimate LV filling pressures.200 202
Echocardiographically derived diastolic abnormalities are consistently demonstrated in HCM,
but an association of these with symptoms or exercise performance has been less easily
demonstrated.176'186 190,203 Using conventional resting transmural Doppler measurements (E/A
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ratio), Maron et al. detected abnormal diastolic indices in most HCM patients, and noted that
the severity of abnormality were increased in patients without LV obstruction.176
Nihoyannopoulos et al. found similar patterns of abnormality in resting transmural flow
characteristics, and showed a weak correlation with peak oxygen consumption (V02) during
exercise testing.190 However, there were no differences in E/A Doppler ratios between
symptomatic and asymptomatic patients. In this study, and in a further study from the same
group that employed radionuclide angiography,187 evidence for LA systolic failure was also
detected. In a study comparing exercise performance to transmitral Doppler measurements as
well as pulmonary vein flow and LA fractional shortening, Briguori et al. found no evidence for a
relationship between resting transmitral flow indices and V02.185 A reasonable correlation
between LA fractional shortening and V02 was detected, suggesting atrial systolic function may
be an important determinant of exercise capacity.
Difficulties in demonstrating robust associations with symptoms or exercise performance are
not surprising given the now well-described phenomena of pseudo-normalization and load-
dependence of the E/A ratio. These parameters perform particularly poorly at estimating LV
filling in HCM.200,201 More recently developed echo measurements including pulmonary vein
Doppler, mitral flow propagation velocity, tissue Doppler and a variety of derived ratios and
intervals are more reliable at predicting LV filling pressures.200,204,205 A brief description of these
newer measurements may help in the interpretation of the clinical studies that use them.
In HCM patients, Nagueh et al. compared a variety of Doppler parameters (including; E/A, the
ratio transmitral E to early mitral annular velocity Ea (E:Ea); early mitral propagation flow
velocity; pulmonary vein inflow characteristics, E and A acceleration/deceleration times) to a
variety of LV diastolic pressure measurements (LV minimal pressure, pre-A LVEDP and post-A
LVEDP).200 E:Ea and propagation velocity correlated well with pre-A LVEDP (r=0.76 and r=0.67
respectively). In a larger group of patients without HCM, they report that E:Ea and a different
measure of LV filling pressure, the mean diastolic LV pressure (M-LVDP), are strongly
correlated.202 However, the E:Ea ratios were in an indeterminate range in more than half the
patients in whom predicted M-LVDP could not be assigned as normal or elevated. Correlations
between E:Ea and LVEDP have subsequently been shown by others, but may be significantly
better in patients with poor LV systolic function.206 In summary, while E:Ea may contribute to
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diastolic assessment, the available studies use quite different measures of LV filling pressure
(pre-A LVEDP, M-LVDP, LVEDP). The accuracy of filling pressures predicted by E:Ea may be
altered by changes in preload and may be different in different patient populations.
In a study of 85 HCM patients, Matsumura et al. found a reasonable correlation between
resting E:Ea ratio and V02, and that E:Ea values were highest in symptomatic patients.189 These
findings have recently been validated in a group of patients with apical HCM.203 However,
although the r-values were relatively modest (r=-0.42189 and r=-0.47203), the studies' findings
are all the more surprising when considered in comparison to those earlier studies where filling
pressures were measured invasively, but where no association was found with exercise
r 188,196performance.
2.4.4.3 Atrial Function
To date, little has been written about the role of atrial function on preload reserve and exercise
tolerance. Briguori et al. reported an association between resting LA fractional shortening and
exercise capacity.186 They suggest that LA fractional shortening reflects LVEDP and that
elevated LVEDP determines exercise capacity. An alternative view is that LA systolic function
contributes to LVEDP, preload reserve and exercise capacity. While Sachdev et al. found that
that LA size predicted exercise capacity in patients with non-obstructive HCM207, the same
group were unable to demonstrate that LA active emptying fraction, ejection force, and kinetic
energy (all measurements obtained at rest) predicted exercise capacity.208
LA pressure-volume studies and assessments of LA function during stress are largely lacking,
though the few studies available in HCM suggest decreased inotropic reserve and decreased
atrial compliance accompany LA enlargement.209 211 The role that primary abnormalities of
atrial inotropic/reservoir function may have in abnormal LV filling remain largely theoretical.
The potential for enhanced atrial function to compensate for abnormal LV
relaxation/compliance, and the characteristics of a secondary atrial myopathy that may
develop in response to chronic and progressive LV disease also deserve further evaluation. As
has been mentioned above, dilation may predict the onset of cardiac failure from ES disease.108
The contribution of LA dysfunction to the syndrome that is HCM is a neglected topic.
2.4.4.4 Measurement Tools and Prospective Intervention Strategies
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Therapeutic options for the symptomatic HCM patient without LVOTO are limited. Renin-
angiotensin-aldosterone blockers, calcium antagonists, and statins have been suggested as
potential treatments.168,212"219 Each of these proposed therapies aims at a particular
pathophysiological abnormality, for example at LV fibrosis/stiffness. The identification of
appropriate patient groups and monitoring of therapy will require an ability to assess the
components of LV filling. No readily available diagnostic techniques allow this, but
echocardiographic approaches are likely to form the basis of any practical tool. The ideal tools
will measure parameters that are load dependent in a linear or predictable way, and will
incorporate a mechanism to vary load. Non-invasive and easily obtained parameters or clinical




3.1.1.1 Collection of Proband DNA and Mutation Detection
Patients referred to the Inherited Heart Diseases section of the NHLBI were evaluated and
recruited for protocols approved by the institute (98-H-0100, 99-H-0065 and 87-H-0057).
3.1.1.2 Methods
Patients: All HCM patients were considered for recruitment for genetic studies. Consecutive,
unrelated proband patients with HCM diagnosed using standard clinical criteria received
genetic counselling prior to consenting for this study. A 12-lead ECG and echo were recorded in
all cases and a pedigree tree was obtained. Each Proband was assigned a unique identification
comprising a composite of a unique family number and a number defining their position in the
pedigree. All first degree relatives were invited for clinical screening. Following the
identification of any novel genetics results, other family members might also be invited;
alternatively, a field-trip to the family's locale would be organised.
Field Trips: Patients evaluated at NHLBI were referred from all US states and from other
countries. Field trips were confined to the continental US states and allowed the clinical
evaluation of and DNA collection from family members at their relative convenience. A field
trip usually comprised two physicians, two research nurses, a portable 12 lead
electrocardiograph and echocardiogram, and equipment for collection of whole blood.
DNA Extraction: Genomic DNA extracted from whole blood as according to the manufacturer's
instructions (Gentra). After the determination of the concentration of extracted and hydrated
DND (generally > 200 ng/microlitre), this was stored at 4 degrees centigrade.
Polymerase Chain Reaction (PCR): PCR formed the basis of all genetics experiments. Generally,
1 microlitre of DNA in a concentration of DNA of 50 ng/microlitre was used for all PCR
reactions. PCR reactions were completed using genomic DNA, primers (in pairs or in separate
forward or reveres reactions) and a premixed formulation incorporating nucleotides and Taq
polymerase (ReadyToGo Beads, Amersham). PCR conditions were determined from the
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manufacturer's guidelines, from predicted PCR conditions (Primer Design, ABI Prism) and by
preliminary tests of PCR conditions for each primer pair. For PCR indications requiring
radioactive labelling, 33P labelled nucleotide was added to the PCR mix.
Primer Design: Whenever available, published primer pairs were used. For novel genes, primer
design was undertaken. Genomic gene structures were predicted using the basic local
alignment sequence tool (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi) a tool that aligns cDNA
gene sequences against searchable genomic DNA sequences.
As much of this work was undertaken before the completion of the Human Genome Project,
libraries of recently sequenced clones were the major source of genomic DNA matches to cDNA
sequences. The genomic structure of a candidate gene was thus identified and ,primer pairs
designed complimentary to intronic sequences flanking a given exon (PrimerDesign, DNAStar).
Primer pairs were manufactured (commercial vendors), and tested for optimal PCR conditions.
Single Stranded Conformational Polymorphisms (SSCP): Electrophoretic separation of 33P-
labelled PCR products (amplified genomic DNA incorporating exon coding sequences) identified
anomalous conformers.220 SSCP was used to screen for exonic coding variants that would
thereafter be sequenced.
DNA Sequencing: Cycle sequencing (ABI Prism 310, Applied Biosystems) according to the
manufacturer's instructions (BigDye Terminator, Applied Biosystems) in forward and reverse
directions provided sequence pherograms. Pherograms were analysed (SeqMan, DNAStar) for
heterogeneity and compared with wild-type sequences for the detection of mutations
(missense or insertion/deletion). Repeat sequencing from stored DNA and restriction digest
were used to confirm the presence of any mutation.
Linkage Analysis: The resources required for Linkage analysis were not available in our genetics
laboratory. Collaborative research with larger laboratories was sought following the detection
of suitably large pedigrees with autosomal dominant unusual disease phenotype. Phenotyping
and the collection/purification of DNA were completed by our group.
3.2 Sarcomeric Gene Mutations
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Mutant sarcomeric genes are the commonest causes of HCM yet; (1) their diversity; (2) the
clinical utility of a genetic diagnosis and; (3) the mechanisms of pathogenicity are poorly
understood. This section describes studies to improve understanding in these areas.
Additionally, identifying HCM patients that do not have sarcomeric mutations facilitates other
research: the search for non-sarcomeric causes of HCM. Some of the results of these efforts
have been presented in abstract form and peer reviewed journals (Table 6).
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3.2.1 Detection ofMutations in Beta Myosin Heavy Chain
3.2.1.1 Abstract
Aims: Mutation-specific natural histories promise to improve risk stratification, pre-clinical
diagnosis and genetic counselling in HCM. Detection of genetic causes of HCM is currently not
routinely available, and the ideal detection strategy is unknown. We investigated the utility of
genetic screening in HCM by performing mutational analysis of P-myosin, one of the
commonest causes of the disease.
Methods and Results: Genomic DNA from 100 consecutive unrelated patients with HCM and
from 200 normal unrelated subjects was screened with SSCP for mutations in the first 23 exons
of myh7 encoding the motor region of p-myosin. Anomalous conformers were sequenced and
mutations confirmed by restriction fragment length polymorphism. The clinical characteristics
of patients with MYH7 mutations were compared with those in whom myh7 mutations were
not detected.
Seventeen missense mutations were identified in 19 patients. Notably, 13 or 76% were
novel. Mutations were detected in both alleles in 2 patients: one was homozygous for
Lys207Gln and another heterozygous for Pro2nLeu and Arg563His. No missense mutations were
detected in control subjects. Left ventricular (LV) wall thickness was similar in patients with
myh7 mutations and in those where myh7 mutations were absent. HCM patients with myh7
mutations had more marked left atrial enlargement and presented more frequently with
syncope than other HCM patients.
Conclusions: These P-myosin mutations detected in 19% of patients most likely account for
only a small fraction of all myh7 associated HCM; detection methods should therefore allow
identification of previously undescribed mutations. The genetic diversity and rarity of most of
the mutations renders phenotype-genotype correlation difficult. Co-existence of more than
one sarcomeric mutation in the same patient may be more common than is appreciated, could
confound linkage studies and may contribute to the marked phenotypic diversity characteristic
of HCM. Further studies are necessary to ascertain the clinical consequences of novel and
compound gene abnormalities, and to determine whether correlating functional domain to
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phenotype provides more useful information about clinical significance of the molecular
defects.
3.2.1.2 Introduction
HCM demonstrates non-allelic and allelic heterogeneity, and at the time this research was
undertaken, mutations in any of 9 genes encoding sarcomeric components were identified as
causes of HCM. The most extensively studied gene is MYH7, coding for (3-myosin heavy
chain.31'32'38'39,221"225 The familial hypertrophic cardiomyopathy database listed 72 mutations in
this gene that by September 2001 when this study's findings29 were published were associated
with HCM (June 2009: there are now 194).226 Almost invariably, these are missense mutations
affecting the motor or head-lever region of the molecule.
Determination of the molecular causes of HCM has enabled description of mutation-specific
natural histories. For example, some (3-myosin mutations are associated with high disease
penetrance and a high incidence of sudden death; others with low penetrance and relatively
benign prognosis.32,43 Importantly, some sarcomeric mutations are associated with mild LV
hypertrophy but a poor prognosis.1213 Molecular diagnosis also allows pre-clinical diagnosis in
children and establishes the diagnosis in adults with mild disease. Hence, increasingly, a genetic
diagnosis is considered potentially important in the management of HCM. However, despite
recent advances, the utility of genetic screening in individual patients is unclear.
It is also uncertain which screening method should be utilized in clinical practice. Mutations
may be detected by, (1) specifically testing for each of more than one hundred identified
mutations, for example by restriction fragment length polymorphism (RFLP); (2) sequencing the
several hundred exons of these 9 genes, with or without preliminary screening such as with
SSCP; or (3) by studying suitably large kindreds using genetic linkage analysis. Following
detection of novel mutations, it is then desirable to prove causality (even in genes known to
cause HCM) and to determine the natural history of the associated HCM.
We sought to determine the prevalence and diversity of MYH7 mutations in a consecutive
cohort of unrelated HCM patients and in normal controls to: (1) evaluate a sequencing based
strategy for routine mutation detection in unselected patients, (2) determine the degree of
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MYH7 heterogeneity in normal individuals, and (3) evaluate feasibility of describing the natural
histories of the associated HCM.
3.2.1.3 Methods
Patients: A hundred consecutive unrelated proband patients with HCM referred to the National
Institutes of Health were studied. Informed consent was obtained under protocols approved
by the Institutional Review Board of the National Heart, Lung, and Blood Institute (Protocol 99-
H-0065).
Clinical Studies: Studies included 2-D echocardiography, 12-lead electrocardiography, and in
selected cases, treadmill exercise testing. HCM was defined as LV wall thickness >13 mm in the
absence of another cause for cardiac hypertrophy. A family history of HCM was defined as
present if obtained at the initial clinic interview and does not include results of subsequent
family screening. A family history of sudden death (SD) was defined as the sudden death of 1 or
more first degree family members under the age of 45 years. In selected cases, family studies
were pursued when mutational analysis had detected novel findings.
Genetic Analysis: Genetic analysis was performed on genomic DNA extracted from whole
blood (Gentra). Using previously described primer pairs and methods, each of the first 23 exons
of MYH7 was amplified by the polymerase chain reaction. SSCP was performed for each exon
for every patient to identify anomalous conformers. Anomalous conformers were sequenced
(BigDye Terminator, ABI Prism 310), to detect sequence abnormalities (SeqMan, DNAStar).
RFLPs were predicted from mutant and wild type sequences (MapDraw, DNAStar) and
mutations confirmed by digestion when appropriate endonucleases were available.
Genomic DNA from 200 unrelated control individuals was used as controls; for each novel
mutation detected, 100 control DNAs were screened by RFLP for that mutant. Uniquely in this
area of research, further 100 unrelated controls were screened by SSCP for each exon in which
a mutation had been detected in HCM patients in order to determine if MYH7 heterogeneity
was found in a normal population. This was felt to be important as prior studies had indicated
that HCM causing mutations are likely to be rare in any cohort of genetically unrelated
individuals, including cohorts with HCM.
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Statistics: Data are expressed as mean ± SD. Continuous variables were analysed using
Student's t-test for unpaired data. Non-continuous variables were analysed using Fisher's exact
test. A p-value of <0.05 was considered significant.
3.2.1.4 Results
Prevalence of Known and Novel P-Myosin Mutations in the HCM Population, and Genotype-
Phenotype Correlations: Results of genetic analysis in the 100 patients with HCM and their
clinical findings are presented in Table 7 and Table 8 respectively.
The mutations affect each of the functional domains of the motor unit of myosin (Figure 7).
Seventeen different missense mutations were detected in 19 patients in 11 of the first 23 exons
of MYH7 (encoding the motor domain of beta myosin). Of these, 13 mutations, or 79%, were
novel. The total number of MYH7 mutants associated with HCM increased to 85 from 72, an
increase in 18%, as a result of this study. Of the 4 previously described mutations, one
(Arg403Gln) is associated with a poor prognosis, one (Leu908Val) is associated with a relatively
benign prognosis, and two (Ser782Asn and Arg663His) are associated with atrial fibrillation.
Mutant alleles with the Leu908Val and Arg663His substitutions were found most commonly,
present in 2 and 3 patients respectively. RFLP confirmed the presence of all novel mutations
except for Asn479Ser for which no available endonuclease discriminates.
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Patient Mutation Exon Charge Change Morphology Clinical Findings
I Arg,43Gly 5 positive-neutral ASH No FH
2 Ser'48lle 5 No ASH FH
3 Lys35'Glu 12 positive-negative mid-cavity No FH
4 Arg4°3Gln 13 positive-neutral ASH SD, HCM and DCM in family
5 Asn479Ser 15 No ASH No FH
6 Glu5°°Ala 15 negative-neutral ASH FH with much SD
7 Gly57!Arg 16 neutral-positive ASH AF, No FH
8 Arg66jHis 18 positive-neutral mid-cavity no FH, 'arrhythmia' in family
9 Arg^'His 18 positive-neutral mid-cavity PAF. SD and HCM in family
10 Arg67'Cys 18 positive-neutral ASH PAF, no FH
11 lle736Thr 20 No ASH FH
12 Ser782Asn 21 No mid-cavity PAF, FH
13 Val763Gly 21 No ASH DCM in family
14 Met827Leu 22 No ASH PAF. FH and AF in family
15 Gln882Glu 22 no ASH FH
16, Leu9°8Val 23 No mid-cavity PAF, No FH
17 Leu9o8Val 23 No mid-cavity AF, SD in family
18 Pro2"Leu*+ Arg663His 7 & 18 *no ASH AF, AF in family
19 Lys207Gln homozygote 7 positive-neutral apical AF, heterozygotes bradycardic
Table 7. Beta myosin (MYH7) mutations identified in 100 unrelated patients with HCM.
ASH, asymmetrical septal hypertrophy; SD, sudden cardiac death; AF, chronic atrial fibrillation; PAF, paroxysmal AF;
FH, family history of HCM; DCM, dilated cardiomyopathy.
All Patients MYH7 Mutations Uon-MYH7 HCM
n=100 n=19 n=81 p-value
age at diagnosis 35+18 31+17 36+18 ns
asymptomatic 8 i(5) 7 (9) ns
cardiac arrest 3 O 3 (4) ns
presyncope 66 15 (79) 51 (63) ns
syncope 33 11 (58) 22 (27) 0.01
chest pain 72 14 (74) 58 (72) ns
dyspnoea 86 16 (84) 70 (86) ns
palpitations 68 16 (84) 52 (64) ns
CHF 13 5 (26) 8 (10) 0.07
ICD 8 3 (16) 5 (6) ns
Atrial Fibrillation 32 9(47) 23 (28) 0.17
septum (mm) 21±7 21+7 21+7 ns
posterior wall (mm) 11±2 11+2 10+2 ns
LVIDd (mm) 45-6 44±7 46+6 ns
LVIDs (mm) 26±6 24+5 27+6 0.06
FS (%) 42±7 46+7 4t±7 0.01
left atrium (mm) 44+10 52+11 43±9 <0.001
ASH (iobstruction) 72 13 (68%) 69 (85%) 0.1
Apical LVH 5 1 (5%) 4 (5%) ns
mid-ventricular D 5 ( 28%) 8 (10%) 0.07
Exercise duration (sec) 450+199 438+236 453+194 ns
ABPR 23 5/11 (45%) 18/58 (31%) ns
Table 8: Clinical Characteristics of HCM Patients With and Without Mutant vs. Beta Myosin.
(), per cent; ns, not significant; LVIDd and LVIDs, LV internal dimension in diastole and systole; FS, Fractional

















Figure 7: Functional Domains of Beta Myosin Affected by Mutants Studied.
The domain affected by each individual mutation was predicted from the crystalline structure of the highly
homologous chicken fast skeletal myosin (PDB Id: 2MYS). This structure encompasses the motor region of myosin
which recent studies suggest comprises five major subdomains; the N-terminal subdomain (black); the upper 50-kDa
subdomain (blue); the lower 50-kDa subdomain (grey) and the converter subdomain (green). Following the
converter, a long helical segment of the heavy chain (blue) binds the essential light chain (ELC) and the regulatory
light chain (RLC) together forming the lever arm (Floudusse et at., 2000). The domains are connected by single-
stranded joints such as the relay (yellow) which allow movement of the subdomains relative to each other. The
motor region is shown with the positions of residues affected by each mutant marked; novel mutations are labelled
in red. Approximate positions of residues Lys207, Pro211 and Gly571are shown; residues Lys207 and Pro211 are contained
in loop 1 overlying the nucleotide pocket which is not resolved on the crystal structure. The region around Gly571 is
also missing, and is in a part of the lower 50K-subdomain thought to make contact with actin. Finally Gin882 and
Leu908 are distal within the lever arm and are not seen on this model.
Double heterozygosity and homozygosity; Unexpectedly, both MYH7 alleles were abnormal in
two patients with end-stage HCM. This was one of the first demonstrations of double
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heterozygosity/homozygosity in HCM, a finding subsequently made also by others.25'27'37,38,5;l
Patient 18 demonstrated double heterozygosity for the Arg663His and novel mutation Pro211Leu
(Figure 8a). He presented at 56 years of age with fatigue. An echocardiogram at 63 years
demonstrated a markedly enlarged left atrium (61mm), cardiac hypertrophy (septum 20 mm,
posterior LV wall 10 mm), normal internal LV dimensions and systolic function (end-diastolic
dimension, 36 mm; end-systolic dimension, 22 mm; fractional shortening, 39%), and LV outflow
obstruction (estimated gradient, 55 mm Hg). An echocardiogram at 76 years showed LV wall
thinning (septum 16 mm), impaired LV systolic function, no outflow obstruction, and associated
with chronic atrial fibrillation and symptoms of congestive cardiac failure. Of 3 siblings, one also
inherited both mutations; one the Arg663His mutation only and the third neither (Figure 8a).
New diagnoses of HCM complicated by atrial fibrillation in the siblings with mutant MYH7 were
made following family screening; the sibling with wild-type MYH7 had normal clinical findings.
Patient 19 is homozygous for the novel Lys207Gln mutation (Figure 8b). Asymptomatic HCM was
diagnosed at the age of 47 years following routine electrocardiography. At the age of 64 years
an echocardiogram showed a markedly dilated left atrium (62 mm), apical HCM with a basal
septal dimension of 15 mm increasing to 21mm towards the apex, posterior LV wall 10 mm, LV
end-diastolic dimension 52 mm, LV end-systolic dimension 30 mm and no LV outflow gradient.
The most recent echocardiogram, at the age of 74 years shows increased left atrial (66 mm)
and LV (56 mm in diastole) dimensions. He was treated with an implantable cardioverter-
defibrillator following several episodes of syncope, and has received several appropriate ICD
discharges interventions. He has had admissions with pulmonary oedema and was in NYHA
functional class III and chronic atrial fibrillation. One surviving sibling, all 4 children, and three
grandchildren are heterozygous for Lys207Gln (Figure 8b). This sibling, aged 80 years was
subsequently diagnosed with mid-ventricular obstructive HCM and an interventricular septal
wall thickness of 35 mm. The echocardiograms of a son (43 years), two daughters (46 and 40
years) and three grand children (9, 3 and 15 years) with the Lys207Gln allele were normal.
Several of the family members including all three children heterozygous for Lys207Gln, but





















§ • c c • g « § c
GACCAOAGC
vWVyVwOACCAGAOC





(9) ^ (,3) ^ (,5) t|
Figure 8: Patients with Compound MYH7 Mutants: DNA Sequences and Pedigrees.
A. Sequencing pherograms for patient 18 demonstrate double heterozygosity (Arg663His and PromLeu). In the
pedigree, ages are in parentheses. One sibling has both mutations, another has Arg663His only, and a third neither.
The siblings with mutations were diagnosed with HCM and atrial fibrillation. The sibling with normal MYH7 alleles
has a normal ECG and echocardiogram. B. Pherograms demonstrate homozygosity for Lys207Gln in patient 19. A
sibling heterozygous for Lys207Gln was diagnosed with mid-cavity HCM, but all other family members with a single
mutant allele were normal.
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Comparison of clinical findings of MYH7 and non-/V7VH7-associated HCM: Two groups of HCM
patients are identified; those with, and those without, MYH7 mutations. The groups of HCM
patients were similar with regards age, gender, family history of HCM or sudden death, exercise
performance, and need for pharmacological and/or other therapies. However, patients with
MYH7 associated-HCM were more likely to present with syncope, and had greater left atrial
dimensions despite a similar severity of LV hypertrophy and higher LV fractional shortening,
Table 2. These differences remain significant after exclusion of the two patients with double
mutations. Patients with /WV7-/7-associated HCM also had a greater tendency to develop atrial
fibrillation, but this did not reach statistical significance.
Genetic Analysis of Normal Controls: All novel mutations (except when no endonuclease was
available) were absent from the DNA of 100 unrelated normal subjects following RFLP (200
alleles). SSCP and direct sequencing of all anomalous conformers for MYH7 exons
5,7,12,13,15,16,18,20,21,22 and 23 in 100 other unrelated normal individuals (200 alleles)
identified several neutral single nucleotide polymorphisms. (SSCP for exon 15 was performed
on DNA of all 200 subjects as RFLP was unavailable for Asn479Ser). Thus, in 200 control alleles
no MYH7 missense mutations were present in the 11 exons affected and each novel mutation
was absent from 400 control alleles.
3.2.1.5 Discussion
Yield and Utility of Genetic Screening Methods: Our study demonstrates MYH7 mutations are
detected in about twenty per cent of patients with HCM. Most of these have not been
described, indicating that mutations identified to date account for a fraction of all MYH7
associated HCM. Only 7 of 19 patients (4 of 17 mutations) had mutations that had been
reported previously. Three of these (Arg4°3Gln, Arg663His and Leu9°8Val) are amongst a
relatively few mutations with well-described natural histories that were similar to those of the
unrelated patients in the present study.29,31,39
This magnitude of MYH7 heterogeneity in HCM patients indicates that genetic screening must
be able to identify novel mutations. As most mutations are rare, and may even be unique to
certain families, genetic screening strategies relying on identification of previously determined
mutations (such as RFLP) will have limited yields; clinically applicable techniques will most likely
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rely on sequencing based strategies. Until automated high throughput technologies, such as
those based on chip hybridisation arrays become reliable, considerable time and expense is
required for reliable mutation detection in HCM.
The validity of ascribing causative roles to MYH7 mutations detected in individual HCM patients
can be questioned. Pedigree expansion with linkage analysis, mutant protein functional assays
and transgenic models contribute to greater proof of causal relationships. In practice,
definitive proof of causality will not be available for most detected mutations. The absence of a
mutation from a number of control DNAs, identified by RFLP, is often cited as proof of cause.
This study has shown that MYH7 heterogeneity in HCM patients is such that most mutations
will also be absent in a large population of unrelated HCM patients, just as in normal controls.
While it has been assumed that MYH7 sequence abnormalities are rare in the normal
population, there has been little proof of this. We did not detect any missense sequence
abnormalities by SSCP in 100 normal subjects in each of the exons identified as having
mutations in this series of HCM patients, and did not find the specific abnormalities by RFLP in
100 other controls. Thus, MYH7 is extremely conserved and coding abnormalities are rare in
the absence of cardiomyopathy. For future novel mutations found in these exons of this gene,
it should not now be necessary to demonstrate their absence from control DNA as a routine
element of the genetic diagnosis. For other genes, particularly myosin binding protein C, this
determination is yet to be made. Thus, these novel mutations are likely to cause HCM as (1)
they involve highly-conserved amino acids; (2) the mutations were absent in 400 alleles from
normal subjects; (3) MYH7 shows no sequence variation in 200 normal alleles and; (4) HCM was
present only in family members with mutation
A further complicating factor is that several sarcomeric gene mutations may be present
in the same patient. Homozygosity and double heterozygosity for sarcomeric gene mutations
have been described previously but are assumed to be rare.50,51,227,228 In this series of
consecutive unrelated patients, abnormalities in both alleles of MYH7 were noted in 2% of the
patients or in 10% of those with MYH7 mutations. If sufficiently frequent, occurrence of
multiple mutations would confound linkage studies. It would also diminish our ability to
attribute the disease to a particular mutation and may, in part, explain the phenotypic diversity
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characteristic of HCM. The likelihood of heterozygosity should also be considered in genetic
counselling of at-risk family members.
Screening for molecular causes of HCM is only valuable for management of patients if the
natural histories of the identified mutations are known and shared by families in which HCM is
caused by the identical genetic defect. Unfortunately, the genetic diversity, the rarity of most
mutations, and limited number of affected subjects, render phenotype-genotype correlations
difficult. Therefore, this aspect of management for improving risk stratification in HCM is still
very much in the clinical research domain.
Clinical Differences between HCM Caused by MYH7 and Non-MYH7 Associated HCM; Our
findings suggest that MYH7 associated HCM differs from non-MYH7 associated HCM in certain
important clinical respects. Despite better systolic function and similar LV wall hypertrophy
and frequency of LV outflow obstruction, patients with MYH7 associated HCM had greater left
atrial enlargement. This implies that MYH7 -associated HCM is complicated by a greater LV
stiffness; alternatively MYH7 mutations contribute directly to a primary atrial myopathy.
Affected patients were also more likely to present with syncope, perhaps related to an
increased incidence of arrhythmias such as atrial fibrillation.
Implications for Mutation-Phenotype Correlations: These findings indicate that most HCM
patients have an uncharacterised mutation whose rarity may disallow adequate description of
the associated natural history in unrelated kindreds. Furthermore, once obtained, application
of this information may be limited to few patients. The large number of MYH7 mutations now
described will permit testing of the hypothesis that site and nature of mutations within the
distinct functional domains of |3-myosin determine clinical outcomes. A recent study linked a
Phe764Leu mutation in MYH7 to dilated cardiomyopathy. In our study, a patient with
obstructive HCM (septum of 32 mm) had a mutation in the preceding residue (Val763Gly).
However, a sibling with this mutation presented with cardiac failure and dilated
cardiomyopathy as a teenager, suggesting mutations in this region may predispose to DCM
rather than HCM. In the two individuals with double mutant alleles, one or both mutations
occurred in a loop (loop 1) overlying the nucleotide-binding pocket. Thus, mutations in this
region may, when homozygote, result in only mild and/or poorly penetrant disease.
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3.2.1.6 Conclusions
MYH7 mutations are found in one fifth of HCM patients and are rare in normal subjects. Most
HCM patients have mutations with undescribed natural histories. Mutation detection methods
will have to rely on sequence-based methods. Compound-heterozygosity occurs more
frequently than has been appreciated and may be responsible for some of the phenotypic
diversity and incomplete disease penetrance and for sporadic cases of HCM. Further work on
genotype-functional consequence-phenotype correlation is needed and may be facilitated by
grouping mutant proteins by functional domain affected.
A major advantage of a candidate gene based screening method of consecutive
unselected patients, such as in this study, is that patient selection is not biased towards those
with a well-defined family history where the causative mutation is likelier to have a more
penetrant and severe phenotype.
3.2.1.7 Study Limitations
Results of mutational analysis clearly depend on the patient population and sensitivity of SSCP
(estimated to be 85%). For simplicity we analysed only one gene. Analysis of other sarcomeric
genes was beyond the scope of this investigation, but may demonstrate that multiple
heterozygosity may be even more frequent and further complicate the phenotypic expression
of HCM.
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3.2.2 Clinical Characteristics of Beta Myosin Hypertrophic Cardiomyopathy
3.2.2.1 Abstract
Background: Mutations affecting myh7, encoding beta myosin, are the most commonly
detected causes of HCM. We hypothesized that the severity of the HCM resulting from any
particular sarcomeric mutation is influenced by the nature and severity of the resulting
molecular functional defect. Additionally, routine mutational analysis frequently detects novel
mutations that may be 'private' to the affected family, and for which little or no clinical
information is available. We therefore sought to determine if (1) (3-myosin mutations are
associated with an HCM phenotype distinguishable from HCM not caused by p-myosin
mutations, (2) mutations affecting the same functional sub-domains of p-myosin (mutant sub-
domains) share phenotypic features.
Methods and Results: We compared findings in 90 unrelated patients with HCM caused by one
of 47 mutations in the motor unit of P-myosin and 125 unrelated HCM patients without p-
myosin mutations. P-myosin HCM was diagnosed earlier and was more frequently associated
with syncope, heart failure and family history of sudden death. Despite their younger age and a
similar magnitude of left ventricular hypertrophy and outflow obstruction, P-myosin patients
had larger left atria and more frequently developed chronic atrial fibrillation, syncope and
heart failure admissions. These complications and systolic impairment progressed more rapidly
in P-myosin patients. Non-significant trends were apparent when comparing mutant sub-
domains; a family history of sudden death was commonest for upper 50kDa mutations, heart
failure was more frequent in upper and lower 50kDa HCM, atrial fibrillation was commonest for
lower 50kDa, and left atrial enlargement greatest in upper and lower 50kDa HCM.
Conclusions: HCM phenotypes are difficult to distinguish on the basis of the causative genetic
defect. However, HCM resulting from p-myosin mutations presents earlier, and disease
complications occur more frequently. The greater atrial dimensions and frequency of heart
failure symptoms suggest that atrial myopathy and diastolic dysfunction are particularly
prominent in p-myosin HCM. Mutations affecting the upper or lower 50kDa sub-domains were
associated with more severe and complicated natural histories; this may facilitate prognostic
predictions following the detection of a novel or 'private' causative mutation.
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3.2.2.2 Introduction
Of the 8 genes encoding the principal components of the human sarcomere, the most
extensively studied gene is MYH7, coding p-myosin heavy chain. MYH7 mutations are also the
most commonly detected causes of HCM and most are missense mutations affecting the motor
or head-lever domain of P-myosin heavy chain.26,27,31,32,39,221-223 The Harvard Medical Genetics
database lists more than 190 MYH7 mutations associated with HCM,
(http://genetics.med.harvard.edu/seidman/cg3/index.html) and investigations continue to
detect novel mutations.26,27,229
Genetic diagnoses have the potential to contribute to the management of HCM. For example,
some MYH7 mutations have been associated with high disease penetrance and a high
incidence of sudden death; others with low penetrance and more benign prognosis.29,32,43
However, our ability to associate natural history with a given sarcomeric mutation has at least
two major limitations: [1] the large number and rarity of most individual mutations and, [2] the
high degree of variability between genotype and phenotype.
The varied phenotypes evident within single families are a characteristic of HCM, and
genotype-phenotype descriptions need to encompass such variability. In such a scheme, a
mutation can be viewed as conferring a probability that HCM will develop, and probabilities
that complications will occur. Indeed, it is the likelihood of any particular outcome associated
with a genotype that is most likely to be useful for making clinical decisions. The evaluation of
several individuals with each of the genotypes is required for the estimation of outcome
probabilities. Such studies would be restricted to the more commonly detected mutations,
whereas the majority of mutants are rare or even apparently unique. Families are often small,
with few members available for study.
It is extremely unlikely that the large number of disease causing mutations will ever be
adequately studied individually. If mutants can be clustered into groups based on certain
criteria, phenotype studies may become more feasible. These criteria may include gene
affected, functional domain affected, amino acid charge change or results of in-vitro functional
assays. This clearly represents compromise, and the relative and absolute merits of mutational
groups based on such assumptions are poorly tested. However, the findings presented in the
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previous section27 suggested that despite similar a severity of LVH, P-myosin HCM had clinical
features distinct from HCM resulting from other causes. We therefore sought to evaluate
whether these findings were confirmed in a larger group of patients with 3-myosin HCM.
Furthermore, we assessed a strategy for intra-gene grouping phenotype studies. As recent
studies suggest myosin's motor domain comprises five major sub-domains230, the disruption of
a subdomain's function by any mutation of its constituent residues may each result in similar
consequences. Motility assays that assess the unloaded velocity of actin translocation by
mutant P-myosin correlate poorly with disease severity and penetrance, suggesting that the
cardiomyopathy results from more subtle disturbances of sarcomeric function.39,58,231,232
Sarcomeric disturbances resulting from different mutations may include abnormalities of actin
binding and release, nucleotide binding, hydrolysis and release, conformational changes in the
motor domain, transmission of the power stroke, and interactions with the myosin light chains.
Recent studies suggest myosin comprises five major sub-domains; these relatively rigid sub-
domains articulate about flexible 'joints' during myosin's power stroke.230 We hypothesized
that as the disruption of a subdomain by a mutation in any of its constituent residues might
result in similar molecular consequences, phenotypic characteristics may be shared by mutants
affecting the same sub-domain.
We therefore sought to determine whether HCM resulting from mutant P-myosin has a natural
history distinct from non P-myosin HCM and if MYH7 mutations affecting the same sub-
domain of the P-myosin motor region are associated with similar phenotypes.
3.2.2.3 Methods
Subjects: Subjects studied were all unrelated proband HCM patients attending the Inherited
Cardiac Diseases clinic and studied under approved protocols described above. A proband
patent was defined as the first member of a family evaluated at NHLBI, and a family history of
HCM was considered positive if a suspicious family history was elicited at the first clinic
interview. All proband patients with MYH7 motor domain mutations detected at the NIH
comprised the P-myosin HCM group, and were compared to a series of control HCM patients in
whom MYH7 motor domain mutations had not been detected following mutation detection
(non P-myosin HCM). The MYH7 mutation group comprised those identified in the study above,
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and others in whom prior or subsequent mutational analysis had been completed. HCM
patients in whom more than one MYH7 mutation had been detected were excluded.
Genetic Screening and Myosin Functional Domain affected: Mutational analysis of the first 23
exons of MYH7 was performed on genomic DNA extracted from whole blood as described
above. The functional domain of |3-myosin affected by each mutation was predicted from the
crystalline structure of the motor region of the highly homologous chicken fast skeletal myosin
(PDB Id: 2MYS): the N-terminal, the upper 50-kDa, the lower 50-kDa, the converter and a long
helical segment comprising the lever arm (Figure 9).230 Mutations were also divided into two
groups (conserved and non-conserved substitutions) defined by the presence or absence of a
charge changing amino acid substitution.
This was predicted from the crystalline structure of the highly homologous chicken fast skeletal myosin (PDB Id:
2MYS). This structure encompasses the motor region of myosin, which recent studies suggest comprises five major
subdomains. The motor region of beta myosin is shown from 4 views: the N-terminal subdomain (black); the upper
50-kDa subdomain (blue); the lower 50-kDa subdomain (grey) and the converter subdomain (green). Following the
converter, a long helical segment of the heavy chain (light blue) binds the essential light chain (ELC) and the
regulatory light chain (RLC) together forming the lever arm).230 Sub-domains are connected by single-stranded joints
such as the relay (yellow) that allow movement of the subdomains relative to each other.
Clinical History: Patient histories were reviewed for clinical data including age of diagnosis,
family history of sudden death, and history of complications including congestive heart failure
Figure 9. Functional Domain of Beta Myosin Affected by Each Mutant.
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(CHF), atrial fibrillation (AF), and cardiac arrest. A family history of sudden death was defined as
the death of 1 or more first degree family members under the age of 45 years.
Echocardiography: Transthoracic 2-dimensional echocardiograms were obtained in all subjects.
The following were recorded from standard views: left atrial (LA) size, LV internal dimensions in
diastole and end-systole, septal thickness and Doppler LV outflow tract velocity.
Statistics; Continuous variables were analysed using Student's t-test and categorical variables
with Fisher's exact test. To further compare features between p-myosin and non P-myosin
HCM patients taking age and length of follow-up into account, the data were analysed using
the general linear model. If there was significant interaction between age (or length of follow
up) and p-myosin status, the features of correspondent age (or length of follow up) groups
were compared. A p-value of <0.05 was considered significant. Data are expressed as mean ±
SD.
3.2.2.4 Results
Subjects: 90 P-myosin and 125 non P-myosin HCM patients were studied. The 90 p-myosin
patients had 47 MYH7 missense mutations of 45 residues: 7 mutations were in the N-terminal
subdomain (9 unrelated patients), 11 were in the upper 50-kDa (15), 9 were in the lower 50-
kDa (23), 10 in the converter (22 patients) and 10 in the lever arm (21 patients) (Table 9Table
1). The mutation was charge-changing in 47 of the 91 P-myosin patients, and in 29/47
mutations.
Comparisons of P-myosin with Non P-myosin HCM: Patients with MYH7 mutations were over
10 years younger than non p-myosin patients when diagnosed with HCM and also had a slightly
longer duration of follow-up (Table 10). Gender ratios were significantly different between the
groups; the proportion of male and female patients were equal for P-myosin HCM and there
were significantly more men in non P-myosin HCM. P-myosin patients also more frequently
described family histories of sudden death. Despite their younger age and similar severity of
septal hypertrophy and LV outflow tract obstruction, P-myosin patients more frequently had a
history of syncope and were more likely to have had episodes of CHF. There was a greater
tendency towards the development of AF in p-myosin patients, who also developed
significantly greater LA enlargement.
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Table 9: Allocation of MYH7 Mutants to Domain of Beta Myosin Affected.
Domain assignments and the number of unrelated patients with each mutation are tabulated. All domains of the
motor region are represented, with similar numbers of mutants in each.
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Non- p-myosin HCM P-myosin -HCM
n=125 n=90 P-value
Clinical Features
Age (years) 50±18 40±16 <0.0001
Female 44 (35%) 46(51%) 0.02
Age at diagnosis (years) 39±17 26±14 <0.0001
Length of follow-up (years) 11±9 14±9 0.02
Family history of SD 17 (14%) 26 (29%) 0.009
Syncope 29 (23%) 45 (50%) <0.0001
CHF 19(15) 27 (30) 0.01
Cardiac arrest 6 (5%) 3 (3%) ns
Chest pain 89 (71%) 69 (77%) ns
Dyspnoea 103 (82%) 77 (86%) ns
Chronic atrial fibrillation 14(11%) 18 (20%) 0.08
Echocardiography
Left atrium (mm) 45±10 50±10 0.0008
Septum (mm) 21±6 22±7 ns
Posterior wall (mm) 11±3 10±2 ns
LV gradient (mmHg) 26±31 21±39 ns
Fractional shortening 42±7 39±11 0.09
Table 10. Clinical Characteristics of HCM Resulting From MYH7 Mutations.
Patient demographics, symptoms and echocardiographic findings are shown. SD, sudden death; CHF, congestive
heart failure
Clinical and echocardiographic features of P-myosin and non p-myosin HCM patients were
compared for six different age groups: <20 years, 20-29 years, 30-39 years, 40-49 years, 50-59
years, and >60 years (Figure 10). Symptoms of dyspnoea, syncope, chest pain (not shown),
palpitations (not shown) and the development of AF and CHF episodes were more prevalent
with increasing age in both HCM groups. Syncope increased in prevalence between successive
age groups for P-myosin patients but remained relatively unchanged in non P-myosin HCM.
Complications of CHF (P=0.002) and syncope (P=0.003) developed earlier and were more
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Figure 10. The Natural History of Beta Myosin HCM: The Effect of Age.
Clinical features and echocardiographic dimensions in HCM patients of different ages with or without @-myosin
mutations. *; P<0.05 comparison of non 0-myosin with 0-myosin HCM of the same age-group.
There was a tendency towards the development of chronic AF at a younger age in P-myosin
patients. LA enlargement was greater in p-myosin patients than in non P-myosin patients
(P<0.001). The LA enlarged with age, and was similar in the oldest age groups. The magnitude
of septal hypertrophy was similar in all age groups except in the <20 years group where septal
thickness was greater in P-myosin patients (P=0.03). There was a significant reduction in septal
thickness between age groups when all patients are considered together (P<0.001). LV systolic
function measured as the fractional shortening (FS) appeared to decline steadily between age
groups in P-myosin patients, and was significantly depressed compared to non p-myosin HCM
in the oldest age groups (P<0.05). FS in the oldest P-myosin age group was significantly lower
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than in the youngest p-myosin age group (45±9% and 34 ±11%; P=0.03) but similar in oldest
and youngest non P-myosin age groups (46 ±8% and 41± 9%; P=ns).
As decline in functional status and the development of complications in HCM is frequently
measured against the length of time from initial diagnosis to the most recent evaluation, or
follow-up, P-myosin and non p-myosin patients were compared for similar follow-up periods:
<4-years, 5-9 years, 10-14 years, 15-19 years and >20 years (Figure 11). For each follow up
duration, P-myosin patients were approximately 10 years younger than non p-myosin patients,
reflecting their younger age at diagnosis (P<0.001). Taking length of follow up into account,
syncope was significantly more prevalent in p-myosin than in non p-myosin patients (P=0.04),
but the prevalence of dyspnoea (P=ns) and chronic AF (P=ns) were not significantly different, p-
myosin patients, but not non p-myosin patients, showed a steady increase in the frequency of
CHF between successive follow up durations, and CHF was significantly more common in P-
myosin patients with the longest duration of follow up (P=0.009). The duration of follow up had
an independent effect over above the effect of p-myosin status on the development of
dyspnoea (P=0.026) and chronic AF (P=0.009). LA sizes in P-myosin HCM were significantly
greater than in non P-myosin HCM (P<0.001). The duration of follow up had an independent
effect to that of P-myosin status on increasing LA size (P<0.001) and on declining FS (P=0.008).
Septal wall thickness was significantly greater in P-myosin than non P-myosin patients in the
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Figure 11. The Natural History of Beta Myosin HCM: The Effect of Time from Diagnosis.
+; P=0.01 comparison between non P-myosin and p-myosin HCM for the same follow up duration.
P-myosin Functional Domain Analysis: Echocardiography measurements of septal wall
thickness and LV outflow gradients were similar for all sub-domain groups and non P-myosin
HCM. (Figure 12) Despite these similarities and the relatively small number of patients in each
domain (Table 9), several significant differences are apparent. A family history of SD was far
commoner in patients with upper 50 kDa mutations, present in 53% (8/15) of cases compared
with 24% (18/75) in all other P-myosin HCM (P=0.03) and only 14% (17/125) non- P-myosin
HCM (P=0.001) Lower 50 kDa mutations were was frequently associated with chest pain
(P=0.04), Dyspnoea (P=0.03) and presyncope (P=0.04) than upper 50 kDa HCM. Paroxysmal AF
was detected in 14% (3/22) of converter patients in comparison with 44% (30/68) of all other P-
myosin HCM (P=0.01), 57% (13/23) of lower 50 kDa HCM (P=0.005) and 47% (7/15) of upper 50
kDa HCM (P=0.06). Similarly chronic AF developed in only 5% (1/ 22) of converter HCM in
69
comparison to 25% (17/68) of all other P-myosin HCM (P=0.06) and 35% (8/23) of lower 50kDa
HCM (P=0.02). In converter HCM, episodes of CHF were reported by only 14% (3/22) in contrast
to 35% (24/68) of all other P-myosin HCM (P=0.06) and by 52% (12/23) of lower 50 kDa HCM
(P=0.01).
LA dimension was greatest in the upper and the lower 50 kDa patient groups. LA size in the
upper 50 kDa was significantly greater than in converter (P=0.006), lever arm HCM (P=0.04) and
non p-myosin HCM (P=0.0002). LA size in lower 50 kDa HCM was also greater than in converter
HCM (P=0.01) and non P-myosin HCM (P=0.001). Differences in FS between domains were not
significant. The fractional shortening (FS) in converter domain patients was significantly lower
than non p-myosin HCM (P=0.009), but similar between non p-myosin HCM and all other
domains. The comparatively low rates of CHF in the converter group is in contrast to the lower
FS; however, abnormal LV filling in diastole, rather than LV systolic impairment is held to be the
important determinant of such symptoms.
3.2.2.5 Discussion
A strategy to correlate phenotype with the affected functional domain is fundamentally limited
by the well described infidelity between mutation and phenotype or penetrance within even a
single pedigree.32,233,234
This study reports clinical findings associated with the largest single series of MYH7 mutations
to date. We have shown that P-myosin HCM has features distinct from HCM resulting from
other causes despite the phenotypic heterogeneity characteristic of HCM. In addition, our data
indicate that mutations affecting the same part of the P-myosin molecule may result in similar
clinical outcomes, and that the charge change effect of mutant substitutions has no or limited
effects on phenotypic expression,
HCM patients with P-myosin mutations were diagnosed at a younger age, were more likely to
have a family history of sudden death, and to develop complications at a younger age than
those without P-myosin mutations. Several adverse symptoms and echocardiographic changes
are also apparent sooner after diagnosis in P-myosin HCM. Importantly, these differences were
apparent despite the younger ages of P-myosin patients and similar magnitudes of LV
hypertrophy and LV obstruction.
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A more severe atrial pathology was a particular feature of P-myosin HCM in our series, and may
account for the greater tendency of AF.235,236 LA remodelling has been proposed as a surrogate
marker of an elevated LV diastolic burden237,238 and our findings may reflect greater LV diastolic
dysfunction resulting from P-myosin HCM. Alternatively the more severe degrees of LA
enlargement may represent a more severe primary atrial myopathy. Alpha myosin heavy chain
is the predominant isoform in normal human atrial muscle. However, there is a switch in
expression to the P-myosin isoform in abnormally loaded atria, presumably as part of an
adaptation to elevated atrial afterload.239-242 We suggest that the atrial response to LV diastolic
abnormalities is especially maladaptive in P-myosin HCM, as normal alpha isoform is replaced
by mutant P-myosin.
A history of sudden death was more frequent in upper 50 kDa HCM, a sub-domain that includes
the malignant Arg403His mutant.31,243 In support of our findings, a study comparing only 11
MYH7 mutations reports that actin binding region mutations (included in the upper 50 kDa)
were associated with poorer prognosis.244 In our study, AF, CHF and LA enlargement were also
more severe in HCM associated with upper (and lower) 50kDa sub-domain mutations.
3.2.2.6 Conclusions
Despite similar magnitudes of LV hypertrophy and LV outflow tract obstruction, there
are differences between HCM associated with p-myosin mutations and non p-myosin causes.
Several characteristic features of HCM are more severe and progress more rapidly in p-myosin
HCM. There are some phenotypic similarities in HCM resulting from different mutations in the
same p-myosin sub-domain. Mutations in the upper and lower 50 kDa subdomains may result
in the most severe forms of HCM. The finding that each P-myosin sub-domain may have similar
features could facilitate prognostic predictions when the natural history of the causative MYH7
mutation is as yet undefined.
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Figure 12: Clinical Characteristics of Beta Myosin HCM: Mutant Domain Analysis.
Clinical features and echocardiographic dimensions in HCM patients with mutant beta myosin compared for
functional domain affected. Statistical comparisons are described in the results section.
3.2.2.7 Limitations
The limitations of this study include; (1) The relative frequency of some mutants may bias the
sub-domain description toward that of the mutant. In particular, the Arg663His mutation is
over represented; (2) The non (3-myosin group is used as a control to contrast the behaviours of
p myosin HCM. Phenotypic distinctions between defined non P-myosin or of sarcomeric and
non-sarcomeric causes of HCM are also possible and are not addressed in this study.
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3.2.3 Molecular and Phenotypic Effects of Heterozygous, Homozygous and
Compound Heterozygote Beta Myosin Heavy Chain Mutations
This work was undertaken in collaboration with the University of Vermont, Department of
Molecular Physiology and Biophysics, Burlington, Vermont, USA, and Dakota Cardiovascular,
P.C. Rapid City, SD, USA
All clinical assessment, family screening and mutation detection/genotyping was completed at
or by NHLBI. (J-myosin functional assays were performed by the Vermont group on mutant and
wild-type protein obtained at NHLBI from biceps muscle biopsy. The cardiologists at Dakota
Cardiovascular greatly facilitated the large-scale screening, in South Dakota, of the larger of the
two families (Figure 14) studied here
3.2.3.1 Abstract
HCM has variable penetrance and phenotype. Heterozygous mutations in myh7, encoding (3-
myosin heavy chain, are the commonest cause of HCM, and it has been proposed that
'enhanced' mutant actin-myosin function is the causative molecular abnormality. We studied
individuals from families where members have two, one or no mutant myh7 alleles to examine
for dose effects. In one family, a member homozygous for Lys207Gln had cardiomyopathy
complicated by left ventricular dilatation, systolic impairment, atrial fibrillation and defibrillator
interventions. Only one of five heterozygous relatives had HCM. Leu908Val and Asp906Gly
mutations were detected in a second family in which penetrance for Leu908Val heterozygotes
was 46% (21/46) and 25% (3/12) for Asp906Gly. Despite the low penetrance, hypertrophy was
severe in several heterozygotes. Two individuals with both mutations developed severe HCM.
The velocities of actin translocation (Vartin) by mutant and wild-type (WT) myosins were
compared in the in-vitro motility assay. Compared to WT/WT, Vactin was 34% faster for
WT/D906G and 21% for WT/L908V. Surprisingly Vactin for L908V/D906G and K207Q/K207Q
mutants were similar to WT. However, the apparent enhancement of mechanical performance
with mutant/WT myosin was not observed for mutant/mutant myosin. This suggests that
Vactin may be a poor predictor of disease penetrance or severity and that assays of power
production may be more appropriate, or that the limited availability of muscle samples from
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patients prohibits any definitive conclusions. Finally, severe FICM in heterozygous individuals
occurs despite very low penetrance suggesting these mutations alone are insufficient to cause
HCM and that uncharacterised modifying mechanisms exert powerful influences.
3.2.3.2 Introduction
HCM has been causally linked with gene mutations encoding various components of
the sarcomere, including P-myosin heavy chain (P-MHC). Although expression of mutant
proteins initiates a cascade of events ultimately leading to pathological left ventricular (LV)
hypertrophy, a true mechanistic understanding of this cascade and its initiation are poorly
understood.41 Simplistically, the extent to which a mutant protein's function has been altered
should correlate with the severity of the HCM phenotype and, therefore, characterizing a
mutant protein's functional capacity may aid in developing a mechanistic view of this
hypertrophic response. However, variations in penetrance that occur for a given mutant
protein, even within a given family, suggest that other factors make powerful contributions to
the development of this disease.
As many as 20% of HCM patients possess one more missense mutation of the gene encoding p-
MHC.26,27,229 Myosin is a hexameric protein consisting of two heavy chains and two associated
light chains per heavy chain. Each heavy chain has a globular catalytic head domain that has
actin binding, ATP hydrolytic and motor activities. Beyond the globular head, two heavy chains
associate in an a-helical coiled-coil rod allowing the myosin molecule to polymerise into thick
filaments within the sarcomere. Thus, each myosin molecule is a double-headed structure,
where both heads are necessary for myosin to exhibit its maximal force and motion generation.
245
In most cases, the point mutations are associated with only one P-MHC allele, leading to a
patient that is heterozygous for the mutation such that 50% of the expressed myosin will be of
the mutant form.
Although earlier reports suggest that diminished mutant myosin function was the primary
cause for HCM,58,231,232,246 recent reports from our laboratory suggest that the same mutant
myosins have enhanced function.39,224,225 These and other data led to numerous hypotheses
regarding the aetiology of HCM. For example, LV hypertrophy may develop as a compensatory
response to a mutant's diminished function.58 Alternately, enhanced function could lead to the
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hypercontractile state characteristic of HCM19,41 and may result in heterogeneous force profiles
within the muscle along with depletion of sarcomeric energy reserve 30,247 leading to myocyte
injury, fibrosis and hypertrophy.248
HCM patients with two mutant sarcomeric alleles have been identified by us and
others.27'50'51,228,229'249 Such patients provide an opportunity to compare clinical phenotypes and
mechanical capacity of mutant (3-MHC associated with individuals having one or two mutant
alleles. With two mutant alleles, expression of mutant myosin in which both heavy chains carry
a mutation will exist, which may help define the impact of the mutation on myosin molecular
function. In addition, the penetrance and severity of the disease may be gene dose dependent
which would result in patients with a more severe clinical phenotype. Here we have identified
several patients with point mutations in both P-MHC alleles. These patients were uniformly of a
severe HCM phenotype. Mutant myosin prepared from biopsy of the upper portion of the
biceps muscle obtained from these patients and family members were characterized for the
effect of the mutation on myosin's ability to move actin in a motility assay.
3.2.3.3 Methods
Patients and Genetic Analysis: Patients with HCM and their family members in pedigrees
where two mutant MYH7 alleles had been identified were studied.27 Informed consent was
obtained under protocols approved by the Institutional Review Boards of the NHLBI, (99-H-
0065 and 98-H-0100) and the University of Vermont (IRB00000485).
Clinical studies and genetic analysis were completed as described in the section on General
Methods. Disease penetrance (%) was defined as: (phenotype and genotype positive
individuals/ genotype positive individuals)*100.
Biopsy and Myosin Preparation; Skeletal muscle myosin was isolated from samples of human
biceps tissue (~10 mg) obtained through a small incision over the upper portion of the biceps
muscle in the non-dominant arm under local anaesthesia. The biceps muscle is made up of
about 40-60% slow fibres, 250 which express the cardiac P-MHC isoform. Therefore, the isolated
myosin will be a mixture of both normal and mutant heavy chains as well as fast and slow
skeletal myosin isoforms. This concern was mitigated by comparison of motility results for
myosins isolated from the biceps versus cardiac and coleus tissues (see Results). Myosin
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purification from small tissue samples for use in the in vitro motility assay has been previously
described in detail.39,224,251
The In-Vitro Motility Assay: Standard methods were used for the in vitro motility assay with
special care taken to remove all non-functional myosin.39,252 This last step is critical so that the
internal load contributed by non-functional myosin is eliminated. Actin prepared from chicken
skeletal muscle was fluorescently labelled by incubation in tetramethylrhodamine
isothiocyanate-phalloidin overnight.252,253 Assays were carried out at 30°C using a 30-p.l
chamber to which the following solutions were added and removed39: 1) 100 pg/ml myosin; 2)
bovine serum albumin; 3) 1 p.M unlabeled actin in actin buffer (25 mM KCI, 25 mM Imidazole, 1
mM EGTA, 4 mM MgCI2, 10 mM DTT, oxygen scavengers, pH 7.4); 4) actin buffer with 1 mM
MgATP; 5) 6 x 30 pi washes with actin buffer; 6) 10 nM labeled actin; 7) 1 mM MgATP in actin
buffer with 0.375 % methylcellulose. Step 3 and a comparable step in the initial myosin
isolation procedure removes denatured, rigor-like, non-functional myosin that might act as a
load to the free movement of actin filaments in the motility assay.39,254 Actin movement was
visualized, recorded, and digitally analysed to determine actin filament velocity, Vactin.252,255
3.2.3.4 Results
Genetic Testing and Clinical Correlates of the Molecular Defects: Two HCM pedigrees with two
mutant MYH7 alleles were studied. The mutant alleles were K207Q/K207Q. in family A (figure 7)
and L908V/D906G in family B (figure 8). The D906G is a novel mutant reported here for the first
time. Mutants K207Qand L908V had been reported previously.27,31
In family A (Figure 13), the proband was homozygous for K207Q, a non-conservative mutation
in a loop spanning the ATP-binding pocket. He had been diagnosed with HCM at the age of 47.
Both parents are assumed to be heterozygous. His father died in his mid 40's with a history
strongly suggestive of HCM, but his mother died at the age of 92 years. The proband has
survived to his 70's, but his HCM had been complicated by chronic AF, multiple episodes of
syncope and therapeutic interventions of a defibrillator-cardioverter device. Serial
echocardiograms demonstrate progressive LV dilatation and systolic impairment and reduction
in septal thickness, severe LA enlargement and the development of pulmonary hypertension.
No other family member was homozygous and 9 were heterozygous, including a sister who was
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subsequently diagnosed with HCM at the age of 80 years. She has a history of frequent
presyncope and syncope and a septal wall thickness of 38 mm with mid ventricular obstruction.
There was no history of hypertension. Eight other family members heterozygous for K207Q had
not developed LV hypertrophy at the ages of 46, 43,40, 18, 15, 14, 13, and 9 years (20%
penetrance over the age of 18 years). Five of these individuals have a resting sinus bradycardia













Figure 13. Pedigree of Family with MYH7 Mutant K207Q.
The proband is marked with an arrow. The numbering of individuals corresponds to that the table below (Table 11).
Individual Age (yrs) Heart rate (bpm) Echo
11-2 80 81 HCM
111-1 46 56 Normal
III-2 43 45 Normal
III-3 40 74 Normal
IV-1 18 91 Normal
IV-3 15 54 Normal
IV-2 13 53 Normal
IV-4 13 44 Normal
IV-5 9 48 Normal
Table 11. Cardiac Findings in individuals heterozygous for Beta Myosin Mutant K207Q.
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For the second family (Figure 14), a four-generation pedigree was founded after two brothers
from a family with F1CM married two sisters from another family also with FICM. We
established that each family had a different MYH7 mutation affecting the rod region of pMHC,
a conservative substitution L908V and D906G, a charge changing substitution. Two
descendants have both L908V and D906G and several dozen others have either L908V or
D906G. Both L908V/D906G compound heterozygotes developed FICM, but the penetrance for
L908V/WT was 46% (21/46), and 25% (3/13) for D906G/WT (P=ns). The two double
heterozygotes both had prominent mid-LV cavity hypertrophy, moderate to severe LA
enlargement and paroxysmal AF. LV phenotype in penetrant heterozygotes (both for the
D906G and the L908V) varied from mild LV hypertrophy to severe LV hypertrophy with LV
outflow obstruction. Sudden death and defibrillator discharges were also reported for several
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Figure 14. Pedigree with MYH7 Mutants D906G and L908V.
Only family members with a mutant allele are shown; genotype negative individuals are excluded for clarity and to
promote anonymity.
The in vitro motility assay: The effects of the MYH7 mutations on myosin mechanical function
were assessed by characterizing skeletal muscle P-MHC from biceps muscles. This approach
was similar to that previously used by ourselves and other investigators.39'232 The biceps
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express P-MHC as well as fast skeletal myosin isoforms. To control for any differences in actin
filament velocities resulting from differential expression of the fast skeletal, normal, and
mutant P-MHC rather than an effect due to the mutant myosin itself, we compared the results
from our previous studies of the L908V mutation isolated from both heart and soleus muscle














Figure 15. A Comparison of the In-Vitro motility of Mutant and Wild-Type Beta Myosin.
The Motility Assay compares the velocity of actin translocation (Vactirl) produced by mutant (L908V) and wild-type
beta-myosin extracted from biceps, cardiac and soleus muscle biopsies are compared. Biceps and cardiac muscle
myosins produce similar Vactin, suggesting biceps is a suitable source for (3-myosin heavy chain. The cardiac and
soleus data were published previously by the Vermont group.256.
Normal biceps P-MHC (WT/WT) from control samples moved actin with a Vactin of 1.4±0.1 pm/s,
whereas L908V/WT moved actin 21% faster (p<0.05, figures 3 and 4). The increased Vactin for
the L908V agrees qualitatively with our previous observation of faster Vactin for the L908V when
isolated from either heart (where no skeletal myosin is expressed) or soleus tissue samples
(Figure 15).39,232 Thus, any confounding effects due to the known mixture of fast and slow
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myosin isoforms that are normally expressed in the biceps250 are minimal, allowing the biceps
to serve as a valid tissue preparation for assessing mutant myosin mechanical performance.
Enhanced Vartin was also observed for D906G/WT p-MHC where Vactin was 1.9 ± 0.1 pm/s or 34
% faster than control (P<0.005, Figure 15). In contrast, L908V/D906G p-MHC had Vactin similar
to controls (1.5 ± O.lpm/s). Thus the effect on Vactin of the individual mutations do not appear
to be additive and in fact may even cancel each other. A similar result was observed for the
K207Q/K207Q mutation with Vactin of 1.5 pm/s being similar to normal values. However, as
myosin from a K207Q heterozygote was not available for comparison it is not possible to
compare this double mutant with a K207Q/WT. It is important to note that due to the limited
number of patients (L908V/D906G, n=2; K207Q/K207Q, n=l) it may not be possible to draw any
statistical conclusions.
3.2.3.5 Discussion
The homozygote and double heterozygote patients in this and other reports have a clinical
course characterized by either severe LV hypertrophy51,249 and/or progressive LV systolic
dysfunction, severe LA enlargement and AF,26,27,50 suggesting a gene dose effect on the severity
of phenotypic expression. The phenotypic progression to LV dilatation and systolic impairment
is relatively uncommon, described in only about 10% of HCM patients.257,258 Animal models
exist that demonstrate that the cardiac pathologies of the heterozygote and homozygote
'malignant' sarcomeric protein mutations result in significantly different
cardiomyopathies.259,260 To our knowledge, no non-penetrant homozygote or double
heterozygotes have been reported in humans or homozygous transgenic animal models,
consistent with a view that gene dosage also affects penetrance.259,260
Assaying myosin's molecular mechanics allows us to test the hypothesis that the extent of
alterations to mutant myosin function may be related to the severity of the HCM cardiac
phenotype. If so, then the clinical prognosis for HCM patients may be predicted based on
readily measurable parameter of myosin molecular motor function. Therefore, we isolated
myosin from the biceps muscle of patients with the following mutations: L908V/WT,
D906G/WT, L908V/D906G and K207Q/K207Q and assessed their ability to propel actin
filaments in the in vitro motility assay. This assay serves as a molecular model system to
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characterize the actomyosin interaction that relates to unloaded shortening in muscle. Of note,
the L908V/WT and the D906G/WT mutations enhanced rather than compromised myosin's
unloaded velocity generating capacities. The L908V and D906G are located in the S2-segment
of the myosin rod, far from the motor domain where ATP hydrolysis and actin binding occur.
This raises the important question of how the mutations in the S2 segment can affect the
mechanical performance of the motor domain. The potential for long distance communication
between the catalytic site and domains either proximal or distal to this site are possible
through structural elements within the myosin motor domain (for examples see review 261 ).
Another explanation is that muscle myosin needs both heads to generate maximum force and
motion245 and that coordination of the heads requires the region of the coiled-coil rod near the
S2-segment to unwind or breathe.255 It is possible that the L908V and the D906G mutations
exert their effect through alterations to head-head interactions by virtue of their effect on S2-
segment flexibility.
With patients heterozygous for either the L908V or the D906G mutations, the predominant
mutant myosin specie is a heterodimeric myosin with one normal and one mutant head,
assuming random association of the P-MHC. Therefore, the 20-35% enhanced Vactin for these
mutations may not be the maximum possible effect. Indeed, myosin from a transgenic mouse
homozygous for the R403Q HCM mutation had a 60% enhancement in Vactin compared to a 16%
increase for the heterozygote.224 On the basis of these findings and on the observed severe
clinical phenotype, myosin from patients expressing both L908V and D906G in separate heavy
chains was expected to alter Vactin to a greater extent than myosin heterozygous for either
mutation. However, Vactin was similar to normal controls (Figure 16). A trivial explanation for
the lack of an effect is due to the limited number of patients (n=2), which prevents any
statistically definitive statements from being made. This, too, was the case for the single
patient where both MYH7 alleles code for K207Q, a mutation affecting a surface loop that
spans the entrance to the nucleotide-binding pocket. Therefore, the true effect of having a
double mutation on myosin function cannot be determined at this time, although the severity
of the clinical phenotype for these patients strongly suggests that a mutational effect does exist
for these myosins. The paucity of data on double mutants is due to the apparent rarity of such
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patients, and the probability that the same double mutations are present in other HCM
pedigrees must be exceedingly low.
Figure 16. Comparisons of Vactin for Wild-Type and Mutant Myosin.
* t-test significance at p<0.05.
In the present study, Vactin was the only measured index of contractile function. However, the
normal functioning of the heart is critically dependent on its ability to generate power (the
product of force and velocity). Therefore, changes in Vactin alone may not represent the
fundamental molecular abnormality that ultimately results in the HCM phenotype. Power
producing capacities for mutant myosins have yet to be determined in previous studies and it
may be possible that a mutant myosin exhibits increased Vactin yet generates either reduced or
greater power than normal myosin. Finally, a more precise description of myosin power
production may uncover how the primary insult in myosin function leads to the development
of the HCM phenotype, which is more severe in patients with double P-MHC mutations.
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3.3 Non-Sarcomeric Causes of Hypertrophic Cardiomyopathy: Candidate Gene
Approach for the Detection of Novel Mutations.
Methods for the identification of new genetic causes of HCM include the Candidate Gene
approach and Linkage Analysis. The candidate gene approach identifies genes that are likely, on
the basis of known or presumed function of their protein product, to be involved in some
aspect of the hypertrophic response. Thus, following the detection of a P-myosin mutation
through linkage analysis,221 a candidate gene approach rapidly led to the detection of
mutations in all other 'candidate' sarcomeric genes. Genes that regulate intracellular calcium
concentrations, as well as those that are implicated in calcium-sensitive hypertrophic signalling
are identified as candidate causes of HCM. The role of the products of these genes in mediating
cardiac hypertrophy has been shown by a variety of in-vitro and transgenic animal studies.53,58"
71 Publications and presentations derived from this work are tabulated below (Table 12).
Scientific Sessions
• Mohiddin SA, Antaramian A, Farrell E, Gomez A, Lin J-P, Yu Z-X, Valdivia H, Lameh Fananapazir L. A
Naturally Occurring Sorcin Missense Mutation (F112L) Is Associated with Flypertrophic Cardiomyopathy,
Hypertension, and Impaired Modulation of Cardiac Ryanodine Receptor. American Heart Association,
2002.
• Eisenberg ML, Mohiddin SA, Fananapazir L, Bierer BE. Role of Sorcin in Calcium Homeostasis and Signaling.
American Society for Cell Biology, 2002.
Table 12. Published Research and Presentations of Findings: Non-Sarcomeric Mutations.
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3.3.1 Identification of Candidate Genes and Mutation Detection
3.3.1.1 Introduction
Intracellular calcium concentrations are tightly regulated. Release of Ca2+ from the sarcoplasmic
reticulum (SR) is an important signal transduction mechanism that plays a critical role in
numerous cellular functions. In cardiac myocytes, excitation -contraction (E-C) coupling is a
Ca2+-dependent process; depolarisation opens voltage-dependent Ca2+-channels (L-type or
dihydropyridine receptors, DHPR), allowing a small influx of extracellular Ca2+ (/Ca). ka is
insufficient to evoke full contraction, but triggers a larger release of Ca2+ from the SR through
the ryanodine receptor (RyR), a process termed Ca2+-induced-Ca2+-release (CICR).262-263 CICR
elevates [Ca2+]| to fully contracting levels, and the magnitude and duration of cardiac
contraction depends to a great extent on CICR and the Ca2+ extrusion mechanisms that restore
Ca2+ to resting levels. As Ca2+ is both the trigger and the output of RyRs, CICR is expected to be
an all-or-none event. In intact cells, however, CICR is finely graded by /Ca, implying the existence
of mechanisms that terminate CICR. Several agents, including FKBP12.6, sorcin and
phospholamban modulate RyRs and CICR.70-252"264
In addition to initiating cardiac contraction, Ca2+ mediates many intracellular signals
including those responsible for cellular proliferation and cell death, which, in turn, lead to
cardiac hypertrophy and heart failure.70-265"273 Experimental perturbation of several
components involved in the control of cytoplasmic [Ca2+] both in vitro and in vivo leads to
cardiomyopathic states, characterized by LV hypertrophy, altered myocardial contractility,
diastolic dysfunction, and arrhythmia.70-271 Cytosolic [Ca2+] is reportedly elevated in certain
models of cardiomyopathy, and in others the inhibition of Ca2+ mediated signals prevents
cardiomyopathy.70-265"270-273
3.3.1.2 Methods
Identification of Suitable Genes: A literature review identified several candidate genes, coding
proteins implicated in myocellular calcium regulation or in calcium dependent hypertrophic
signalling. The final selection from the large number of candidate genes thus identified was
made according to (1) the prior description of cardiac hypertrophy in transgenic animal models,
(2) the cardiac specificity of the gene expression, (3) the importance of a gene product's role in
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calcium dependent signal transduction or calcium regulation, as inferred from in-vitro studies,
and (4) on the basis of information available regarding the evolutionary conservation of the
protein sequence.
Following the identification of candidate genes, the genomic DNA structure was established
using BLAST and primer design, SSCP and sequencing was completed as described previously.
Clinical investigations, including expanded family studies are also described above.
3.3.1.3 Results
Candidate Genes Studied: The genes identifies for mutational analysis are listed in Table 13.




Cardiac or ryanodine type 2
Cellular Function
Calcium channel, mediating
CICR from the SR
SRI Sorcin Inhibitor of RyR and CICR
PLN Phospholamban Inhibitor of SERCA re-uptake
of calcium into the SR
CABIN1 CABIN1 inhibits calcineurin-mediated
signal transduction
FKBP 12.6 FK506 binding protein IB Inhibitor of RyR and CICR
Table 13. Genes identified as candidate causes of HCM.
Included in this table are those involved in calcium signalling that have been identified with roles important in
hypertrophic signalling. The concept of the hypertrophic circuit of the cardiomyocyte was introduced earlier in this
thesis (Figure 3).
Mutation Detection: Coding changes affecting the amino acid sequence were detected in RyR2,
PLN and SORCIN. RyR2 and PLN coding changes were subsequently identified as being present
in alleles from control subjects (polymorphisms) or did not co-segregate with the disease in
family members. A heterozygous SRI allele (coding sorcin F112L) was identified in two
unrelated HCM patients, and was absent in the DNA from 198 other unrelated HCM patients
and 200 unrelated control subjects.
Conclusion: Mutations in genes encoding this class of protein are unlikely to make important
contributions as causes of HCM. Rarely, mutations in these genes may, however cause HCM,
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and we have identified one such mutation for further study. As this class of proteins is
implicated in hypertrophic cellular pathways, any polymorphisms identified are worthy of
examination for their potential to modify disease expression.
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3.3.2 Sorcin Mutant (F112L)
This work was undertaken in collaboration with Hector Valdivia's laboratory in the Department
of Physiology, University ofWisconsin.
The F112L sorcin mutation was detected at NHLBI. All subsequent clinical assessment, family
screening, mutation detection/genotyping, smooth muscle cell culture and confocal
microscopy were completed at or by NHLBI. Cloning, expression and mutagenesis of sorcin and
functional assessment were performed by collaborators at the University of Wisconsin. Results
from this collaboration were presented at the American Heart Association's annual scientific
Sessions (2002) and were awarded the Samuel Levine Young Investigator award (S A Mohiddin).
The publication of this sorcin variant has subsequently led to basic research efforts by other
groups, including the development of a mutant animal model and the description of mutant
effects in cardiac myocytes.274,275
3.3.2.1 Abstract
Background: HCM is considered a disease of the sarcomere. However, in many cases a
sarcomeric mutation is not found, indicating diverse aetiologies. Transgenic studies identify
important roles for Ca2+ signalling in hypertrophy. We determined whether F112L sorcin, a
mutation affecting a protein that regulates Ca2+ release by the ryanodine receptor (RyR), was
associated with HCM.
Methods: Family members of proband patients with mutations were clinically evaluated. We
determined sorcin's distribution in human tissue, and assessed mutant protein function.
Results: A missense mutation in sorcin resulting in substitution of a highly conserved amino
acid (F112L) was identified in two unrelated subjects. F112L-Sorcin was significantly associated
with an apical form of HCM (logarithm of odds (LOD) score 3.57) and hypertension (LOD score
3.68) in the two families. F112L-Sorcin was absent in unaffected family members and 200
control subjects. Sorcin was localized to cardiac myocytes, vascular smooth muscle cells,
endothelial cells, and glomerular podocytes. The recombinant mutant F112L-sorcin displayed
markedly attenuated conformational changes in response to Ca2+, a property that allows wild-
type sorcin to translocate from the cytosol to membrane-bound targets (RyR). Wild type (WT)
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Sorcin abolished RyR activity, whereas F112L-Sorcin had no effect. Finally, WT decreased the
amplitude of Ca2+ sparks in ventricular myocytes, but F112L-sorcin had limited effects.
Conclusion: We describe for the first time the association of a sorcin mutation with FICM and
hypertension. The F112L mutant lacks the inhibitory action of sorcin on RyR-mediated Ca2+
release. Our findings suggest that the F112L mutation alters myoplasmic [Ca2+] by impairing
modulation of RyRs by sorcin. In turn, this may account for some FICM and hypertension cases
through several potential mechanisms. Sorcin may represent a novel target for
pharmacotherapy of hypertension and heart failure.
3.3.2.2 Introduction
FICM demonstrates both non-allelic and allelic genetic heterogeneity, and results from
one of more than a hundred mutations in genes encoding sarcomeric proteins.41 Identified
molecular defects account for only half of the cases, and it is likely that non-sarcomeric genes
may also be responsible. Non-sarcomeric causes of FICM are largely uncharacterised, and may
be associated with distinct or compound phenotypes.
We identified a heterozygous SRI allele (coding sorcin F112L) in two unrelated HCM
patients (see previous Chapter), and did not detect this allele in in the DNA of 198 other
unrelated FICM patients and in 200 unrelated control subjects. We therefore investigated
whether mutations in sorcin (chromosome 7q21.1), encoding a 22 kDa protein (198 amino
acids) that regulates intracellular Ca2+ concentration ([Ca2+],) are associated with human
HCM.(16-24)
3.3.2.3 Methods
Subjects. Informed consent was obtained in accordance with a study protocol approved by the
IRB of NHLBI. Following the initial detection of the F112L sorcin allele in two unrelated families,
we sought to evaluate all family members for HCM and hypertension and all were genotyped.
Clinical investigations included history, physical examination, 12-lead electrocardiography,
echocardiography and, in some, CMR imaging. Individuals were either invited to the NIH
Clinical Center in Bethesda, MD, or were evaluated during a field-trip. HCM was defined as a
maximal LV wall thickness of 13 mm or greater in the absence of another explanation for the
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increased wall thickness (>15 mm in patients with hypertension), presence of asymmetrical LV
hypertrophy, and/or LV outflow obstruction. Hypertension was defined as systolic and diastolic
blood pressures of greater than 160 mm Hg and 90 mm Hg, respectively.
Genetic analysis: The genomic structure of sorcin was determined using Basic Local Alignment
Search Tool (BLAST) searches of genomic sequence databases, and PCR primers designed as
described above. Amplifications of exon 5 (encoding the 112 phenylalanine amino acid residue)
was performed using primers; 5'-ATCCTTAGAAAATATCGCAAAATACAG-3'and
5'-ACTTCTACCAATGAATGGAGAGTTCTA-3'. PCR conditions were 35 cycles at 94 °C,
65 °C and 72 °C for 30 seconds each. Control DNA was screened using SSCP, and any
anomalous conformers were sequenced (ABI Prism). The computer package for determining
the association between phenotype and the F112I sorcin mutation was LINKAGE (Version
5.1).276
Tissue preparation and Immunofluorescence: Samples of control human renal artery and
kidney were flash-frozen in dry ice and isopentane immediately upon surgical removal. Samples
of the LV were obtained at autopsy from an adult subject without heart disease. All tissues
were stored at -80 °C until use. Tissues were embedded in Tissue-Tek OCT compound (Ted
Pella, Redding, CA), snap frozen in liquid nitrogen and serially sectioned in a cryostat at a
thickness of 5-10 pm, placed on slides coated with 3-aminopropyltriethoxysilane and stored at
-80 until processed.
Cultured human smooth muscle cells were also studied (37°C fetal bovine serum). Culture
preparations were treated with thapsigargin following which cells were fixed at various time
points. Thapsigargin increases cytosolic Ca by inhibiting the reuptake of Ca into the
sarcoplasmic reticulum (SR).277
For immunolabelling the human tissue samples we used the following primary antibodies singly
or in combination; rabbit polyclonal anti-sorcin278; monoclonal anti-sorcin (Zymed, CA);
monoclonal anti-Von Willebrand factor-VIII (Dako, CA); monoclonal anti-smooth muscle alpha-
actin (Dako, CA); and monoclonal anti-synaptopodin (Research Diagnostics, NJ). Sections were
incubated with primary antibodies overnight at 4 °C, and sections were then incubated for 1
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hour at room temperature with the appropriate FITC- and/or rhodamine conjugated anti-rabbit
and mouse secondary antibodies (Vector, CA). For negative controls, the primary antibody was
replaced by normal IgG. Sections were mounted using Vectashield mounting medium with
nuclear counter stain (Vector laboratories) and examined with a laser scanning confocal
fluorescence microscope (Leica TCS-4D DMIRBE, Germany).
Cultured smooth muscle cell preparations were labelled with similar primary
antibodies, nuclear stains, and with ruthenium red (Sigma) to label the SR.
Structural modelling of sorcin: The structural model of the Ca2+-binding domain of sorcin
(residues 33-198) is based on the homology of sorcin with other members of the penta-EF hand
family of proteins.279 Mutant and wild-type models were generated (Insight ll-Biopolymer
software, Biosym Technologies). A Richardson style rendering of the protein secondary
structure was produced (WebLab viewer, Biosym Technologies).
Planar bilayer technique: Recording of single RyRs in lipid bilayers was performed as described
previously.280 Briefly, a phospholipid bilayer of PE:PS was formed across an aperture of -200
pm diameter in a delrin cup. The cis chamber (900 jul) was the voltage control side connected
to the head stage of a 200A Axopatch amplifier, while the trans chamber (800 pi) was held at
virtual ground. Both chambers were initially filled with 50 mM cesium methanesulfonate and
10 mM Tris/Hepes pH 7.2. After bilayer formation, cesium methanesulfonate was raised to 300
mM in the cis side and 100 to 200 pg of SR vesicles were added. After detection of channel
openings, Cs+ in the trans chamber was raised to 300 mM to collapse the chemical gradient.
Single channel data were collected at steady voltages (-30 mV) for 2-5 min. Channel activity
was recorded with a 16-bit VCR-based acquisition and storage system at a 10 kHz sampling
rate. Signals were analyzed after filtering with an 8-pole Bessel filter at a sampling frequency of
1.5-2 kHz. Data acquisition and analysis were done with Axon Instruments software and
hardware (pClamp v8.0, Digidata 200 AD/DA interface).
Cloning, expression and mutagenesis of sorcin: The human sorcin gene was obtained from
ATCC (New York, NY) and amplified by PCR from the clone YH18D08.RI to introduce Xho\ sites.
The PCR product was then subcloned into pGEX-5x-3 (Pharmacia) using standard procedures.
The mutant F112L-sorcin was constructed according to the manufacturer's instructions
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(QuickChange XL site-directed mutagenesis kit, Stratagene). Wild-type sorcin and F112L-sorcin
were expressed in E. coli BL21 (Promega) and then purified in a Glutathione Sepharose column,
also according to manufacturer's instructions. The recombinant proteins were cleaved from the
column with Factor X activated (Novagen) at room temperature overnight.
Isolation of cardiac cells and Ca2+ imaging: Ventricular cells were isolated by collagenase
digestion of perfused mice hearts.280,281 Cells were suspended in Tyrode medium and kept at
room temperature until used, usually within 6 hours. The cardiac myocytes were permeabilized
with saponin (0 01 % for 45-60 s) in an internal solution containing (mM): 120 potassium
aspartate, 3 MgATP (free [Mg2+] ~1 mM), 10 phosphocreatine, 5 U ml1 creatine phosphokinase,
and 8% dextran, pH 7-2. For measurements of intracellular [Ca2+], myocytes were perfused
with the internal solution described above plus 30 |uM Fluo-4 salt and EGTA/CaCI2 ratios set to
yield 100 nM to 300 nM free [Ca2+], Free [Ca2+] was calculated according to equilibrium
constants given by Fabiato using a computer program (MaxC, Stanford University, CA) and
verified with a Ca2+ electrode.282 Saponin and sorcin were applied onto the cells with a
perfusion system that uses a fast step three-channel micropipette (Warner Instruments).
Confocal images (BioRad MR-1) were recorded with a plan apofluor 60X oil inmersion objective.
The scan line was oriented along the long axis of the cell. Fluo-4 was excited at 488 nm, with
emitted fluorescence measured at 515 nm. Ca2+ transients were reconstructed by stacking 512
consecutive line scans and performing a time-intensity plot using IDL 5.4 software. [Ca2+]i was
calculated using a pseudo-ratio method assuming a Kd and resting [Ca2+], of 1.1 pM and 100
nM, respectively.283 Ca2+ spark frequency, amplitude and intensity were measured with a
computer program running in IDL software. All experiments were performed at room
temperature (21-23 °C).
Ca2+titration of sorcin: As other members of the penta-EF hand family of proteins, sorcin
undergoes structural changes with [Ca2+].284,285 The structural changes were monitored by
measuring the intrinsic fluorescence of the protein. Direct fluorescence titrations of sorcin
were carried out in PBS buffer, 1 mM EGTA and different CaCI2 concentrations to yield the free
[Ca2+] specified in Fig 4. The emission spectrum of sorcin (1-3 pM) in the range of 303 to 400




Genetic Analysis: The missense mutation in exon 5 of sorcin (Figure 17a, b), resulting in
substitution of leucine for phenylalanine at amino acid residue 112 (F112L-Sorcin), was not
detected in 200 unrelated control subjects.. F112 is an invariant residue in a completely
conserved region of sorcin that forms a helix-loop-helix motif known as an EF hand (Figure 17c).
No other missense or nonsense coding abnormalities were detected.
Members of the two affected families were screened for HCM and F112L-Sorcin, and are
designated family A, of European and Native American origins, and family B, which is African-
American (Figure 18). Clinical data was available in 9 of 10 family members with F112L-Sorcin.
Eight of the 9 subjects were noted to have HCM, several with an apical distribution of LV
hypertrophy (Figure 19). The electrocardiogram was abnormal in 6 of the 9 family members
with F112L-Sorcin, including a junctional tachycardia in one subject. All of the 8 patients with
cardiomyopathy had a history of hypertension. The one family member with the F112L-Sorcin
but without LV hypertrophy was hypertensive. Two members of the family, without this
mutation, aged greater than 50 years, also had hypertension, but neither had LV hypertrophy
by echocardiography. The mutation was not present in any family member without























Figure 17. The Detection of a Novel Mutation in Sorcin, a Candidate cause for HCM.
Panel A. PCR products of exon 5 in an affected family member have anomalous electrophoretic mobility (arrow).
Panel B. The corresponding pherogram illustrates the T to C transition at codon 112 in exon 5 (arrow) resulting in
substitution of leucine for phenylalanine. Forward (F) and reverse (R) sequencing is shown in the top 2 rows, and WT
sequence is shown in the lowest row. Panel C. Human and hamster sorcin are 95% similar. Substitution F112L is at
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Figure 18. Genotype and Phenotype of two Families with Mutant Sorcin (F112L).
Figure 19. Cardiac Magnetic Resonance Images in HCM Associated with Mutant Sorcin.
Panels A, B and C. Short axis and four-chamber two-dimensional echocardiographic views, respectively, illustrating
apical hypertrophic cardiomyopathy in the patient lll-l (kindred B). Panels D, E, and F are cardiac MRI images from
patient 111-6 (kindred A); D is a long axis view in end-diastole, and E and F are short axis end-diastolic and end-systolic
images demonstrating severe hypertrophy with almost complete obliteration of the LV cavity.
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F112L-Sorcin is associated with cardiomyopathy and hypertension: HCM has a prevalence of
about 0.1 - 0.2 % in the general population and the apical variant is even less common.
Assuming a phenocopy rate of 1% and a disease penetrance of 90%, (spouses coded unknown),
the logarithm of odds (LOD, see later section) score for the association of the F112L-Sorcin and
cardiomyopathy was 3.48 for family A (p<0.0001), and 3.57 for both families combined (p
<0.00005). To examine the association of hypertension with F112L-Sorcin, variable phenocopy
rates were used; 1%, 3%, 5%, 7%, and 14% for the age groups of 29 years or less, 30-49 years,
50-59 years, 60-69 years, and 70-79 years, respectively.285 Assuming a disease penetrance of
90% (spouses coded unknown) the association between the F112L-Sorcin and hypertension in
family A was 3.65, and 3.68 for both families combined (p = 0.00002).
Sorcin is present in human cardiac myocyte, smooth muscle cells of arteries, podocytes of
renal glomeruli, and cardiac myocytes: Using immunoblot analysis with polyclonal and
monoclonal antibodies, we determined that sorcin was present in human heart, renal artery
and kidney tissues (data not shown). Immunocytochemistry indicated that sorcin is confined to
a peripheral, sarcolemmal location of cardiac myocytes where it may co-localize with both RyR
and DFIPR (Figure 20). In contrast, sorcin was evenly distributed throughout the cytoplasm in
smooth muscle cells, endothelial cells, and podocytes of the glomerulus (Figure 20). Sorcin was
much more abundant in the smooth muscle cells of arterioles than in larger conduit arteries,
suggesting its greater importance in resistance-sized vessels. Endothelial cells of the
glomerulus did not contain sorcin, in contrast to endothelial cells of the arterioles. In cultured
smooth muscle cells, a dynamic and dramatic alteration in the intracellular distribution of





Figure 20. Distribution of Sorcin in Human Heart and kidney.
A: Human left ventricle. (1) Sorcin (labelled green) is confined to a sarcolemmal, or at least peripheral, location in
cardiomyocytes (2). Endothelial cells (arrow) from an intracardiac capillary contain both factor VIII (green) and sorcin
(red). (3) A small intracardiac artery is shown in cross section. Sorcin (red) is present in media smooth muscle cells
and endothelial cells (labelled green for factor VIII). B. Human renal artery. (1) Endothelial cells labelled with factor
VIII (red) of the medium sized renal artery are weakly positive for sorcin (green). Nuclei are stained blue. The media
smooth muscle cells are also weakly positive for sorcin. (2) In contrast, smooth muscle and endothelial cells of a
resistance-vessel sized adventitial arteriole (arrow) in the same renal artery are strongly positive for sorcin (green,
with nuclei stained red). (3) An adventitial artery at higher magnification. C. Human renal glomeruli. (1) Sorcin (red)
is confined to podocytes identified by dual labelling with anti-synaptopodin antibody (green); (2) In contrast to the
endothelial cells in panels A and B, glomerular endothelial cells labelled for factor VIII (green) do not express sorcin
(red). (3) The vascular pole of a glomerulus demonstrates the distribution of sorcin (red) in the afferent/efferent
arterioles and in the podocytes.
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Figure 21. Intracellular Localization of Sorcin in Cultured Vascular Smooth Muscle Cells.
Sorcin (labelled green) is localized in cultured coronary smooth muscle cells before and at various time points
following treatment with thapsigargin (TG). At baseline, sorcin is confined to the cytosolic compartment where it
appears to be evenly distributed. Eighty seconds following treatment with TG, cytosolic sorcin appears in spark-like
concentrations, with this appearance persisting for at least three minutes. At 300 seconds, cytosolic sorcin is
prominently arranged in a striated arrangement, thought to represent co-localization with the endoplasmic
reticulum (ryanodine staining not shown). Sorcin is now also detected in the nuclear compartment, suggesting a role
for sorcin in nuclear signalling. By 10 minutes, Sorcin appears to have largely returned to a baseline distribution,
thought some cells still demonstrate sorcin content.
Predicted changes in the 3-D structure of sorcin induced by the F112L mutation: Sorcin shares
remarkable similarity with other members of the penta EF-hand family of proteins.287 The
canonical EF-hand is a helix-loop-helix motif that coordinates Ca2+ with high affinity and is
typically recognized in analyses of the protein primary structure. In sorcin, the five EF-hand
motifs encompass the majority of the protein (amino acids 33-190) and are proposed to adopt
a three-dimensional arrangement that is similar to that of calpain, another member of the
penta EF-hand family. We used the crystallographic coordinates of the structurally conserved
regions of calpain to model the spatial arrangement of the five EF-hand motifs of sorcin.
Crystallographic data have now confirmed the validity of the model.288,289 Sorcin's F112 is
located in the third EF-hand, at the end of the first helix and before the beginning of the Ca2+-
binding loop (Figure 17 and Figure 22). The net effect of the F112L mutation is the replacement
of the 7-carbon alkyl group of phenylalanine that includes a planar phenyl ring by the 4-carbon
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alkyl group of leucine. In the model, F112 stabilizes the third EF-hand by linking the first with
the second helices through hydrophobic interactions. In energy minimization runs, the
nonpolar core of the phenyl ring cannot be replaced by the shorter alkyl group of leucine,
leading first to destabilization of the third EF-hand, followed by repositioning of the adjacent
EF-hands. This cascade of effects finally results in a thermodynamically stable F112L-sorcin
(Figure 22) that is radically different from WT-sorcin. Thus, the amino acid F112 appears to
contribute importantly to the tertiary structure of sorcin.
ABC
WT Sorcin F112L Sorcin F112L Sorcin
minimal structure before energy minimization minimal structure
Figure 22. Three-Dimensional Structure ofWild-Type and F112L Mutant Sorcin.
All images show a Richardson style rendering of secondary structure, with rods corresponding to a-helices, arrows to
P-sheets, and ribbons to random coil. (A) Minimal structure of WT-sorcin. The phenylalanine residue at position 112
is represented as a CPK structure. (B) F112L-sorcin before energy minimization. Note the gap between a-helices D
and E of the third EF-hand resulting from the absence of the phenyl group of phenylalanine. (C) F112L-sorcin after
energy minimization. Note the severe destabilization of the protein's original conformation.
Effect of the F112L sorcin mutation on Ca2+-induced conformational changes: Sorcin
undergoes conformational changes upon binding Ca2+.284,285 In the absence of Ca2+, sorcin is
largely soluble and likely to be located in cytosolic compartments. Ca2+ binding causes
structural rearrangements that expose large hydrophobic surfaces, allowing sorcin to interact
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with membrane-bound target proteins. These Ca2+-dependent transitions are proposed to
constitute a signalling mechanism that prompts sorcin to exert its cellular effects: in vitro, these
transitions are detected as reductions of the protein's intrinsic fluorescence.284 285 Figure 23 (A)
shows that increasing [Ca2+] gradually quenches the intrinsic fluorescence of WT-sorcin. Similar
to hamster sorcin recombinant human WT-sorcin also undergoes structural reorganization that
exposes tryptophan residues to solvent, decreasing its intrinsic fluorescence.279 A plot of
fluorescence maximum (330 nm) as a function of [Ca2+] yields a sigmoid relationship (Figure 23
B, inset) with ED50(Ca) (the [Ca2+] that causes half-maximal fluorescence quenching, = 2.3 pM).
In sharp contrast, F112L-sorcin has an intrinsically higher fluorescence intensity/nmol protein
(Figure 7B), displays smaller changes in absolute fluorescence, and a lower [Ca2+] is needed to
transition the protein (EDS0(ca) = 0.12 pM). Thus, the F112L mutation appears to reduce sorcin's
plasticity, an effect likely to hinder its response to intracellular Ca2+ signals.








































Figure 23. Fluorescence Emission Spectra of Wild-Type and F112L-sorcin.
(A) Quenching of the intrinsic fluorescence of WT-sorcin (A) and F112L-sorcin (B) by increasing concentrations of
Ca2+. (C) Normalized fluorescence emission at 330 nm for WT-sorcin and F112L-sorcin. Data points were fitted with
the equation E = Emax / [1 + ([Ca2+]/IC50)], where E is fluorescence emission at 330 nm and IC50 is the [Ca2+] necessary
to produce half-maximal fluorescence quenching (WT-sorcin = 2.8 pM; F112L-sorcin = 200 nM). Results are
representative of 6 experiments with less than 10% error.
Effect of F112L-sorcin on RyR: We tested the ability of F112L-sorcin to modulate cardiac RyRs.
Figure 24A and B show traces from continuous recordings of cardiac RyRs reconstituted in
planar lipid bilayers (at +40 mV and activated by ~5 pM cytosolic [Ca2+]). In the absence of
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sorcin, the channel switches between periods of reduced and high activity, which is reflected in
the diaries of channel activity (Figure 24 E and F) as sweeps of high PQ alternating with low PD.
Cis (cytosolic) addition of 1 pM and 2 pM WT-sorcin, severely reduced and completely
abolished, respectively, bursts of high P0, producing marked inhibition of channel activity
(Figure 24 C and E), as reported previously.290 By contrast, similar and higher concentrations of
F112L-sorcin failed to suppress the bursts of channel activity (Figure 24D), producing little
effect on overall channel P0 (Figure 24 F). Thus, F112L-sorcin is incapable of reproducing the
effect of its parent molecule. The structural disarray of F112L-sorcin has a functional correlate.
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Figure 24. Effect of Wild-Type and F112L Sorcin on Cardiac Ryanodine Channel Openings.
Ryanodine Channels are reconstituted in lipid bilayers. Single-channel openings are shown as upward deflections in
all panels. Cs+ is the charge carrier and flows from the trans (luminal) to the cis (cytosolic) side of the channel.
Holding potential: -40 mV. Scale bar is 200 ms (x-axis) and 30 pA (y-axis). (A) and (B) RyR activity under a constant
[Ca2+] of ~5 pM before (labelled "control") and ~ 1 min after the addition of the specified concentration ofWT-sorcin
(C) or F112L-sorcin (D). Traces in each panel are from a single experiment, which is representative of 6 (WT-sorcin)
and 4 (F112L-sorcin) experiments. (E) and (F) are bar representations of the open probability (P0) integrated every
1000 milliseconds. Average P0 under each condition is given in the text.
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Cellular effects of WT-sorcin and F112L-sorcin\ Intracellular Ca2+ waves and Ca2+ sparks, the
elementary Ca2+ release events are manifestations of RyR activity in whole cells.263,291 WT-sorcin
and F112L-sorcin were perfused onto permeabilized cardiac ventricular myocytes to compare
their ability to modulate Ca2+ waves and Ca2+ sparks. To increase the frequency and duration of
spontaneous Ca2+ release events, cells were loaded with Ca2+ prior to permeabilization by
pacing them at 1 Hz for 30 s. Permeabilized cells were also perfused with an internal solution
containing 150 nM free Ca2+ instead of the normal 80-100 nM Ca2+. (4) Increasing Ca2+ load
sensitises RyRs to cytosolic Ca2+,292 and the elevated [Ca2+] in the internal solution drives RyRs
closer to threshold. Under these conditions, mouse ventricular myocytes display several foci of
Ca2+ release readily detected by line-scan confocal microscopy (Figure 25 A, control). These
"hot spots" produce Ca2+ release events that propagate along the cell's longitudinal axis
without colliding with Ca2+ release events from neighbouring sites. These propagating "Ca2+
wavelets" have a greater amplitude and duration than normal Ca2+ sparks but lower than overt
Ca2+ waves.
Perfusion of ventricular myocytes with 1 pM WT-sorcin blunts Ca2+ wavelets and turns them
into discontinuous Ca2+ release events (Figure 25 A, WT-sorcin). The modified release events
resemble isolated Ca2+ sparks indicating that WT-sorcin restrains RyR activity. These results are
in line with the inhibitory effect of WT-sorcin observed on reconstituted RyRs. By contrast,
cells perfused with an identical amount of F112L-sorcin exhibit discrete Ca2+ wavelets, although
their intensity and periodicity are lower than control (Figure 25 B). While WT-sorcin decreases
the average intensity of Ca2+ wavelets from 2.17 to 1.43 F/Fo, F112L-sorcin decreases it from
2.08 to 1.82 F/Fo. Thus, F112L-sorcin may partially block Ca2+ release events in whole cells, in
contrast with its complete lack of effect on RyR activity in bilayer experiments.
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A
Figure 25. Effect of Wild-Type and F112L Sorcin on Ca2+Wavelets and Ca2* Sparks.
Left panels are line-scan images of permeabilized cardiac ventricular myocytes before (labelled "control") and after
perfusion with 1 pM WT-sorcin (A) or 1 pM F112L-sorcin (B). Bar scale: x ms (x-axes) and x pm (y-axes). Right panels
are surface plots of Ca2+ levels of the corresponding figure.
3.3.2.5 Discussion
We have undertaken a candidate-gene approach to determine whether mutations affecting a
protein that regulates Ca2+ release from intracellular stores are associated with HCM.
Numerous transgenic studies have established the importance of similar proteins in cardiac
hypertrophy.41,70,271 This study is the first to determine that abnormalities in this class of genes
are associated with HCM, and the first to establish a role for sorcin in human disease.
We report that a sorcin missense mutation (F112L) is associated with an unusual (apical) form
of HCM and systemic hypertension in two families. We also demonstrate that sorcin is present
in endothelial cells, vascular smooth muscle cells, cardiac myocytes and podocytes of the renal
glomerulus. Ca2+dependent signalling has been shown to mediate several central behaviours of
these cell types, and sorcin may therefore play a significant role in the modulation of Ca2+
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signalling in critical components of the cardiovascular system. The mutant (F112L-Sorcin) also
has a reduced capacity to inhibit RyRs; we hypothesize that F112L-Sorcin precipitates a chain of
events that result in the cardiovascular alterations observed in these individuals.
Association of F112L sorcin mutation with HCM and hypertension: The causality of F112L-
sorcin for the HCM phenotype is supported by the following: (a) highly significant co-
segregation of the phenotype with the mutation; (b) presence in affected members of two
unrelated families from different genetic backgrounds, (c) absence in all unaffected members
of both families, (d) absence in 400 chromosomes from control subjects, and (e) the fact that
F112 is highly conserved across several species, reflecting its functional significance.
Hypertension, which also co-segregated with F112L, could also account for cardiac
hypertrophy. Hypertension is typically associated with symmetrical LV hypertrophy, whilst the
affected patients in our study mostly had asymmetric septal hypertrophy or the uncommon
apical HCM variant. While hypertension has been associated with asymmetric LV hypertrophy,
apical LV hypertrophy is not described in large studies of hypertensive patients.293,294
Additionally, fewer than half of hypertensive patients develop LV hypertrophy.293,295 it is
therefore likely that the severity of LV hypertrophy and its distribution are due, at least in part,
to the cardiac expression of F112L. As with most molecular defects that have been linked with
HCM, phenotypic penetrance associated with sorcin is incomplete suggesting that other
environmental and genetic factors may also be important in determining disease expression.
F112L-sorcin, RyR and DHPR: Sorcin is a Ca2+-binding protein (KDCa ~ 1 pM) member of the
penta EF-hand group of proteins.279 In cardiac myocytes, sorcin localizes to the sarcolemma and
the dyadic junctions, where DHPRs are in close proximity to RyRs.278 In in-vitro experiments,
sorcin is able to bind to RyRs and to reduce its Pa with a Kd < 1.0 pM.(19) Under conditions of
low Ca2+, sorcin dimerizes and remains soluble in the cytosol. In high [Ca2+] sorcin's EF hands
bind Ca2+ and conformational changes expose hydrophobic residues following which sorcin
translocates from soluble (cytosol) to membrane-bound target proteins, presumably
RyRs.284,285,287 It is hypothesized that sorcin dissociates from RyRs when [Ca2+] is low, re-
associating after CICR when [Ca2+] is high. In such a scenario, sorcin's [Ca2+]-dependent
inhibition of RyRs provides a restraint for CICR. Additionally, sorcin has been found to bind to
the pore-forming subunit of the cardiac DHPR, albeit with unknown functional
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consequences.296 Given the proximity of DHPRs and RyRs in the dyadic junction, it is tempting
to speculate that Ca2+-dependent translocation of sorcin mediates inter-channel
communication, modulating DHPR voltage sensitivity according to Ca2+ release from
intracellular stores.
We propose that the F112L-Sorcin mutation fails to modulate RyRs by disrupting sorcin's third
EF hand and impairing Ca2+ responsiveness. In support of this hypothesis we have shown that
activity of isolated RyR are unaffected by F112L-Sorcin and that the formation of Ca2+ waves in
cardiac myocytes is minimally affected by F112L-Sorcin. Sorcin's dose-dependent effect on RyR
activity (Figure 23 and Figure 24) suggests the pathologic mechanism is haploinsufficiency.
Alternatively, mutant sorcin may have a dominant negative effect; for example by competing
with WT for Ca2+ or by dimerizing with WT and inhibiting its response to increases in [Ca2+].
Further studies are necessary to determine interactions of WT-sorcin with F112L-sorcin and
effects of sorcin on DFIPRs. Sorcin's role in cardiac E-C coupling, endothelial or smooth muscle
cell vasomotor control, glomerular function, and in other aspects of Ca2+ signalling are
unknown, but its distribution and the mutant's known functional consequences suggest
potential mechanisms by which F112L sorcin results in cardiomyopathy and hypertension.
F112L-sorcin and cardiomyopathy: Alterations of E-C coupling and Ca2+ handling are common
findings in animal models of cardiac hypertrophy and in hypertrophic and failing human
hearts.70,265"270 This study suggests that F112L-sorcin, by improperly regulating CICR, may be
directly responsible for cardiac hypertrophy. We confirm that sorcin is present in cardiac
myocytes, and demonstrate that F112L-Sorcin is associated with apical or asymmetric HCM and
is incapable of modulating the activity of isolated RyRs. Net alteration in Ca2+ transients may
account, at least in part, for the LV hypertrophy, as the frequency and amplitude modulation of
local Ca2+ release events play a fundamental role in controlling several cell functions which
include hypertrophy, hyperplasia, and cell death.267,270 Additionally, hypertension may
contribute to the cardiac phenotype.
F112L-sorcin and hypertension: The demonstration that sorcin is present in the smooth muscle
cells of smaller arterioles, endothelium and glomerulus, suggests several roles in blood
pressure regulation, through effects on vasomotor tone and/or intravascular volume.
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a) Vascular smooth muscle: Local and global increases in smooth muscle cell [Ca2+] control
myogenic tone297,298, determining systemic vascular resistance. Abnormal regulation of DHPR or
RyR by F112L-sorcin may impair Ca2+ homeostasis in arterial smooth muscle cells, resulting in
hypertension. Incomplete inhibition of RyRs by F112L-sorcin may prevent quenching of CICR
resulting in global [Ca2+] elevation and vasoconstriction.
(b) Modulation of endothelial function: Endothelial cells are actively involved in controlling
arterial vascular tone through production of several vasoactive substances including endothelin
and nitric oxide.298,299 The presence of sorcin in endothelial cells is a novel and intriguing finding
of this study and suggests that sorcin may, through Ca2+-dependent mechanisms, play a role in
endothelial cell-mediated vasomotor control.
(c) Renal control of blood pressure. Sorcin is markedly expressed in podocytes and in the
afferent and efferent glomerular arterioles (Figure 20). Podocytes contribute to the integrity
and regulation of the filtration barrier of the glomerulus.300 Their foot processes contain a
contractile apparatus that responds to vasoactive substances like angiotensin II and endothelin.
These lead to an increase in intracellular Ca2+ by opening intracellular Ca2+ stores.300,301
Abnormalities of podocyte function or in afferent/efferent arteriolar tone may result in
hypertension.
3.3.2.6 Summary
A missense mutation of a conserved residue of sorcin (F112) reduces its ability to
modulate RyRs. F112L-sorcin mutation is associated with apical HCM and hypertension. HCM
may result from the expression of F112L-sorcin in ventricular myocytes, while hypertension
may result from dysfunctional sorcin activity in vascular and glomerular cells. Our findings
establish sorcin as a cause of non-sarcomeric HCM, propose functions for this protein in
cardiovascular and other organs, and may lead to novel therapeutic targets for the therapy of
hypertension, cardiac failure and LV hypertrophy. The association of HCM with sorcin suggests
mutations in similar genes may also cause human HCM and our findings may represent a
template for a novel and distinct form of hypertension with cardiomyopathy.
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3.4 Linkage Analysis for the Detection of Novel Genetic Causes of
Hypertrophic and Dilated Cardiomyopathy.
Large pedigrees with a hereditary disease where the clinical features are unusual or unique
may be suitable for genetic approaches to identify the genetic locus linked with the disease.
Linkage analysis associates any given genetic locus (each locus is usually a polymorphic region
within the genome, such as a microsatellite marker or a single nucleotide polymorphism) a
hereditary trait.302 Meiotic crossover creates allele recombinants; the probability that a known
locus on a chromosome is inherited along with an unknown disease causing gene decreases the
further apart these two locations are on a chromosome, and with an increasing number of
meioses. Gene sequences that are close together on the same chromosome are linked; a map
comprising of a series of markers across the genome in each member of a pedigree can be
analysed for the probability that any given marker is linked with the disease. A logarithm
(power of 10) of odds score (LOD) describes this relationship. A LOD score of 3 indicates the
chances of a marker not identifying the disease causing locus as less than 1 in 1000. Each locus
includes several genes, and following the identification of a disease associated locus, these
genes are examined for mutations. The power of Linkage analysis may be compromised by
incomplete penetrance and by multiple heterozygosity, two phenomena now known to
complicate the development of familial HCM.27 Similarly, phenocopy (similar disease caused by
a different aetiology) also challenges Linkage analysis. The prevalence of hypertension and
heart failure in unselected populations remain hazards for cardiac evaluation and subsequent
linkage of cardiac phenotypes with LVH or LV dilation with genetic maps. Estimated phenocopy
rates are thus incorporated into most Linkage analyses.
The resource demands required for genome-wide scanning for Linkage analysis were
unavailable in our laboratory. Collaborations with larger laboratories were developed when
suitable pedigrees were identified, expanded and characterised by our section. Publications
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3.4.1 Association of Hypertrophic Cardiomyopathy, Sensorineural Deafness,
and a Mutation in Unconventional Myosin VI (MY06)
This work involved collaboration with the Section on Human Genetics, Laboratory of Molecular
Genetics, and the Hearing Section, Neuro-Otology Branch and Section on Gene Structure and
Function, Laboratory of Molecular Genetics of the National Institute on Deafness and Other
Communication Disorders (NIDCD), NIH.
Clinical assessment family screening and DNA collection included a field trip to study family
members. Cardiac evaluation was completed by our section. Audiometric assessment and
linkage analysis was performed by NIDCD.
3.4.1.1 Abstract
Introduction: Familial hypertrophic cardiomyopathy (HCM) is typically confined to a cardiac
phenotype and is caused by mutations in genes encoding sarcomeric proteins. Occasionally
HCM may be one component of a hereditary multi-system disorder. Sensorineural hearing loss
(SNHL) is similarly genetically heterogeneous. Mutations in the MY06 gene, encoding
unconventional myosin VI, have been found to cause nonsyndromic SNHL, i.e. SNHL in the
absence of any other related clinical features.
Methods and Results: Thirty-six members of a kindred in which autosomal dominant SNHL co-
segregates with HCM were evaluated by history, physical exam, electrocardiography,
echocardiography and audiometry. Ten had SNHL, four additionally had HCM. Six had SNHL
without echocardiographic evidence for left ventricular hypertrophy (LVH). Four of these 6
patients had abnormalities on 12 lead electrocardiogram (ECG), three of the six had a
prolongation of the QT interval. Cardiac symptoms were mild or absent in most affected family
members. Genetic analyses suggested linkage of a cardio-auditory phenotype to a region at
6ql3 encompassing the my06 locus. A novel missense mutation (H246R) of my06 affecting the
highly conserved motor domain was detected in all affected members.
Conclusions: We describe a possible cardio-auditory syndrome associated with a dominant
missense mutation in a gene encoding an unconventional myosin. The cardiac manifestations
may escape detection in pedigrees with my06-associated SNHL. Careful cardiologic
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characterization of these families may clarify the etiologic relationships among HCM, SNHL, and
myosin VI.
3.4.1.2 Introduction
Hereditary SNHL shows a great degree of non-allelic and allelic genetic heterogeneity, and can
be dominant, recessive, X-linked or mitochondrial.144 309 311 Hereditary SNHL is classified
according to mode of inheritance and the presence of clinically detectable extra-auditory
manifestations (syndromic deafness) or their absence (nonsyndromic). The distributions of
mutant gene expression are not necessarily restricted to clinically affected organ systems, and
mutant genes associated with "nonsyndromic" deafness may therefore have subtle extra-
auditory manifestations.
Genetic syndromes restricted to a cardio-auditory phenotype include the long QT syndrome
(LQTS) caused by mutations in KvLQTl (KCNQ1) or in KCNE1 where QT prolongation has
autosomal dominant expression (Romano Ward syndrome), but congenital SNHL with LQTS is
autosomal recessive (Jervell and Lange-Nielsen syndrome).74 In the LQTS, cardiac structure is
normal. Schonberger et al recently described a syndrome of dilated cardiomyopathy (DCM) and
SNHL which was linked to 6q23-24 in two families.74 DCM and SNHL penetrance were both age-
related, though SNHL onset was at a much younger age and appears to have been more
penetrant. Non-sarcomeric causes of HCM are largely uncharacterised, and may be associated
with distinct or compound phenotypes.
Here a pedigree co-segregating progressive, late-onset, autosomal dominant SNHL, QT interval
prolongation and cardiac hypertrophy is described. Linkage analysis indicates the causative
gene is located on chromosome 6ql2. We have identified a mutation in MY06, a gene
encoding a non-muscle or unconventional myosin, in all affected members of the pedigree.
3.4.1.3 Methods
A proband patient diagnosed with hypertrophic cardiomyopathy at the age of 35 years
following presentation with chest pain and dyspnoea was referred for evaluation at the
Inherited Heart Diseases section of the NHLBI. The initial evaluation was notable for a strong
family history of bilateral hearing loss, a family history of poorly characterised cardiac problems
and the recent diagnosis of electrocardiographic QT prolongation in two of his three children.
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The hereditary pattern of hearing loss excluded a mitochondrial inheritance and instead was
strongly suggestive of autosomal dominant inheritance. The apparent association of hereditary
hearing loss, LV hypertrophy and QT prolongation suggested a possible novel hereditary
disease; we therefore evaluated all consenting family members.
Subjects: Subjects were studied according to NHLBI (98-H-0100 and 99-H-0065) and NIDCD (97-
DC-0180) protocols approved by the respective Institutional Review Boards. Written consent
was obtained from all family members who participated in the study. Family members were
evaluated by interview, clinical examination, 12-lead ECG, transthoracic echocardiography,
pure-tone and speech audiometry, tympanometry, and acoustic reflex testing.
Clinical Evaluation: Hypertrophic cardiomyopathy was diagnosed when echocardiographic
measurements of left ventricular (LV) wall dimensions were greater than 13 mm in the absence
of other causes of LVH. The QT interval was determined manually from the 12-lead ECG by an
experienced electrophysiologist blinded to patient identity and results of aetiological
evaluations, and the corrected QT (QTc) was calculated using the Bazett formula. The QTc was
considered prolonged if > 470 msec in males and > 480 msec in females.312 Pure tone
audiometry was performed at 0.25, 0.5, 1, 2, 4, 6, and 8 kHz for air conduction and at 0.5, 1, 2,
and 4 kHz for bone conduction. Pure tone averages (PTA) were calculated for air conduction
thresholds at 0.5, 1, 2 and 4 kHz. Individuals were considered affected if they showed bilateral
PTAs greater than the 95th percentile when compared to age/sex-adjusted normative data.313
Genetic analysis: Genomic DNA was obtained from peripheral blood as described above. PCR of
polymorphic short tandem repeat (STR) markers was performed with fluorescent dye-labeled
primers, and STR amplicons were analysed (ABI 377 DNA Sequencer, Genescan and Genotyper
software, Applied Biosystems). After excluding linkage to several known loci for SNHL and
LQTS, a genome-wide scan was performed using the Weber v.9a marker set (10 cM resolution,
Marshfield Medical Research Foundation). Two LOD scores were calculated using the FASTLINK
version of the LINKAGE software package.314 Individuals were assigned to one of three liability
classes based on the SNHL phenotype: class 1 (age > 50) 95% penetrance and 1/100
phenocopy rate; class 2 (age 25 to 50) 90% penetrance and 1/1000 phenocopy rate; class 3
(age < 25) 30% penetrance and 1/10,000 phenocopy rate. Simulated LOD scores were
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generated using SLINK315 and calculated under the assumptions described above. Additional
simulations were based on the cardiac phenotype alone and a single, highly penetrant,
syndromic trait. MY06 was evaluated for mutations using previously described primer pairs
and direct sequencing (Big-Dye Terminators, Applied Biosystems).304
3.4.1.4 Results
Clinical Findings: The proband (111-3) was diagnosed with hypertrophic cardiomyopathy at the
age of 35 years following evaluation for exertional dyspnoea and chest pain (Figure 26). Several
episodes of presyncope and syncope had occurred since age 20. One episode of self-limiting
atrial fibrillation was associated with severe presyncope. A 12-lead ECG showed sinus rhythm
(SR), left atrial hypertrophy (LAH), left axis deviation (LAD), a q-wave in lead AVL, biphasic
septal T-waves and a corrected QT interval (QTc) of 584 msec (Figure 27). Transthoracic
echocardiography shows a non-dilated and hyperdynamic LV, systolic anterior motion of the
mitral valve and normal LV outflow velocities. Magnetic resonance imaging of the heart
measured the anterior septum to be 21 mm, posterior wall 12 mm (normal septum and
posterior wall dimensions 6-llmm), ejection fraction 65% and LV mass 270 gm (mean in
normal adults 87±12 gm). (Figure 28) There was no family history of syncope or sudden death
at a young age.
The proband had bilateral, symmetric, mild-to-severe SNHL affecting high frequencies to the
greatest degree, resulting in a down-sloping audiometric configuration. The onset was in the
early postlingual period of the first decade of life, followed by steady and gradual progression.
Speech audiometry and acoustic reflex testing results were consistent with cochlear hearing
loss. A history of progressive hearing loss affecting several generations within the family was
evident, suggesting autosomal dominant inheritance. The onset and natural history of SNHL
was similar in other affected family members (age range: 5-54 years). The two youngest
affected subjects had SNHL affecting only middle and low frequencies (at five and ten years of
age). In contrast, affected adults had hearing loss affecting all frequencies to varying degrees,
with a variety of audiometric configurations. The highest observed pure-tone average (0.5 / 1 /
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Figure 26. MY06 Mutation, Hereditary Left Ventricular Hypertrophy and Hearing Loss.
Genotype and phenotype are summarized on the pedigree. Several descendants of 11-3 and 11-4 were studied; none
had cardiomyopathy or SNHL and have been omitted from the pedigree to promote anonymity. An "R" below the
pedigree symbol indicates a carrier of the mutant Arg246 allele of MY06; an "H" indicates homozygosity for the




Figure 27. ECGs from Family Members with Mutant MY06.
Leads V1-V3 are shown for all; lead II is also shown for ll-l, 11-2,111-2 and 111-5. All ECGs recorded at 10 mm/mV at rate
25 mm/sec. ll-l, 111-2 and 111-3 all have LVH on echocardiography. 11-2,111-5 and IV-6 had normal echocardiograms. 11-2
has a very prolonged QT interval and 111-5 has borderline first-degree heart block. The ECG in IV-6 was considered
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normal for age (5 years). A stylised recording is shown at bottom to identify the component waves of the ECG
(P,Q,R,S and T) and the QT interval.
Figure 28. Cardiac Magnetic Resonance Imaging in Mutant MY06.
Magnetic resonance cardiac imaging in proband 111-3. The panel on the left is a short-axis view of the patient's mid-
left ventricle in cross-section and a normal left-ventricle is shown in the panel on the right for comparison. Both
images are to the same scale. There is marked hypertrophy of the proband's LV walls, particularly of the
intraventricular septum. RV, right ventricle; LV, left ventricle; IVS, intraventricular septum.
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Figure 29. Composite Puretone Audiograms of Individuals with Mutant MY06.
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The rates of progression and audiogram configurations are highly variable, although all affected subjects were
consistent in that the hearing loss was bilateral and sensorineural.
Clinical evaluation of family members subsequently determined that other family members
who have SNHL also have ECG and echocardiographic abnormalities (Table 15). The most
typical phenotype includes bilateral low-frequency SNHL progressive in severity from the end of
the first decade of life, apical LVH and a prolonged QT interval. In the youngest family member
(IV-6, age 5 years) with early signs of SNHL, no ECG or echocardiographic abnormalities were
detected, and in another with early SNHL, (IV-3, age 10 years) the ECG showed right axis
deviation (RAD), LAH and increased voltages despite a normal echocardiogram. Family member
11-3 was not evaluated in our audiological clinic (age 74 years) and is reported to have a late-
onset hearing loss, several ECG abnormalities and has inferior wall hypokinesia, mitral annular
calcification, and mitral and aortic valve regurgitation on echocardiography. She has no
descendants with SNHL or cardiomyopathy. It was thought that this individual was both a
cardiac and auditory phenocopy. There were no instances of ECG abnormalities detected in
individuals with normal hearing. We concluded that a possible cardio-auditory syndrome was










0-1 75 mutant Yes 5S1 qwave in lead AVL: LVH: LAH: LBBB Apical LVH. SAM, hyperdynamic non-dilated
0-2 S9 mutant Yes 529 Borderline 1'HB Normal for age
H-3* 74 wild-type No 512 qin lead AVL: LVH; LAH; wide QRS complex Mild AI. mod MR. inferior hypokinesia
01-1 39 mutant Yes 468 qm leads OLAVF Apical LVH
01-2 43 mutant Yes 505 q m leads 0.01, AVR; Posthemi Mock; biphasic t-w!aves Apical LVH. trivial SAM
1II-3 36 mutant Yes 584 qm lead AVL; LAD; LAH; bipbasic t-waves Septal LVH
01-4 50 mutant Yes 435 Normal Normal
10-5 41 mutant Yes 459 Borderline |-HB:LAH Normal
IH-6 50 mutant Yes 516 None available
IV-1 12 mutant No 589 borderline QT elevation Normal
IV-3 10 mutant Yes 44? LAH: RAD possibly normal for age Normal
IV-6 5 mutant Yes 424 None Norma!
IV-IO 28 mutant No 425 None Normal
*11-3 was considered a double phenocopy with late-onset 1searing loss and cardiac abnormalities consistent wit valvular an;i ischemic disease
ProlongedQTc durations are in bold type.
LVH-left ventricular hypertrophy
LAH-left atrial hypertrophy
LBBB-left bundle bfsnch block
1®HB-Srstdegree adio-ventricular block
RAD-rightaxis deviation
SAM-systobe anterior motion of the mitral valve
AI-sortie valve incompetence
MR-mitral valve regnrgrtation
q^xQX^RS- q-wave. t-wave. QT interval and QRS complex on die ECG (see figure 2A)
Table 15. Cardiac Abnormalities and Hearing Loss Associated with Mutant MY06.
Clinical details on selected members of the pedigree. Individuals can be identified from Figure 26.
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Genetic Analysis: The pedigree structure and size of family 641 (Figure 26) allows a simulated
maximum LOD score of 4.4, assuming a dominant, syndromic trait with greater than 90%
penetrance in all generations. Consideration of the cardiac phenotype resulted in maximum
simulated LOD scores of only 1.8 (assuming 50% penetrance for LV hypertrophy316). After
excluding loci associated with familial SNHL (at that time), we performed a 10 cM resolution
genome wide scan. Affection status for the purposes of linkage analysis was determined by the
presence of SNHL. Individuals were assigned to one of three liability classes, based on the SNHL
phenotype: class 1 (age > 50) 95% penetrance and 1/100 phenocopy rate; class 2 (age 25 to 50)
90% penetrance and 1/1000 phenocopy rate; class 3 (age < 25) 30% penetrance and 1/10,000
phenocopy rate. No markers showed perfect co-segregation with the SNHL phenotype. The
maximum LOD score obtained was 2.98 with marker D6S1681 at 6ql3. Analyses with additional
markers at 6ql3 revealed that all affected individuals had the same haplotype spanning 30 cM
(D6S1017 to D6S1031). Two individuals, IV-1 and IV-10, were normal for audiological
examination at ages 12 and 28 years respectively, also inherited this haplotype - raising the
possibility of incomplete penetrance.
Genes localized to chromosome 6ql3 include KCNQ5 and MY06 encoding non-muscle myosin
VI; the latter was recently associated with dominant (DFNA22) and recessive (DFNB37)
nonsyndromic sensorineural deafness.304,317 Given that mutations of KCNQ4 caused non-
syndromic deafness (DFNA2) and KCNQ1 cause the cardio-auditory phenotype Jervell and
Lange-Nielson syndrome, we first sequenced the coding exons of the paralogous gene,
KCNQ5,318'319 No mutations in KCNQ5 were found among affected members. Sequence analysis
of the coding exons of MY06 revealed a novel transition mutation, 737A>G, in all affected
members of family 641. This is predicted to lead to the substitution of a conserved histidine
residue for arginine in the motor region of the myosin VI protein (H246R, Figure 30). This
mutation was not detected in the genomic DNA from 351 individuals of a wide variety of ethnic
backgrounds (702 chromosomes). PLN (encoding phospholamban), a gene recently associated
with dilated cardiomyopathy localized to 6q22.1, was also sequenced to test the hypothesis
that the SNHL and HCM phenotypes were etiologically independent but associated due to the
physical linkage of the causative genes on chromosome 6.320 No mutations in PLN were
identified following sequencing of several affected individuals.
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Mouse Q G K E E R N H H I F Y R L C A G A S
Chicken Q G K E E R N Y H 1 F Y R L C A G A P
Sea Urchin Q N G E E R N Y H V F Y Y L C A G A P
Sea Bass Q S N D E R N Y H 1 F Y
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Drosophila Q S A E E R N Y H V F Y M L L A G A P
Figure 30. Residue 246 of MY06 is Highly Conserved Across Species.
3.4.1.5 Discussion
We describe the novel association of progressive, postlingual autosomal dominant
SNHL and hypertrophic cardiomyopathy. There is a previous report of profound, prelingual
autosomal dominant hearing loss associated with HCM; the same group also report a greater
frequency of hearing loss in HCM patients than in other groups with LVH 320 In our pedigree,
linkage and mutation analysis implicate a missense allele (H246R) of the myosin VI gene
(MY06). Another missense allele of MY06 (C442Y) was recently identified as the cause of
dominantly inherited and progressive SNHL (DFNA22); no other clinical features were reported
in affected individuals.317 No cardiac abnormalities were detected in affected individuals with
recessive missense mutations in MY06 (DFNB37).304 In the mouse, mutations of Myo6 cause
hearing loss and vestibular dysfunction, with no other phenotype reported. 321*322'323 However,
MY06 expression in the human heart was demonstrated by Northern blot.321 The cardiac
phenotype reported here may suggest that only certain MY06 mutations are associated with
cardiomyopathy. In our study, the cardiac findings are relatively benign and mild in all except
the proband. Unless echocardiograms and ECGs are part of the clinical evaluation, a mild or
incompletely penetrant cardiac phenotype may be overlooked. Lastly, we cannot exclude the
possibility that the cardiac and SNHL phenotypes in family 641 are unrelated.
The histidine to arginine mutation affects the highly conserved motor region of myosin
VI. Myosin VI is a non-muscle (unconventional) myosin with a property unique from most other
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myosins; most myosins have motor activity towards the 'plus-end' of actin filaments, dimers of
myosin VI are directed towards minus end.324 325 Several non-muscle myosins have been
associated with human hearing .325-328
HCM typically results from mutations affecting genes encoding components of the
myocyte's contractile apparatus.41 More recently, non-sarcomeric causes have been identified,
but none of these genes encodes a non-muscle myosin. Transgenic knockouts of non-muscle
myosin ll-B develop severe structural cardiac defects similar to human congenital heart disease,
suggesting that at least some unconventional myosins are required for cardiac development.329
There is no evidence for congenital cardiac abnormalities in the family we report here. Rather,
like the hearing abnormality, penetrance of the cardiomyopathy is age-related suggesting it
develops as a consequence of prolonged abnormal myosin VI function. Myosin VI dimerizes and
the mutant protein may have dominant negative effects, impairing the dimer's motor function.
Myosin VI is expressed in the human heart, although its intracellular localization and
role(s) are not described.321 In the cochlea the function of myosin VI is unknown. Myosin VI is
found in the cuticular plate of hair cells where it may be important developmentally and
provide protection by restraining mechanical forces.321'323 Myosin VI is also associated with the
Golgi complex and clathrin coated vesicles in several cell types, and may provide motor power
for intracellular transport, exocytosis and endocytosis.325,330 332 Cells lacking myosin VI function
have smaller Golgi complexes and protein secretion is significantly reduced.332 Myosin VI is
found in the leading edges of growth factor-stimulated fibroblasts, and it may participate in cell
migration and shape changes.333,334 Finally, cell division and morphogenesis in Drosophila are
dependent on myosin VI function.334,335 Thus, myosin VI contributes to a broad range of
cytoskeletal and cellular motility functions. In cardiomyocytes, myosin VI is likely to participate
in similar functions, and the development of cardiac hypertrophy (and SNHL) may follow from a
persistent deficiency in one or more of these functions.
3.4.1.6 Conclusions
Progressive autosomal dominant SNHL and mild cardiac hypertrophy may result from
the expression of mutant non-muscle myosin VI. Subtle cardiac manifestations may escape
detection or lead to misdiagnosis in other individuals with SNHL and MY06 mutations.
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3.5 Autosomal Dominant Dilated Cardiomyopathy: Identification of a Novel
Disease Locus on Chromosome 10q26
Clinical assessments of the members of the family described here, including phenotyping were
accomplished during a field trip. DNA was also obtained, as described in the section on general
methods. Linkage analysis was performed the University of Utah and at Harvard Medical School
(Mark Keating's Laboratory). Following the identification of the disease locus, candidate gene
sequencing was performed in our laboratory.
3.5.1.1 Abstract:
Background: Dilated cardiomyopathy (DCM) is a prevalent disorder characterized by cardiac
chamber dilatation and left ventricular (LV) systolic dysfunction. Previous genetic linkage and
candidate gene analyses with DCM families and sporadic patients have revealed heterogeneous
associated loci and genetic causes.
Methods and Results: A family with fifteen individuals affected with DCM was identified. Blood
was collected from all consenting family members for genotypic analysis. After excluding
linkage to established DCM loci, a genome-wide 10 Centimorgan linkage scan using
microsatellite markers was performed and linkage to chromosome 10q26 was identified. The
peak two-point LOD score of 4.45 was obtained with D10S1651, with a multipoint LOD score of
5.69.
Conclusions: A new locus for autosomal dominant DCM on chromosome 10q26 is identified.
3.5.1.2 Introduction
Dilated cardiomyopathy (DCM) is characterized by progressive cardiac chamber dilatation and
systolic dysfunction. Morbidity and mortality occur as a result of end-organ hypo-perfusion,
thromboembolic events, arrhythmias and sudden cardiac death. DCM is aetiologically
heterogeneous and a strong genetic component is evident. In some pedigrees, highly penetrant
autosomal inheritance is clearly seen. In most cases, familial disease is not readily apparent.
Prospective detailed evaluations of relatives of DCM patients detect familial disease, defined as
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one or more relatives with DCM, in 20-25% of the cases.336,337 Autosomal dominant
transmission patterns are most readily detected, but X-linked, recessive, and mitochondrial
transmission also occurs. We sought to determine the cause of DCM in a five generation family
with multiple members referred for management of congestive heart failure due to DCM. A
simplified pedigree is shown below (Figure 31).
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Figure 31. A Family with Autosomal Dominant Inherited Dilated Cardiomyopathy.
Conventions for gender (females denoted by circle) and affectation status (symbols filled in if the DCM phenotype is
diagnosed) are used.
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3.5.1.3 Methods and Results
Phenotypic Characterization Studies were performed in under protocols approved by the
Institute Review Boards of the National Institutes of Health, and the University of Utah. Family
members were evaluated by clinical history, physical examination, 12-lead electrocardiography,
Doppler and 2-dimensional echocardiography. The diagnostic criteria for DCM were
determined from echocardiographic analysis, and consist of an LV ejection fraction of < 50%, or
a fractional shortening <27% on M-mode, or both. The presence of an LV end diastolic
dimension of > 5.5 cm was used as criteria for ventricular dilatation.338 341 Evidence of
secondary causes of cardiac dysfunction, such as coronary artery disease, myocarditis,
hypertension and excessive alcohol consumption were elicited from the medical history,
physical exam and additional testing, if clinically indicated. Clinical evaluation and the
assignation as affected or unaffected phenotype was performed by the NHLBI. Individuals <35
years of age with normal echocardiographic measurements were classified with uncertain
disease status due to age-related penetrance of DCM.
Initial evaluation of family history revealed 10 previously identified members with history of
CHF. We have phenotypically characterized and collected blood from 61 family members. As a
result of exhaustive screening of all living relatives, we identified a total of 16 individuals
affected with left ventricular dysfunction. In addition to DNA from all living family members, we
also obtained banked tissue samples for genotyping four individuals who died as a result of
DCM.
DNA collection Genomic DNA was extracted from whole blood according to standard
protocols. A gel extraction protocol (Qiaquick, Qiagen) modified for tissue extraction was used
to obtain genomic DNA from formalin fixed, paraffin imbedded autopsy specimens.342
Genotypic analysis genome-wide scan was performed with 400 highly polymorphic (average
heterozygosity >70%) short tandem repeat (STR) Genethon markers spaced at 10 Centimorgan
intervals. 343 The fluorescently tagged primers (Perkin Elmer ABI PRIZM linkage mapping set
version 2.0) permitted PCR product detection on a Megabase automated capillary sequencer,
followed by allele calling using the Genetic Profiler program (Amersham/Pharmacia). PCR based
manual genotyping, using 32P-labelled STR primers was performed using established
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protocols.343 PCR products were resolved by electrophoresis on 6% denaturing polyacrylamide
gels (Sequagel) and visualized by exposure to autoradiograph film (XAR, Kodak) at -70oC for 1
to 24 hours, prior to development. All genotyping was performed blinded to each patient's
clinical status.
Linkage analysis Linkage analysis was performed using the LINKAGE 5.1 software package
running on a DEC Alpha 3000 computer administered by the genetics department at Harvard
Medical School.275,344 Initial evidence for linkage was obtained with marker D10S1651 on the
long arm of chromosome 10. Following the genome-wide scan, genotyping in the region
around chromosome 10q26, showing evidence for linkage, was performed using published STR
markers, in order to confirm linkage and refine the map location of the DCM trait. Multipoint
linkage analysis was performed using the VITESSE software package.345 LOD score calculations
for the four non-recombinant markers provided in table 1 were calculated using allele
frequencies determined from a panel of unrelated individuals.
Identification and mutation screening of candidate genes Positional candidate genes were
screened for mutations by direct sequencing. When the defined genomic structure was
available, primers were designed within the flanking intron to permit amplification of the
exonic and splicing sequences as described above. Three genes expressed in ventricular
myocardium were selected for sequencing; NRAP (gene encoding nebulin related anchor
protein), PICOT and ADAM12. PICOT is a putative inhibitor of protein kinase C and may play a
role in inhibition of hypertrophic signals in cardiomyocytes and in the regulation of
contractility.345 ADAM12 is a disintregrin metalloprotinase, a class of proteins that may
contribute to cardiac remodelling.218,347 NRAP colocalizes with nebulin in cardiomyocytes where
it is thought to play a role in anchoring myocyte contractility and in myofibril organisation. PCR
products from two affected individuals were directly sequenced for mutations in PICOT and
ADAM12 (by the Harvard group). The human NRAP sequence had not been determined and we
undertook to describe the genomic structure of this gene (see next chapter) before mutation
detection could be completed. No mutations in ADAM12, PICOT or NRAP were detected
following exhaustive screening of these genes. The identity of the mutant gene responsible for
some cases of DCM at the 10q26 locus remains unknown.
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3.5.2 Genomic Organization, Alternative Splicing, and Expression of Human
and Mouse N-RAP, a Nebulin-Related LIM Protein of Striated Muscle
The work described in this section was begun to enable a search for n-rap mutations in a
pedigree where a DCM phenotype was linked to a 10q26 locus. n-rap had been described in
the mouse, and the human analog localised to 10q24-26.348 To determine the human cDNA
sequence and the genomic structure of N-RAP, we first used BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and other bioinformatics resources to examine human
sequences (genomic DNA libraries and expressed sequence tags - ESTs) for homology with the
murine sequence. It became apparent that the published murine sequence was erroneous, and
that the true gene product significantly differed in length and sequence. In consequence, we
sought to determine the correct mouse sequences, and to determine the human sequence for
the first time. We also established the tissue distribution of NRAP and described splice variants.
All the work described here was completed at NIH. Collaboration was formed with the
laboratory of Robert Horowits at the National Institute of Arthritis and Musculoskeletal and
Skin diseases. Dr Horowits' group published the first murine NRAP sequences349 and had
developed a research programme dedicated to understanding NRAP's cellular role. The
Horowits' laboratory repeated some of their published experimental work using the corrected
NRAP sequence. All other work was performed in our laboratory.
3.5.2.1 Abstract
Introduction: Linkage analysis identifies 10q24-26 as a disease locus for dilated
cardiomyopathy (DCM), a region including the n-rap gene. N-RAP is a nebulin-like LIM protein
that may mediate force transmission and myofibril assembly in cardiomyocytes. We describe
the sequence, genomic structure and expression of human n-rap, as well as an initial screen to
determine whether N-RAP mutations cause cardiomyopathy.
Methods and Results: Human expressed sequence tag databases were searched with the
published 3528 base-pair (bp) mouse n-rap open reading frame (ORF). Putative cDNA
sequences were interrogated by direct sequencing from cardiac and skeletal muscle RNA. We
identified two human n-rap isoforms with ORFs of 5085 bp (isoform C) and 5190 bp (isoform
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S), encoding products of 193-197 kDa. Genomic database searches localize N-RAP to human
chromosome 10q25.3 and match isoforms C and S to 41 and 42 exons. Only isoform C is
detected in human cardiac RNA; in skeletal muscle, approximately 10% is isoform C and
approximately 90% is isoform S. We investigated apparent differences between human N-RAP
cDNA and mouse sequences. Two mouse N-RAP isoforms with ORFs of 5079 and 5184 bp were
identified with ~ 85% similarity to human isoforms; published mouse sequences were
inaccurate and included cloning artifacts truncating the ORF. Murine and human isoforms have
similar gene structure, tissue specificity, and size. N-RAP is especially conserved within its
nebulin-like and LIM domains. We expressed both N-RAP isoforms and the previously described
truncated N-RAP in embryonic chick cardiomyocytes. All constructs targeted to myofibril
precursors and the cell periphery, and inhibited myofibril assembly. Several human N-RAP
polymorphisms were detected, but none were unique to cardiomyopathy patients.
Conclusions; N-RAP is highly conserved and exclusively expressed in cardiac and skeletal
muscle. Genetic abnormalities remain excellent candidate causes for cardiac and skeletal
myopathies.
3.5.2.2 Introduction
Dilated cardiomyopathy (DCM) is characterized by left ventricular (LV) systolic dysfunction and
dilatation. DCM is inherited in about one third of cases and transmission may be autosomal
dominant or recessive, or X-linked.350 Several genetic causes of DCM have been described and
mutations in several other genes have been implicated in transgenic animal studies.351 Many
genes associated with DCM in human and transgenic studies are involved in propagation of
contractile force generated by the sarcomere to the extracellular matrix, leading to the
suggestion that compromised force transmission is one primary cause of DCM.41,350The DCM-
causing genes at many other loci remain unidentified.350
Linkage analysis in a DCM family identifies a locus at 10q24-10q26 as a primary cause of DCM.
The N-RAP gene has been mapped to this region of the genome 349, and is a prime candidate for
involvement in DCM by virtue of its putative role in transmitting contractile force. N-RAP up-
regulation has been found to precede the development of DCM in mouse models of this
disease.352 In addition, N-RAP co-purifies with cardiac intercalated disks, where it is thought to
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link myofibrils to intracellular membrane-associated complexes for effective force
transmission.353 An analogous role has been postulated for N-RAP at the myotendinous
junctions of skeletal muscles.348
Initial analysis of the mouse N-RAP cDNA sequence indicated that it encodes a protein
containing an N-terminal LIM domain and more than two nebulin-related super repeats.348 In
vitro studies with recombinant N-RAP fragments have shown that the N-RAP LIM domain can
bind talin354 and a-actinin,353 while the super repeats bind actin and the tail region of
vinculin.354 Evidence that errors in sequence identity had been made were available; although
the cDNA sequence predicted that mouse N-RAP is 133 kDa, immunoblot analysis identified N-
RAP migrating at 190 kDa on denaturing gels.348
In addition to its postulated role in linking the ends of myofibrils to membrane-associated
complexes, studies in cultured chick cardiomyocytes implicated N-RAP in the process of
myofibril assembly. As these cells spread in culture, immature fibrils containing punctate a-
actinin Z-bodies, a-actin, and muscle tropomyosin are formed.355"359 Time-lapse studies showed
that the closely spaced a-actinin beads in these structures aggregate laterally to form nascent
myofibrils.359 These structures incorporate titin and muscle myosin, the latter of which may
exist as preformed bipolar thick filaments that are oriented and incorporated into the nascent
myofibrils by their interactions with the titin filaments.357,359,360 Like non-muscle myosin lib, N-
RAP is present in all of the myofibril precursors, but is not found in the mature sarcomeres.361
In mature myocytes, N-RAP contains distinct regions that target to the cell periphery, the actin
filaments, and the Z-lines when expressed as GFP-fusion proteins, and over-expression of any
of these regions of N-RAP can inhibit myofibril assembly in the cultured cardiomyocytes.352 This
functional data led to the proposal that N-RAP is an organizing centre during the first steps of
myofibril assembly, controlling the integration of a-actinin and actin to form the first
premyofibril complex at the membrane.362
Here we report the cDNA sequence, genomic structure, and subcellular localization of human
N-RAP. We also compare these data to newly determined mouse N-RAP cDNA sequence as well
as mouse genomic data, and show that the N-RAP gene and gene product are highly conserved
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between species. Finally, we describe polymorphisms in human N-RAP and a screen for N-RAP
mutations in a family with DCM linked to chromosome 10q24-26.
3.5.2.3 Materials and Methods
Subjects: All subjects were studied following their informed consent obtained under protocol
98-H-0100 of the National Heart, Lung and Blood Institute of the National Institutes of Health.
Identification of Human N-RAP cDNA Sequence and Genomic Structure: Complementary
database searches and direct sequencing identified human cDNA and genomic sequences.
Searches of human expressed sequence tag (EST) databases were performed using the Basic
Local Alignment Tool (BLAST) of the National Center for Biotechnology Information (NCBI, at
http://www.ncbi.nlm.nih.gov/BLAST/) with serial segments of the 3528 bp mouse N-RAP cDNA
open reading frame (ORF) as query. Human EST sequences allowed the design of
complementary primers (PrimerSelect, DNAstar, Wl) for the polymerase chain reaction (PCR)
and the amplification and direct cycle sequencing (BigDye terminator, ABI Prism 310, Applied
Biosystems, CA) of sections of N-RAP cDNA. Total RNA was extracted from adult human heart
and skeletal muscle (Quiagen, CA), and 1st strand cDNA synthesized with either random
hexamer or oligo-dT primers (RT-PCR beads, Amersham Biosciences Corp., Piscataway, NJ).
Rapid amplification of cDNA ends (RACE) identified the terminal 5' and 3' cDNA sequences in
adult human skeletal and cardiac muscle cDNA as per manufacturers instructions (Marathon
cDNA, Clontech, CA). Briefly, gene specific primers and adaptor primers complimentary to
incorporated oligonucleotide sequences at the 5' and 3' ends of full-length cDNA allow PCR
amplification and sequencing of cDNA ends. Overlapping cDNA sequences were aligned into a
single contig (Seqman, DNAstar, Wl) that was extended and confirmed by additional rounds of
direct sequencing.
Completed N-RAP cDNA sequences were entered as the query in BLAST and BLAST Like
Alignment Tool (BLAT, at http://genome.cse.ucsc.edu/index.html) against non-redundant (NR)
and high throughput genomic sequence databases to identify intron/exon boundaries.
Genomic DNA structure was required to conform to the constraints of initiation, and
termination, splicing and polyadenylation. PCR primer pairs were designed complementary to
the flanking intronic regions of each exon to allow confirmation of genomic sequence by direct
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sequencing. For genomic DNA Sequencing, human genomic DNA was extracted from whole
blood (Puregene, Gentra, MN).
Identification of Mouse N-RAP cDNA Sequence and Genomic Structure: Using PCR
amplification, RACE and direct sequencing, the full-length mouse N-RAP was re-sequenced
from adult mouse cDNA (Marathon cDNA, Clontech, CA) using methods similar to that used in
human N-RAP sequencing. In addition, the full length open reading frame of adult mouse N-
RAP was amplified by RT-PCR, cloned and sequenced. mRNA was isolated from adult mouse
skeletal or cardiac muscle (Poly(A)Pure, Ambion lnc„ TX) and cDNA was synthesized (GIBCO BRL
Superscript Preamplification System, Life Technologies, MD) with random hexamers as primers.
The full-length N-RAP open reading frame was amplified using a forward (5'-
ATGAATGTGCAGGCCTGCTCT-3') and reverse (5'-TCACATCAGCAGAGTCTTCTT-3') primer
(Advantage2 PCR Enzyme system, Clontech, Palo Alto, CA) using an amplification protocol of 1
cycle at 95 °C for 1 minute; 35 cycles at 95 °C for 30 seconds, then 68 °C for 3 minutes; and
then 1 cycle at 68 °C for 3 minutes. PCR products were gel purified and cloned into the
pcDNA3.1/NT-GFP-TOPO plasmid vector (Invitrogen Corp., Carlsbad, CA). Plasmids were
propagated in One Shot TOPIO E. coli cells (Invitrogen, Carlsbad CA) and purified using the
Quantum Prep Plasmid Miniprep Kit (BioRad Laboratories, Inc., Hercules, CA). The inserts were
completely sequenced as described below.
In addition to amplification of the full-length open reading frame as described above, defined
regions of the adult murine N-RAP transcript were amplified using primer pairs flanking exon 12
(forward: 5'-GACCGATGTGGCCAGGTTTACTCAGAAG-3'; reverse: 5'-
CAGGGGAACCAGCCTCATCGTTGTTTG-3') and exons 37-40 (forward: 5'-
TGATGGGCATGAAAGGGACAGGAT-3'; reverse: 5'-ATCCCCGGGCCCCTCCTGTT-3'). The
amplification protocol used was 1 cycle at 95 °C for 1 minute; 35 cycles at 95 °C for 30 seconds,
then 68 °C for 1 minute; and then 1 cycle at 68 °C for 1 minute.
RNA Electrophoresis: PCR amplification of human skeletal cDNA using primer pairs flanking
exon 12 of N-RAP (forward: 5'-GGTTACCCGGAGGAGTATGAGGAGCACAGG-3'; reverse: 5'-
TCAGCACGGTAATTCACATGACTCAGC-3') produced two electrophoretically sized products of
approximately 550 and 650 bp. Each band was excised from the gel and the DNA extracted.
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Following sequencing to confirm the products as N-RAP sequence, P32 labelled probes
complementary to each product were generated by PCR. An additional probe complementary
to an 113 bp sequence towards the 3' end of N-RAP was also generated by PCR (forward: 5'-
CCAGTGATTTCCGGTACAAAGAGG; reverse: 5'- GAGCCTGCCAACGTTGAGGAAATG). Human
multiple-tissue northern blots (MTN, Clontech, CA) were probed according to the
manufacturers instructions, to confirm the size of full-length N-RAP mRNA.
Immunofluorescence and Immunoblot: Human biopsy samples and adult mouse tissues were
dissected and stored at -80 °C until use. Samples were prepared for immunoblot analysis as
previously described (Luo et al., 1997b). Briefly, samples were homogenized in 12 volumes of
homogenisation buffer (20 mM Tris, 2 mM EDTA, 20 pg/ml leupeptin and 100 pg/ml PMSF, pH
8.0) and mixed 1:1 with 2x SDS sample buffer. Equal amounts of protein were electrophoresed
on Novex 4-20% polyacrylamide gels (Invitrogen, Inc., Carlsbad, CA) and transblotted onto
polyvinylidenedifluride (PVDF) paper. Filters were exposed to a specific polyclonal anti- N-RAP
antibody diluted 1:1000, horseradish peroxidase-conjugated donkey anti-rabbit secondary
antibody diluted 1:5,000 (Amersham), and ECL detection reagents as previously described.348
For sectioning, tissues were embedded in Tissue-Tek OCT compound (Ted Pella, Redding, CA),
snap frozen in isopentane cooled with dry ice, and serially sectioned in a cryostat at a thickness
of 10 pm. The sections were transferred to slides coated with 3-aminopropyltriethoxysilane
and stored at -80 °C. Sections were washed with PBS (phosphate buffered saline, pH 7.4),
overlayed with blocking solution (5% goat serum in PBS) for 30 minutes, and then exposed to
blocking solution containing a 1:1000 dilution of primary anti-N-RAP antibody (Luo et al.,
1997b) for 1 hour. The sections were washed 3 times with an excess of PBS, and then overlayed
with blocking solution containing a 1:100 dilution of fluorescein linked antibody from donkey
against rabbit immunoglobulins (Amersham Biosciences Corp., Piscataway, NJ). After
incubation for 1 hour, the sections were again washed 3 times with an excess of PBS, and then
mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Blocking and
antibody incubations were at 37 °C.
Primary cultures of chick cardiomyocytes were prepared from 7-10 day chick embryos as
previously described.351 After 1 day in culture, the cells were transfected with the full-length
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mouse N-RAP isoform S or C open reading frames newly cloned into pcDNA3.1/NT-GFP-TOPO
as described above, as well as with the vector encoding unfused GFP. Cardiomyocytes were also
transfected with a previously described GPP-N-RAP construct (Carroll et al., 2001). The
transfection mixtures contained 0.5 pg of plasmid DNA and 6 pi of FuGene (Boehringer
Mannheim Corp., Indianapolis, IN), a non-liposomal transfection reagent, in normal growth
media. Samples were fixed 3 days after transfection and stained with monoclonal antibody
against sarcomeric a-actinin (Sigma, St Louis, MO) diluted 1:20; bound primary antibody was
detected using a 1:100 dilution of rhodamine-linked secondary antibody (rabbit anti-mouse
whole antibody, Sigma) as previously described.361
Stained sections and cultured cells were observed with a Zeiss Axiovert 135 microscope
equipped for incident-light fluorescence and phase contrast microscopy using a 63x oil
immersion objective with a numerical aperture of 1.25. Images were collected using a
Photometries CoolSnap fx CCD camera (Roper Scientific, Inc., Tucson, AZ ) interfaced with a
Power Macintosh computer. Quantitative image analysis was performed on a Macintosh
computer using the public domain NIH Image program (developed at the U.S. National
Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). The
percentage of the area of each cardiomyocyte that contained mature myofibrils as visualized by
a-actinin staining was taken as a measure of myofibril content, as previously described.362
Mutation Detection: Genomic DNA was screened for single-strand conformation
polymorphisms (SSCP - as previously described in section on general methods)220 for every
exon in 50 unrelated patients with either DCM or hypertrophic cardiomyopathy that had
progressed to a dilated phase. Anomalous conformers were sequenced in both directions.
Every exon of N-RAP was sequenced from the genomic DNA of two affected members of the
family with 10q24-26 linked DCM.
3.5.2.4 Results
cDNA Sequence and Gene Organization of Human and Murine N-RAP: Two human N-RAP
cDNA isoforms were identified with ORFs of 5085 bp (isoform C; GenBank accession AY177621)
and 5190 bp (isoform S; GenBank accession AY177620), encoding products of 193 and 197 kDa,
respectively. These open reading frames are ~50% longer than predicted by the previously
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published mouse N-RAP sequence.348 To address this discrepancy, we re-sequenced murine N-
RAP cDNA and found that it was highly similar to the newly sequenced human cDNA. We
identified mouse N-RAP isoforms C and S (Genbank accession numbers AY177623 and
AY177622, respectively), with open reading frames of 5079 and 5184 bp, respectively.
Genomic database searches localize human N-RAP to chromosome 10q25.3 and match
isoforms C and S to 41 and 42 exons respectively (BLAST search, UCSC genome build freeze July
2002, Genbank accession AL390197); genomic database searches localize murine N-RAP to
mouse chromosome 19 (NCBI document ID 20890983), and indicate a gene organization similar
to human N-RAP. As illustrated below (Figure 32 A), human and mouse N-RAP genes are each
distributed over approximately 75 kb of genomic DNA. For human N-RAP, exonic and flanking
intronic sequences were confirmed by sequencing from genomic DNA. For mouse N-RAP, the
full-length ORF was amplified from skeletal and cardiac mRNA, cloned into plasmids, and
sequenced. In both humans and mice, the presence of exon 12 in isoform S and its absence in
isoform C is the only difference between the two isoforms.
The exon boundaries in the ORF are completely conserved between mouse and human N-RAP.
An N-terminal LIM domain (residues 6-57) is encoded by the first two exons plus the first codon
of exon 3; the rest of exon 3 encodes a short linker region. Exons 4-41 encode 46 copies of 31-
38 residue repeats that are homologous to nebulin modules (Figure 32 B,C).363,364 For the most
part, each exon encodes a single module; the exceptions are exons 19, 24, 30, 35, and 40,
which each encode two orthree modules (Figure 32 B).
The first 11 modules, encoded by exons 4-14, are single repeats that share 40% similarity with
single repeats near the N-terminus of nebulin. Modules 12-46, encoded by exons 15-41, are
organized into five super repeats each containing 7 modules (Figure 32 D); the N-RAP super
repeats are highly homologous to each other and to nebulin super repeats, sharing 41%
identity and 64% similarity to super repeats near the centre of human nebulin.353'364
The highly conserved organization of exons between human and mouse N-RAP is reflected in
the primary sequence (Figure 33). Human and mouse N-RAP are 84% identical and 90% similar.
The 52-residue LIM domain is most highly conserved, differing by only one residue between
human and mouse N-RAP. The linker region is 75% similar between human and mouse, while
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the simple repeat and super repeat regions are 87% and 93% similar, respectively. The
similarity decreases to 73% in the C-terminal residues that follow the super repeats.
A. N-RAP Gene Organisation
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Figure 32. Structure of N-RAP and its Gene Product.
(A) Schematic representation of exons found in the human and mouse N-RAP genes. The N-RAP gene spans more
than 75,000 base pairs in each species, and the exon organization is conserved. (B) N-RAP domain organization and
corresponding exons. Exons 1 and 2 together encode a LIM domain; exons 4-14 encode single repeating modules;
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and exons 15-41 encode 5 super repeats, each of which contains 7 single modules. Exon boundaries correspond to
module boundaries, except where dashed vertical lines indicate multiple modules encoded by a single exon. Exon 12
is alternatively spliced (filled box). The alignment of human N-RAP modules (C) and super repeats (D) is shown.
Similar residues are boxed.
The alignment also includes the original mouse N-RAP sequence.348 The main difference
between the present results and the previously determined translated sequence is a frame
shift within module 32 resulting from a single nucleotide insertion relative to the new
sequence; this change put a premature stop codon in frame in module 33, resulting in a
truncated open reading frame that did not include the last two super repeats (Figure 33). In
addition, the previously determined N-RAP sequence did not contain module 9, which is
encoded by the alternatively spliced exon 12. Three additional short regions of sequence
mismatch between the original and the new mouse N-RAP sequences are evident in the simple
repeat region; these are the result of frame shifts from single nucleotide insertions or
deletions. Finally, the previously published cDNA does not include exons 37-40.
Alternatively Spliced N-RAP Transcripts in Skeletal and Cardiac Muscles: A 12-tissue human
tissue northern blot incubated with a probe complementary to 113 bp near the 3' end of N-RAP
identifies a single transcript in heart and skeletal muscle of a size equivalent to that predicted
by our sequencing data (Figure 34 A). As expected, N-RAP isoforms differing by only 105 bases
were not resolved by this technique.
In order to detect and compare the relative levels of each isoform expressed, we PCR amplified
a region that included exon 12 and several flanking exons from human and mouse skeletal and
cardiac muscle cDNA. Two bands were detected in skeletal muscle with sizes corresponding to
those expected for products including or excluding exon 12 (Figure 34 B); the results show that
in both mouse and humans, more than 90% of N-RAP transcripts in skeletal muscle include
exon 12. In contrast, only the smaller PCR product was detected in cardiac muscle, showing
that cardiac N-RAP does not contain exon 12. These differences were confirmed by direct
sequencing of both products in human cDNA.
Since exons 37-40 are not found in the originally sequenced mouse N-RAP cDNA, we searched
for alternative splicing in this region by PCR amplifying exons 36-41 from mRNA. A single
prominent band was detected in mouse skeletal and cardiac muscle with a size corresponding
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to that expected from the new N-RAP sequence (Figure 34). In contrast, no PCR product was
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Figure 33. Alignment of Human and Murine N-RAP Protein Sequences.






Figure 34. Differential Expression of N-RAP Splice Variants in Cardiac and Skeletal Muscle.
(A) Northern blot detection of N-RAP in 12 human tissues. A 5-6000 base pair sized product is identified only in
skeletal and cardiac muscle. (B) PCR amplification of NRAP cDNA from skeletal muscle (S) and heart (H) between
exons 10-16 in humans and exons 9-14 and 36-41 in mouse. The expected sizes using the human exon 10-16 primers
are 650 bp and 550 bp for isoforms S and C, respectively, and the expected sizes using the mouse exon 9-14 primers
are 549 bp and 444 bp for isoforms S and C, respectively.
N-RAP Protein in Skeletal and Cardiac Muscles: Immunoblotting identifies a single ~190 kDa
band as N-RAP in adult mouse skeletal and cardiac muscles (Figure 35A), as previously reported
and in agreement with the sequences presented above.353 A band with the same mobility is
detected in blots of adult human skeletal muscle and heart, along with a prominent band
migrating at ~65 kDa. Immunofluorescence with this antibody demonstrates that N-RAP is
specifically concentrated at the intercalated disks in human hearts (Figure 35 B,C), a localization
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pattern that is identical to that previously observed in mouse hearts.353 The results are
consistent with the smaller band detected in human striated muscles being a proteolytic
fragment of N-RAP, but do not rule out the possibility that this is an unrelated intercalated disk
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Figure 35. N-RAP is Localized to the Intercalated Discs in Skeletal and Cardiac Myocytes.
(A) Total proteins from mouse and human striated muscles separated by SDS polyacrylamide gel electrophoresis and stained with
coomassie blue (left panel), and corresponding blot probed with anti-N-RAP antibody (right panel). Lanes 1 and 2 were loaded with
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adult mouse skeletal muscle and heart homogenates, respectively, and lanes 3 and 4 were loaded with human skeletal muscle and
heart homogenates, respectively. Immunoblot detection reveals a major band at ~190 kDa in all samples, corresponding to the
molecular weight predicted from the full-length cDNA sequences. An additional band is detected at ~65 kDa in the human samples.
The positions of molecular weight markers and predominant muscle proteins (myosin heavy chain and actin) are indicated. (B,C)
Frozen section of human cardiac muscle stained with N-RAP antibody and imaged with phase contrast (B) or fluorescence (C)
optics. N-RAP is concentrated at the intercalated disks (arrowheads). Autofluorescent, phase dense lipofuscin granules are also
visible (arrows).365
We used primary cultures of embryonic chick cardiomyocytes as a model system in which to
observe the targeting and phenotypic effects of N-RAP isoforms. Our previous work showed
that myofibrillar components are diffusely localized after 1-2 days in culture, but after 3-4 days
are organized into mature striated myofibrils.361,352 We found that this time-course of myofibril
accumulation could be reproducibly quantified by measuring the percentage of the
cardiomyocyte area containing mature myofibrils, as defined by broad periodic bands of a-
actinin staining.352 Our previous studies showed that GFP-tagged N-RAP domains could inhibit
myofibril accumulation in this system.362
We expressed full-length mouse N-RAP isoforms S and C as GFP-fusion proteins in primary
cultures of embryonic chick cardiomyocytes; for comparison, we also transfected cells with the
truncated mouse GPP-N-RAP construct previously thought to be the full-length cDNA.362 This
construct is identical to N-RAP isoform C except that it does not include the last two super
repeats. To visualize myofibrillar structures, cells were fixed and stained with antibodies against
sarcomeric a-actinin. Cells were transfected at day one and fixed at day four, since our
previous study showed that this protocol yields maximal effects on myofibril assembly.352
We found that the truncated N-RAP was associated with myofibril precursors and the cell
periphery, but did not remain associated with mature sarcomeres (Figure 36 A-D). Many
examples were found in which the truncated N-RAP appeared to inhibit myofibril accumulation
(Figure 36 C,D), as previously reported.362 In contrast, GFP alone was diffusely distributed in
transfected cells, and did not affect myofibril accumulation (Figure 36 E,F).
Like the truncated N-RAP, both full-length N-RAP isoforms were associated with myofibril
precursors and the cell periphery, but did not remain associated with mature sarcomeres
(Figure 37 A-B, E-F). In addition to incorporating into myofibril precursors, we observed many
cardiomyocytes in which over expression of either isoform apparently inhibited myofibril
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assembly (Figure 37 C-D, G-H). Quantification of the extent of myofibril accumulation shows
that both of the full-length N-RAP isoforms as well as the truncated isoform C significantly
inhibit myofibril assembly when compared to myocytes expressing GFP alone (Figure 38); in







Figure 36. Expression of N-RAP Inhibits Myofibril Accumulation.
Cultured embryonic chick cardiomyocytes transfected with GFP-tagged NRAP constructs (A-D) or GFP alone (E,F).
Double exposures show a-actinin staining (left panels) and GFP fluorescence (right panels). Truncated N-RAP fusion
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protein is found in myofibril precursors characterized by closely spaced or continuous a-actinin staining (arrows) and
at the cell periphery, but not in mature sarcomeres identified by periodic wide bands of a-actinin (A-B). In addition,
many cells were observed in which truncated N-RAP appeared to have inhibited myofibril accumulation when
compared to neighbouring untransfected cells (C,D). In contrast, cells transfected with GFP alone exhibited GFP












Figure 37. Chick Cardiomyocytes Transfected with N-RAP Splice Variants.
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Constructs encode GFP-tagged mouse N-RAP isoform C (A-D) or isoform S (E-H). The GFP-tagged proteins are
visualized in green (right panels), and alpha-actinin staining is visualized in red (left panels). Each N-RAP fusion
protein is found in myofibril precursors characterized by closely spaced or continuous alpha-actinin staining (arrows)
and at the cell periphery, but not in mature sarcomeres (A-B, E-F). In addition, many cells were observed in which
each construct appeared to have inhibited myofibril accumulation (C-D, G-H).
25-i
QFP isoform S isoform C truncated
isoform C
Construct
Figure 38. Myofibril Content in Cardiomyocytes expressing N-RAP constructs.
Each full-length N-RAP isoform, as well as the truncated isoform C that lacks the C-terminal two super repeats,
inhibits myofibril accumulation to the same extent when compared to cardiomyocytes expressing GFP alone. Each
bar represents the mean ± sem from 24-27 cells. Values for the N-RAP constructs are significantly different from GFP
alone (p < .01).
Genomic Sequencing and Cardiomyopathy: Several polymorphisms causing single amino-acid
sequence changes were detected in 50 unrelated DCM or HCM patients and normal controls
(table 1). We found no coding sequence or splice donor/acceptor abnormalities that were
unique to members of the family with DCM linked to chromosome 10q24-26.
3.5.2.5 Discussion
The genomic and cDNA sequences for human and mouse N-RAP have been identified. N-RAP is
expressed as at least two splice variants in cardiac and skeletal muscles, where there is a
degree of isoform specificity. Sequence analysis indicates that N-RAP has a highly conserved N-
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terminal LIM domain followed by either 10 or 11 simple repeats and then by 5 highly conserved
C-terminal super repeats, each of which contains 7 single repeats. The N-RAP super repeats are
most similar to those found in the central region of nebulin, a large actin-binding protein of
skeletal muscle composed of a C-terminal SH3 domain, 22 central super repeats, and simple
repeats linking the super repeats to the non-repetitive C-terminal and N-terminal regions.363,364
The N-RAP simple repeats are most similar to the simple repeats near the N-terminus of
nebulin.
N-RAP is a much larger protein than previously reported, containing an additional two super
repeats at the C-terminal end (Figure 33). Cloning and sequencing artefacts are likely to have
been responsible for errors in the published sequence. The sizes of the N-RAP mRNA detected
by northern blot and the N-RAP protein detected by immunoblot, both previously348 and in this
report, are consistent with the predictions of the sequence presented here. In addition, we did
not detect transcripts missing exons 37-40 by RT-PCR (Figure 34), as predicted from the
previously published mouse N-RAP sequence. Interestingly, human N-RAP cDNAs with large
numbers of exons missing are represented in the Genbank database (e.g. accession numbers
AK056605, AK096875). Flowever, to date there is no evidence that these smaller forms
represent actual functional transcripts.
The two N-RAP splice variants identified differ by a single 105 bp exon which encodes a single
4.1 kDa nebulin-like repeat. These size variants, and perhaps other isoforms, have to date not
been resolved by RNA or protein electrophoresis. The repetitiveness and conservation of
domain coding within individual exons suggests that yet further splice variations may alter the
number, specificity or separation of the nebulin-like repeats. The inclusion of exon 12 in the
predominant skeletal isoform adds a single nebulin-like repeat, and may be fundamental to
differences in the role of N-RAP in skeletal and cardiac muscle; in adult cardiac muscle N-RAP is
concentrated at the intercalated disc, whereas in skeletal muscle N-RAP is localized at the
myotendinous junctions.348
In cultured embryonic chick cardiomyocytes, N-RAP is found in the earliest myofibril precursors
found at the cell periphery.361 We found that both full-length N-RAP isoforms targeted to the
cell periphery and to myofibril precursors when expressed as GFP-fusion proteins (Figure 37),
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and that they were equally effective in inhibiting myofibril assembly (Figure 38). Previously we
showed that the N-RAP LIM domain targets to the cell periphery, while the simple repeat
region targets to Z-lines and the super repeats target to actin filaments.362 Over-expression of
each N-RAP region interfered with myofibril assembly, leading to a model in which N-RAP acts
an organizing centre during the first steps of myofibrillogenesis, controlling the assembly of a-
actinin and actin into Z-bodies with associated thin filaments.362 Inhibition of this process by
over expressing full-length N-RAP suggests that the stoichiometry of the molecular components
found in pre-myofibrils is critical for proper assembly to take place. Alternatively, murine and
chick N-RAP may have significant differences, or yet other N-RAP isoforms may be expressed in
the developing myocyte. The truncated N-RAP previously described362 contains the LIM
domain, the simple repeats, and three of the five super repeats, and exhibits localization and
inhibition of myofibril assembly that is indistinguishable from the new full length N-RAP
constructs.
Unfortunately, our expression studies in chick cardiomyocytes have not revealed any functional
differences between the N-RAP isoforms. This may be because the single module encoded by
the mouse skeletal muscle-specific exon has a binding partner that is only expressed in skeletal
muscle; a second possibility is that the isoform difference is a mammalian adaptation that does
not occur in avian muscles. Further work will be needed to test these hypotheses.
The early upregulation of N-RAP in mouse models of DCM352, along with its likely involvement
in force-transmission and cardiomyocyte development348'354'362, indicate that genetic
abnormalities affecting N-RAP are excellent candidate causes of familial cardiomyopathy. A
screening and sequencing strategy using genomic DNA has not identified mutations likely to
cause DCM in a family with DCM linked to a locus that includes N-RAP, or in 50 unrelated
cardiomyopathy patients. However, several polymorphisms have been detected (Table 1) and
these may contribute to a genetic milieu that modifies the expression of several cardiac and
skeletal muscle diseases.
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RESIDUE JBSTITUTION A CHARGE
207 GTG-GGG VAL-GLY 0->0
208 GTG-GCG VAL-ALA 0->0
249 TAT-TGT TYR-CYS 0->0
282 GCT-ACT ALA-THR 0->0
344 GCT-ACT ALA-THR 0->0
360 CAG-CGG GLN-ARG 0->P
484 GAC-AAC ASP-ASN N->0
490 TCG-TTG SER-LEU 0->0
519 AAT-ATT ASN-ILE 0->0
674 GCC-GTC ALA-VAL 0->0
884 CGC-TGC ARG-CYS P->0
966 GAT-GGT ASP-GLY N->0
1069 TTT-TTA PHE-LEU 0->0
1112 GCG-GTG ALA-VAL 0->0
1183 GTT-ATT VAL-ILE 0->0
1531 CTG-CCG LEU-PRO 0->0
1566 CGC-TGC ARG-CYS 0->P
1681 GCT-GTT ALA-VAL 0->0
Table 16. Coding changes detected in human N-RAP.
Residues are numbered according to the longer skeletal isoform (N-RAP isoform S). Residue charges are indicated as
neutral (0), negative (N), or positive (P).
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4 Clinical Studies
4.1 Cohort Clinical Studies
Prospective and retrospective observational studies of cohorts of HCM patients comprise the
majority of clinical HCM research. Indeed, the viability of large research HCM units has
depended on their ability to maintain data on large cohorts of patients referred for tertiary
opinion. From these databases specific data sets are examined for relationships with outcomes
usually of premature death or success following intervention for symptomatic LVOTO. In the
clinic, the majority of our working knowledge comes from these studies. The risk of bias in
these studies is very real. Publication bias, bias inherent in studies of tertiary centre cohort
studies (or any with implicit or explicit inclusion criteria) and those resulting from double-
unblinded, non-randomised studies completed by enthusiastic stake-holder principal
investigators dependant on profile for future funding.
This section describes a retrospective study that examines claims, published in the New
England Journal of Medicine366, that the presence of systolic compression of epicardial arteries
(commonly referred to as myocardial bridging) in children with HCM is powerfully and
independently associated with SD risk. The authors also advocated cardiac surgery or coronary
stenting in treatment.
Other retrospective studies that were completed at NIH are not presented here; Table 17
includes references to that work.
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Table 17. Published Research and Presentations of Findings: Clinical Studies.
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4.1.1 Myocardial Bridging in Children with Hypertrophic Cardiomyopathy
Quantification of sudden death (SD) risk in HCM remains somewhat of a holy grail. Children and
adolescents (aged 18 years or less) diagnosed with HCM are thought to have particularly high
sudden death risks (Figure 39). In addition, lifestyle changes (such as avoidance of exercise) are
more subject to non-compliance and therapeutic strategies (such as implantable defibrillators)
are subject to more complications than for adult patients.
In 1998, Yetman et al published a retrospective study in the New England Journal of Medicine
with an astonishing claim; almost all SD in children with HCM was likely to be caused by
myocardial ischaemia resulting from myocardial compression of epicardial coronary arteries
(coronary 'bridging').365 The authors suggested that, in affected individuals, surgical division of
the muscular bridge overlying the coronary arteries may lead to an improved prognosis.
Furthermore, in their study, myocardial bridging developed independently of the magnitude of
hypertrophy, and other important clinical features of the disease.
The claim that a single risk factor could accomplish risk stratification with nearly perfect
predictive power (Figure 39) stood in contrast to the marked heterogeneity that is a prominent
feature of HCM. The clinical implications of the study, particularly with the status afforded by
the nejm, included routine cardiac catheterisation in all children with HCM. A large minority
would subsequently be considered for with major cardiac surgery.
Children with HCM referred to the Inherited Cardiac Diseases section at the NHLBI
were routinely considered for inclusion in research protocols, many of which included cardiac
catheterisation and myocardial perfusion scintigraphy. We therefore examined the cohort of
children that had undergone selective coronary angiography at the NIH.367,370,371
4.1.1.1 Abstract
Background: It has recently been suggested that systolic compression of epicardial coronary
arteries is an important cause of myocardial ischaemia and sudden death (SD) in children with
hypertrophic cardiomyopathy (HCM). We examined the associations between systolic
compression of the coronary vessels and their intramural (septal) branches with myocardial
perfusion abnormalities and clinical outcome in children with HCM.
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Results. Angiograms from 57 children with HCM were reviewed for the presence of coronary
and septal artery compression. Coronary compression was present in 40 % of the children. The
left anterior descending artery was most commonly affected and multiple sites found in 4
children. Myocardial perfusion abnormalities were more frequently present in children with
coronary compression than in those without, (94% versus 47%, p=0.002). Coronary
compression was also associated with more severe septal hypertrophy and higher left
ventricular (LV) outflow gradient. Septal branch compression was present in 65% of the
children and was significantly associated with coronary compression, severity of LV
hypertrophy and outflow obstruction. Multivariate analysis demonstrated that LV septal
thickness and septal branch compression, and not coronary compression, were independent
predictors of myocardial perfusion abnormalities. Coronary compression was not associated
with symptom severity, ventricular tachycardia on Hotter or induced at electrophysiologic study
or a worse prognosis.
Conclusions. Compression of coronary arteries and their septal branches are common in HCM
children and are related to the magnitude of LV hypertrophy. Several mechanisms contribute
to the development of myocardial ischaemia in HCM, and our findings suggest that coronary
compression does not make an important contribution. Rather, LV hypertrophy and
compression of intramural arteries may significantly contribute to the development of
myocardial ischaemia in HCM.
4.1.1.2 Introduction
HCM is often associated with disabling symptoms, arrhythmias and sudden cardiac death.
Several mechanisms, including myocardial ischaemia, are thought important in the aetiology of
sudden death (so).84'89'90'98'372"378
HCM patients often have regional myocardial perfusion abnormalities as demonstrated by
exercise thallium scintigraphy and positron emission tomography (PET) and by net production
of myocardial lactate.89,379"384 SD is most common in paediatric populations (Figure 39), and
stress induced myocardial perfusion abnormalities are associated with increased risk.384 387
There are several mechanisms potentially responsible for ischaemia in HCM including the
obstruction, by systolic compression, of epicardial and intramyocardial arteries.89,366,388
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Yetman et al. suggested that systolic compression of epicardial arteries in children with
HCM persists into diastole resulting in coronary insufficiency and myocardial ischaemia.366 In
their study, compression was associated with reduced survival, ventricular tachycardia, chest
pain and impaired exercise performance. The magnitude of LV hypertrophy and severity of
obstruction were not associated with compression. In contrast, prognosis in children without
coronary compression was excellent (Figure 39). It is suggested that surgical division of the
bridge may improve prognosis.
YearsfromDiagnosis
Figure 39. Survival Estimates of Children Diagnosed with HCM.
Based on these studies, 366'385'387'389 ^e annual mortality from cardiac deaths in children is estimated at
approximately 4% per year. It is reported that in the absence of coronary bridging, survival is significantly improved.
To validate their findings, we investigated relations between SD, systolic coronary compression
of intra- and epicardial arteries, myocardial perfusion abnormalities and severity of
hypertrophy in a larger group of HCM children who had been followed for a longer period and
whose management represented more current practice.
4.1.1.3 Methods
Children with HCM who underwent selective coronary angiography at the NIH between January
1989 and April 1999 were studied. HCM was defined echocardiographically as a hypertrophied,
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non-dilated LV in the absence of another cause for the increased cardiac mass. Cardiac events
were sudden death or resuscitated cardiac arrest. Survival was determined according to the
age of the children, not years from diagnosis, as the majority of cardiac events occur in the
second and third decades of life.390
Right and left heart hemodynamic measurements and selective coronary angiograms were
obtained at catheterisation. All coronary segments showing evidence of compression were
assessed quantitatively to determine the severity of compression. Coronary compression was
defined as a maximum systolic compression >50%.366 Identification of exact diastolic/systolic
boundaries from selective coronary angiograms is not accurate; angiographic determination of
diastolic persistence of compression is not reliable and was not measured. Septal perforator
branches of the LAD were considered compressed when they were angiographically obliterated
in systole. Treadmill exercise tests were performed using the Bruce protocol. Exercise thallium
scintigraphy was available for most subjects. A region of reduced thallium uptake was
determined to be reversible or fixed, and the presence or absence of apparent cavity dilatation
was also determined.
Holter recordings were analysed for the presence or absence of ventricular tachycardia (VT.
The QT, QTc intervals and QTc dispersion were measured from the 12-lead ECG.
Electrophysiology (EP) studies were performed in a subset of the children using previously
described methods.90
Two-sample data were compared by Student's t-test. Cardiac survival rates for patients with
and without coronary compression were determined by Kaplan-Meier estimates and compared
with the log rank test. Multivariate logistic regression analysis was used to determine the
independent contributions of LV wall thickness, LV outflow obstruction, septal compression
and bridging to thallium perfusion abnormalities. A p<0.05 indicated significant differences.
4.1.1.4 Results
Characteristics of the Study Population: 57 children with HCM admitted to the National
Institutes of Health had selective coronary angiograms. These children had a high prevalence of
risk factors associated with sudden death (Table 18).
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Risk Factor Prevalence
Cardiorespiratory arrest, syncope and/or presyncope 35 (61%)
Family history of >2 premature sudden death 12(21%)
Myocardial ischaemia 31 (54%)
VT during ambulatory Holter monitoring 14 (25%)
Genetic abnormality associated with a poor prognosis 4 (6%)
Severe LV hypertrophy (LV wall thickness >30 mm) 12 (21%)
Flat* or hypotensive BP response to baseline exercise 26 (46%)
More than one of the features listed above 53 (93%)
Table 18. Prevalence of Risk Factors for Sudden Death in the Study Population.
Angiographic Findings: We detected coronary compression more frequently than previously
reported and at sites other than the mid LAD. Coronary compression (Figure 40) affected 28
coronary segments in 23 (40%) children. Multiple coronary sites were identified in 4 (7%)
children: 2 coronary segments in 3, and 3 segments in 1 child. Compression was of the mid-
LAD in 13(46%), proximal LAD in 1 (4%), distal LAD in 2 (7%), a diagonal branch in 5 (18%), an
obtuse marginal branch in 4 (14%), and the posterior descending artery in 3 (11%). The mean
length of the compressed segment was 15±7 mm, range 6-39 mm, with a mean narrowing of
76±18%. The maximum compression was between 75-100% in 13 (46%) and complete systolic
occlusion was seen in 8 (29%). Coronary compression less severe than used in the current
definition was detected in additional children. Septal artery compression was detected in 37/57
children (65%). It was detected in all 23 children with coronary compression, but only 14/34
without coronary compression, p<0.001.
Clinical Features: The ages of diagnosis and cardiac catheterisation and the symptom status
were similar in children with and without compression (Table 19). Cardiac events (2 sudden
deaths, 4 cardiac arrests) occurred in 2 children with a compressed coronary and 4 without.
The cumulative survival rate at 20 years of age in children with coronary compression was
85±10% and without was 82±8%, p=0.9. In addition, LV systolic dysfunction occurred in 3
children without coronary compression, in 1 child following transmural myocardial infarction
(none in children with coronary compression). One child in each group underwent cardiac
transplantation for severe symptoms and exercise limitation.
Echocardiography: Mean septal thickness in children with coronary compression was 28±8 mm
Vs. 19±8 mm in those without coronary compression, p<0.001, and 26±9 mm compared to
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17±5 mm in children with or without septal compression, p<0.0005. Children with coronary or
septal compression had higher LV outflow gradients than children without any compression
(Table 19 and Table 20).
Hemodynamic Variables: Mean resting LV outflow gradient was greater in patients with either
coronary or septal compression than without (Table 19 and Table 20)
Figure 40. Coronary and Septal Perforator Compression in Children with HCM.
Diastolic frames are on the left. (A). 6-year old boy with compression of the mid-LAD and its septal branches. (B).
13-year old girl with compression of the posterior descending artery and its septal branches. (C). Compression of
septal branches of the LAD in the absence of LAD compression. Large arrows indicate sites of bridging of epicardial
arteries and small arrows indicate compression of septal branches.
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Coronary Compression All children No Compression Compression P value
n= 57 n=34 n=23
Age at diagnosis (range) 10±6 11±6 (.03-18) 10+6 (0.1-17) 0.23
Age at angiography (range) 15±4 15±4 (6-20) 14+4 (4-20) 0.35
Follow up (years):
from diagnosis 8±6 9±6 8+6 0.7
from catheterisation 4±4 5±4 313 0.08
Male 43 (75%) 28 (82%) 15 (65%) 0.25
Family history of SD 12 (21%) 8(24%) 4(17%) 0.74
Clinical presentation
asymptomatic 10 (18% ) 6(18%) 4(17%) 0.99
syncope 23 (40%) 15 (44%) 8 (35%) 0.67
cardiac arrest 4 (7%) 3 (9%) 1 (4%) 0.64
Echocardiographic indices
interventricular septum (mm) 23±9 19±8 28+8 0.0004
posterior LV wall (mm) 11±3 12±4 11+3 0.43
septum to posterior LV wall ratio 2.2±1.1 1.8±0.9 2.7+1.2 0.001
LV outflow gradient (mm Hg) 28±35 16128 45+37 0.002
Cardiac catheterisation
systolic LV (mm Hg) 123±28 116+21 133+34 0.03
LV outflow gradient (mm Hg) 23±31 14+24 37+34 0.005
septal compression (%) 37 (65%) 14 (41%) 23 (100%) <0.0001
Exercise thallium scintigraphy (n=48) (n=30) (n=22)
abnormal study 31 (65%) 14 (47%) 17 (94%) 0.002
number of abnormal segments 86/288 (30%) 34/180(19%) 52/108 (48%) <0.0001
Table 19. Characteristics of Children with Systolic Coronary Compression.
P values refer to comparisons of 'No Compression' with 'Compression'.
Septal Perforator Compression Absent present P value
(n=20) (n=37)
Echocardiographic indices
interventricular septum (mm) 17±5 2619 0.0004
posterior LV wall (mm) 12±4 1113 0.30
septum to posterior LV wall ratio 1.5±0.5 2.5+1.2 0.001
LV outflow gradient (mm Hg) 13±29 35+36 0.02
Cardiac catheterisation
systolic LV (mm Hg) 117±16 127+31 0.2
mean aortic pressure (mm Hg) 78±13 6917 0.01
LV outflow gradient (mm Hg) 10±15 30131 0.01
coronary bridging (%) 0/20 23/37(76%) <0.0001
Exercise thallium scintigraphy (n=17) (n=31)
abnormal study 4 (24%) 27 (87%) <0.0001
number of abnormal segments 9 (9%) 77 (41%) <0.0001
Table 20. Characteristics of Children with Systolic Septal Perforator Compression.
P values refer to comparisons of 'No Compression' with 'Compression'.
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Exercise thallium scintigraphy: Reversible myocardial abnormalities were present in 31 of 48
(65%) children (Figure 41). Abnormalities in myocardial thallium uptake were much commoner
in children with coronary and septal compression (Table 19 and Table 20). LV hypertrophy was
greater in patients with reversible thallium abnormalities (septum, 26±9 mm versus 16±3 mm,
p=0.0001) and LV outflow gradients at cardiac catheterisation were higher (26±33 mm Hg





Figure 41. Myocardial Perfusion Scintigraphy.
Images obtained during exercise, in the upper row, and following rest and re-injection below. Reversible apical,
subendocardial, posterior and septal defects are seen in this child with mid LAD compression. These defects cannot
all be due to LAD compression.
The distribution of thallium abnormalities were often unrelated to the coronary artery
compressed, and were similar in the children with LAD compression to those in children with
compression of another coronary. Stress-induced apparent LV cavity dilatation thought to
represent subendocardial ischaemia and not easily attributed to occlusion of a single coronary,
was present in over a third of the children. Almost half of the children without coronary
compression had reversible abnormalities. Multiple regression analysis identifies LV septal
thickness and septal perforator compression, and not LV obstruction or coronary compression,
as independent predictors of reversible myocardial thallium uptake abnormalities (Table 21).
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Thus, factors other than coronary compression are important in the aetiology of perfusion
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Table 21. Relation of Myocardial Perfusion Abnormalities to Selected Clinical Parameters.
Logistic regression model for predicting reversible myocardial perfusion abnormalities. Sd: Standard Deviation.
Exercise and Electrophysiology: There were no significant differences in mean exercise
duration, resting and peak systolic blood pressure in children with and without coronary or
septal compression. The mean QT and QTc intervals, and QTc dispersion were not significantly
different in children with and without. Non-sustained VT was recorded in 17% of the children
during ambulatory ECG monitoring. EP was performed in 36(63%) of the children; sustained VT
was induced in 28% of studies. Differences in VT on Holter and VT induced at EP study in
children with or without coronary compression were not statistically significant.
4.1.1.5 Discussion
Myocardial ischaemia in HCM: Evidence for myocardial 'ischaemia' in HCM is provided by
stress-induced; (1) chest pain and electrocardiographic changes: (2) reversible myocardial
perfusion defects at thallium scintigraphy (3) limitations in coronary flow reserve (CFR); and (4)
anaerobic metabolism in patients with HCM who have a history of chest pain.89,379"384,391
Myocardial ischaemia results from true hypoxia (mismatch of flow supply to myocardial
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demand), or from abnormalities in production and utilization of high-energy
phosphates.30'392'393
CFR limitation in HCM, like thallium perfusion defects, is often most striking in the
subendocardium and does not typically show single coronary distribution.89 CFR is lowest in
HCM patients with microvascular abnormalities detected following biopsy.381'383'384'388'394
Myocardial perfusion may also be limited by elevated LV diastolic pressure, abbreviated
diastolic intervals and systolic arterial compression as illustrated in Figure 42.395
Figure 42. Impaired Coronary Perfusion Pressure in a Patient with Non-Obstructive HCM.
Simultaneous recordings of arterial pressure and LV pressure in a young patient with severe LV hypertrophy, no
outflow obstruction, septal artery compression but no coronary compression. (A) The gradient between arterial and
LV pressure in diastole, as indicated by the shaded area, drives myocardial perfusion. (B) Following infusion of
isoproterenol, LV diastolic pressures have risen dramatically, aortic diastolic pressure has fallen and the diastolic
period is abbreviated. Myocardial perfusion pressure and duration are severely diminished, as shown by the
dramatic reduction in the shaded area.
Definitions and Prevalence of Coronary Compression: Coronary angiography demonstrates
systolic compression of epicardial coronary arteries in a proportion of otherwise normal hearts.
A length of a normally epicardial artery is crossed by a myocardial band or 'bridge' that
contracts and compresses the underlying artery in systole.396"398 In this article, bridging refers
to the muscle bridge and the angiographic findings are termed coronary compression.
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In adult populations without cardiomyopathy, systolic coronary compression is seen at
angiography in 0.5% to 12%, most often affecting the mid left anterior descending artery
(LAD).397,399 Muscle bridges are found much more frequently at autopsy or aorto-coronary
bypass (5-86%). These also most frequently cross the mid LAD but have been described over
most epicardial arteries. Therefore, anatomic muscular bridges not always lead to coronary
compression visible at angiography. An intra myocardial segment of an epicardial artery, most
often of the mid LAD, should possibly be considered a (frequent) coronary variant rather than a
coronary anomaly. Pharmacological agents like nitroglycerin and isoproterenol increase the
angiographic severity and incidence of compression, with detection rates increasing to 40% in
patients undergoing angiography.398
In hypertrophic hearts coronary compression is more common; myocardial hyperdynamic and
hypertrophic adaptations may extend to previously 'silent' bridges that become compressive.
Coronary compression is found in 30 to 80% of adults with HCM or with aortic stenosis.397,399
Studies in adults with HCM have described no relationship to ischaemia.89
Coronary Compression and Myocardial Ischaemia: It has been previously suggested that
coronary compression: (1) results in coronary insufficiency and myocardial ischaemia and; (2)
may provide protection against the development of coronary atheroma. The latter, reviewed
elsewhere, is not considered here.397
Coronary flow occurs predominantly in diastole, with only 15 % of myocardial flow
occurring in systole. Systolic compression may result in ischaemia, if the contribution of systolic
flow becomes critical, or if a sufficient severity of compression persists into diastole.
Compression may result in elliptical narrowing of the coronary and not concentric narrowing
typical of coronary disease. Relations between the minimum diameter and luminal diameter
are different from a circle; a concentric decrease in arterial diameter of 50% decreases luminal
area by 75%, the area will only be reduced by approximately 30% if the artery is distorted into
an ellipse.397 To reduce flow significantly, diastolic coronary compression must remain at
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Figure 43. Bridged Coronary Arteries Compress as an Ellipse.
(A). The reduction of luminal area of a compressed coronary follows elliptical geometry rather than concentric
geometry. (B). The minimum systolic diameter of a compressed coronary results in significantly less luminal area
reduction than concentric narrowing.
Multiple case reports implicate compression as the cause for ischaemic syndromes in patients
with otherwise normal coronary arteries.400"404 Surgery to de-roof or bypass the bridge and
coronary stenting have been associated with symptomatic improvement in case reports and
small uncontrolled series.405"409 Noble et al.400 demonstrated increased myocardial lactate
production following atrial tachy-pacing in symptomatic patients with coronary compression,
although approximately 25% of their patients may have had myocardial hypertrophy, itself
associated with myocardial lactate production and symptoms.89 Quantitative angiography and
coronary Doppler flow studies detect some diastolic persistence of compression, but its
hemodynamic significance is not established.410"412 No controlled study demonstrates increases
in morbidity or mortality associated with coronary compression, and the 5-year survival is
similar to that of an unselected population.397 In several of the case reports describing
ischaemic syndromes (chest pain or myocardial infarction sudden death or ventricular
tachycardia) patients also had myocardial hypertrophy, possibly representing HCM. The
literature remains equivocal.
Lastly, in HCM and other hypertrophic conditions, angiographic obliteration in systole of the
septal perforator branches of the LAD and PDA (often termed septal blanching), occurs
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commonly. It is present in approximately 70% of patients with aortic stenosis or HCM, and has
previously been associated with the degree of LV hypertrophy and thallium perfusion
abnormalities.413"415 Doppler studies demonstrate reversal of coronary flow in systole, an
abnormality correlating with severity of septal compression.415,416 Therefore, in the presence of
systolic septal compression, epicardial compression may not be of additional significance in
limiting coronary flow and surgical release of the compressed coronary will not improve
myocardial perfusion.
4.1.1.6 Conclusions
There are several mechanisms for SD in HCM other than ischaemia, and ischaemia is
multifactorial in aetiology. This study finds no evidence that epicardial compression is an
important cause of myocardial perfusion abnormalities in HCM children. Previously described
associations may have been confounded by associated features, such as the magnitude of
myocardial hypertrophy. Rather, our data support the hypothesis that LV hypertrophy and
septal artery compression are important determinants of the severity of perfusion
abnormalities. It remains possible that in a few patients, a severe degree of coronary
compression contributes to ischaemia. In the children studied here, there was no evidence that
this contribution was significant even in those with the most severe compression. Currently,
there is little evidence to suggest relief of coronary compression in children with HCM will
improve symptoms or prognosis.
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4.2 Prospective Randomised Studies
Prospective randomised controlled trials (RCT) are largely absent from HCM research, and
despite the relatively extensive published HCM related research. In the development of
therapies for HCM, the three central themes have been: (1) Prevention of sudden death (SD);
(2) Relief of symptoms associated with LVOTO; and (3) Attempts in prevention/regression of LV
hypertrophy. NO RCT examine SD prevention.
Two RCT compared the effects of dual chamber (DDD) pacing on LVOT gradients and symptoms
in obstructive HCM, with results that are generally interpreted as showing no benefit for
pacing, but are best viewed as equivocal.129,131,417,418 In consequence, DDD pacing for this
indication has largely been abandoned in favour of alcohol septal ablation (ASA) and LV
myectomy (LVM) despite these latter modalities never being subjected to similar scrutiny by
randomised trial.
Finally, two small randomised studies examining effects on LV mass of pharmacological agents
followed from studies in animals of statin therapy and renin-angiotensin-aldosterone system
(RAAS) antagonism (refs).419,420 A small study randomised 19 HCM patients to losartan or
placebo and reported a small reduction in LV mass following a year of losartan therapy
compared with placebo.419 Routine clinical practice has not followed the results of this study. A
pilot study of statin therapy in humans did not corroborate the animal data and found no
effects on LV mass of atorvastatin (80mg) compared with placebo for 9 months in 22
randomised patients.420
Thus clinical practice in HCM is based on little or no evidence of the quality expected in
modern cardiology. Even the effect of the DDD trials has been to favour more invasive but less
completely evaluated alternative treatments. Given the considerable research interest in HCM
evident in any literature searches, it is surprising that RCTs have not been designed and
completed. Reasons for this may include:
1. Clinical heterogeneity and cohort size: Cohort sizes offering sufficient statistical power
to demonstrate treatment effect is the most evident obstacle. For example, with the
primary outcome as mortality, it has been estimated that as many as 34,000 HCM
patients would be needed for the screening phase of a trial of ASA against DDD that
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eventually enrolled 600 patients in each treatment arm.421 The heterogeneity in
disease and the high prevalence of asymptomatic patients determines the low
screening to trial-eligible ratio. As this claim is made by the principal investigators of
M_PATHY, a trial of DDD pacing for the same indication that has proved influential in
it's abandonment129, the conclusion that recruitment difficulties are 'virtually
insurmountable' is curious. Mortality rates are low, but other outcome measures are
also of interest. Symptom status currently determines indications for invasive
treatment for LVOTO. The influential DDD trials report symptom status and exercise
testing as the principal outcome measure where a large placebo effect is reported in at
least one of these studies. Objective measures of well-being and exercise capacity
rather than mortality are surely the relevant outcome measures for a treatment
indicated on symptomatic grounds. Similarly, magnitudes of LVH, LV scarring at delayed
gadolinium enhancement, LVOTO, systolic function, left atrial size, pulmonary
pressures and other measurements are useful surrogate markers of disease severity.
2. Established Practice: Nonetheless, only two or three Centres world-wide have had the
cohort size required for single-centre trials; multi-site collaboration, an essential model
in the coronary disease and heart failure trial successes is necessary. The large centres
may be inhibited from pursuing single site trials by virtue of mutually-exclusive
established stakes in a particular treatment. Thus, a tertiary centre promoting ASA may
not have a similar expertise/experience in LVM necessary for a meaningful comparative
trial, and visa-versa.
3. Collaborative Studies: The two pacing studies depended on multi-site collaborations in
the USA and Europe. These efforts have not been replicated for ASA or LVM. One of the
reasons for this may be the limited number of centres that offer both treatments, and
the understanding that either therapy has the best outcomes in high volume centres;
clearly this complicates randomisation. Pacing enthusiasts argue that the same is true
of DDD therapy in that despite the availability of pacemaker implanting services, the
management of pacing parameters for this indication is specialized. Anecdotally, in
patients receiving implants elsewhere, we have seen inappropriate pacing set-ups
including high septal lead placements, excessively short programmed A-V delays and
AAI pacing. Additionally, as rates of procedural complications in these trials were
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higher than expected in routine pacing practice, it is likely that operators relatively
inexperienced with this pacing indication predominated.
However, problems with equal access to alternative invasive techniques should not be
impediments to trials of pharmacological therapy or device therapy in the assessment of
strategies to prevent death from arrhythmia, stroke and heart failure, or of treatments aimed
at reversing left ventricular hypertrophy and fibrosis. It remains difficult to account for the
reluctance of the HCM research community to perform such studies; an environment of
antagonistic competitiveness between rival investigators and an entrenched approach to
management developed over decades of clinical practice may be important contributing
factors.
At NIH, we completed two single-site randomised trials. A double-blind placebo controlled trial
investigating RAAS antagonism began in 1994 and was completed in 2003. The results were
presented at the Scientific Sessions of the American Heart Association in 2003(Table 22).
Results of a randomised study comparing ASA with DDD pacing was presented at the Scientific
Sessions of the American Heart Association in 2004 (Table 22).
Scientific Sessions
• Fananapazir L, Mohiddin SA, Begley DA, McAreavey D, Biddle S, Tripodi D, Plehn J, Owens D,
Agyeman K, Norman JE, Arai AE. Double-Blind Placebo-Controlled Study of Inhibition of Renin-
Angiotensin System on Cardiac Mass in Human Hypertrophic Cardiomyopathy. American Heart
Association, 2003.
• Mohiddin SA, Tripodi D, Kent K, McAreavey D, Plehn J, Fananapazir L. Randomized Therapy for
Obstructive Hypertrophic Cardiomyopathy: Long Term Outcome of dual chamber pacing and alcohol
septal ablation. American Heart Association, 2004.
Table 22. Published Research and Presentations of Findings: Randomised Trials.
160
4.2.1 Regression of Left Ventricular Hypertrophy in Hypertrophic
Cardiomyopathy: Randomised Placebo Controlled Trial of Inhibitors of
the Renin-Angiotensin System
The NIH group led by Dr Fananapazir began this trial in 1994 before I joined in 1998;
recruitment was completed in 2003. The primary outcome was change in LV mass following six
months treatment with a angiotensin converting enzyme inhibition (ACE-I), angiotensin
receptor blockade (ARB), ACE plus ARB or placebo. CMR measures of LV mass were obtained in
collaboration with Dr Andrew Arai of the department of Cardiac Energetics of the NHLBI.
Patient assessment and recruitment, cardiac catheterisation, exercise testing and safety
monitoring were performed by our group. Key to safety considerations were study criteria
excluding patients with LVOTO at rest or on provocation (isoprenaline infusion and catheter
measured gradients) and patients with symptoms worse than NYHA II. A consequence of the
latter is that the study was not designed to detect improvement in symptom status following
treatment, but was better powered to detect deterioration in well-being.
4.2.1.1 Abstract
Background: We postulated that angiotensin converting enzyme (ACE) inhibition and/or
angiotensin-ll receptor (ATi) blockade causes regression of left ventricular mass in hypertrophic
cardiomyopathy (HCM).
Methods and Results: Eighty-nine patients with non-obstructive HCM with preserved left
ventricular systolic function, aged 20-55 years, participated in a double-blind study and were
randomised to receive placebo, losartan (50 mg/day), enalapril (10 mg/day) or losartan (50
mg/day) plus enalapril (10 mg/day) for six months. Enalapril and the combination therapy
significantly reduced left ventricular mass, but losartan alone did not. Left ventricular mass
regression was independent of variations in arterial pressure. The drug regimens did not
adversely affect left ventricular volumes, or treadmill heart rate and blood pressures. Cough,
hypotension, and/or light-headedness occurred in six patients or 26% on combination therapy,
three patients or (13%) on enalapril, and two patients (10%) on losartan. No patient died during
a mean follow-up period of 4.0±1.5 years. The group treated with combination therapy, but not
other treatment groups, reported a significant improvement in NYHA symptom status.
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Conclusions: Enalapril is well tolerated in non-obstructive HCM, and reduces left ventricular
mass. ACE inhibitors may be considered in HCM patients with symptoms of heart failure and
preserved or impaired LV systolic function. Further studies are necessary to confirm this finding
and to evaluate its potential beneficial effects on long-term outcome.
4.2.1.2 Introduction
Left ventricular (LV) hypertrophy is a major independent risk factor for morbidity and mortality
from cardiovascular disease.422 The severity of myocardial hypertrophy in HCM is also
associated adverse outcomes.92,98,375,423 In addition to adverse outcomes that may include end
stage heart failure and increased risk of sudden death it is also associated with LV diastolic
dysfunction, myocardial fibrosis, myocardial perfusion abnormalities and disabling
symptoms.175,376
The renin-angiotensin-aldosterone system (RAS or RAAS) comprises a series of enzymatic steps
that generate or modulate several biologically active species including angiotensin-ll (Ag-ll) and
aldosterone. In addition to the classical or endocrine RAAS, a local or paracrine/autocrine RAAS
may respond to localized stimuli and tissue requirements.424 427 Mechanical stretch and
autonomic activity activate cardiac RAS cascades, and many or all RAS components, including
aldosterone, are produced in s/'fu.424"427 428
Several adverse cardiovascular effects of RAAS activity are attributed to Ag-ll activity at the
angiotensin-1 receptor (ATi) receptor. Activation of ATX receptors on fibroblasts,
cardiomyocytes, smooth muscle cells and endothelial cells promotes hypertrophy, mitogenesis,
fibrosis, vasoconstriction and arrhythmogenesis.6 In contrast, Ag-ll activity at AT2 receptors is
reported to oppose some or all the effects of AT2 activity.7,10 ATj receptor antagonists do not
inhibit AT2 receptors, and may actually augment their activity by increasing Ag-ll availability.6
This, along with findings suggesting that local RAS production of Agll may occur independently
of renin and ACE activity (thus 'escaping' systemic AEE inhibition), suggests that the optimal
inhibition of local cardiac RAS requires combination therapy.424"427 428429
Animal models and clinical studies of hypertensive cardiomyopathy have demonstrated that
ACE, AT! and aldosterone inhibition ameliorate myocardial fibrosis myocyte hypertrophy and
perfusion abnormalities, and may reduce the incidence of atrial fibrillation and heart
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failure.424,430"440 Observations that these effects did not correlate with the activity of circulating
ARAS components or with the magnitude of blood pressure reduction suggested a role for local
RAAS in the development of the cardiomyopathy.
The LV hypertrophy in HCM develops principally as a consequence of mutant gene expression
(often encoding sarcomeric proteins) rather than to pressure overload.32,441 HCM is
characterized by myocyte hypertrophy, hyperplasia and disarray, and hyperplasia of several
other cell types including fibroblasts endothelial cells and smooth muscle cells 166-388<442-444
Myocardial fibrosis is a common pathologic feature and is often more pronounced than in
hypertensive cardiac hypertrophy 166 167-442'445-446 Evidence that RAAS activity also contributes to
the severity of this form of cardiomyopathy was suggested by the observation that in
comparison to the ACE insertion (I) polymorphism, the deletion (D) polymorphism is associated
with increased plasma ACE concentrations and occurs at an increased frequency in HCM
patients than in unaffected family members447 or in unrelated controls448, and may also
influence the severity of LV hypertrophy.449 Common polymorphisms in both ATj and AT2
receptors may also influence the magnitude of hypertrophy.450,451 Finally, in a mouse model of
human sarcomeric gene HCM, Agll blockade reduces the degree of myocardial fibrosis.452
The utility of RAS manipulation in HCM remains clinically unproven. The primary hypothesis of
this study is that RAAS activity is involved in the genesis and maintenance of LV hypertrophy in
HCM, and ACE inhibitors and/or ATa receptor antagonism will cause regression of the increased
LV mass, leading to improved symptoms and cardiac functional indices.
4.2.1.3 Methods
Patients and Study Design: This double blind, placebo controlled study was performed under
informed patient consent according to a protocol approved by the Intramural Research Board
of National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). The
primary goal of this study was to determine whether six months of ACE inhibition and/or AT2
receptor blockade therapy reduces LV hypertrophy in patients with HCM.
Between 1994 and 2003 all patients evaluated in the HCM clinic of NHLBI were evaluated non¬
invasive^ (clinical history and echocardiography) for entry criteria. Consent for invasive
evaluation was obtained in one hundred and thirty-one consecutive patients. Of these 42
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subjects did not meet criteria (Table 23), and 89 patients were randomised to receive daily
placebo, an ACE-inhibitor (enalapril 10 mg/day), an ATI receptor blocker (losartan 50 mg/day),
or enalapril (10 mg) plus losartan (50 mg). Randomisation by the pharmacy department was
performed separately for men and women. Patients in the four arms of the study were well
matched with regards to clinical characteristics (Table 24).
Safety considerations; As vasodilators may aggravate LV outflow obstruction, only patients
with non-obstructive HCM were included in the study. Following randomisation, heart rate and
blood pressure were monitored for 3 days on drug therapy. In the absence of an adverse event,
the patient received study drug for six months. Haemoglobin, platelets, electrolytes, renal and
hepatic function were checked at baseline and at 1, 3, and 6-month follow-up. Urinary
pregnancy test was performed monthly in women of child-bearing age. Only patients with mild
or no symptoms (NYHA I or II) were recruited because of concerns regarding potential adverse
effects of RAAS inhibition on symptoms in patients with unobstructed HCM.
Evaluations: Studies at baseline and at completion of the 6 months of the protocol included: (1)
echocardiography; (2) symptom limited treadmill and bicycle exercise tests; (3) exercise
radionuclide angiography; (4) cardiac magnetic resonance imaging (CMR)31; (5) cardiac
catheterisation and angiography; and (6) measurements of plasma ACE and Ang-ll
concentrations, and of renin activity (PRA). ACE genotype was also determined.453
CMR: End expiratory cine CMR was performed on a 1.5T cardiac MRI scanner using a four-
element cardiac phased array coil. Computer assisted planimetry was used to quantify
myocardial dimensions, volumes, ejection fraction and mass. In 10 water-filled phantoms,
measured volumes correlated with actual volumes: actual volume=1.0187 x measured volume -
0.0262, R2=0.9942.
Radionuclide angiography: Parameters of LV filling measured peak filling rate (PFR), time
to peak filling rate (TPFR), and atrial contribution to LV stroke volume by methods described
previously.89 LV systolic function was determined by estimating rest and exercise LV ejection
fractions.
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RAS: ACE genotype was determined by previously described methods.453 Blood samples for
PRA, ACE, and Ang-ll concentrations were collected after >15 minutes lying supine following an
overnight fast.
Statistical Analysis: Data are expressed as mean ± 1 SD. Data were compared using Student's t
test. Pearson's test was used to examine the correlation between variables. A two-sided p<0.05




LV wall thickness >16 mm* by MRI
LV outflow gradient of 0 30 mm Hg gradient at rest, and 0 55 mm Hg following isoproterenol infusion to a
heart rate of about 120 beats per minute at cardiac catheterisation
NYHA functional class l-ll.
Exclusion:
significant other cardiovascular disease
chronic atrial fibrillation
bleeding disorder or anaemia
renal impairment (blood urea nitrogen > 22 mg/dl and serum creatinine >1.4 mg/dl);
K+ <3.3 mmol/l or >5.1 mmol/l
hypertension: basal systolic and diastolic pressures of >160 mm Hg or >95 mm Hg, respectively, on two
occasions separated by one hour of rest
hypotension: sitting systolic arterial pressure <100 mm Hg confirmed 30 minutes later
pregnancy and lactation
impaired LV systolic function: LV ejection fraction <50% (radionuclide angiography)
dependence on diuretics, verapamil, (3-blockers, or antiarrhythmic drugs
sensitivity to ACE inhibitor e.g. angioedema
ACE inhibitor or losartan treatment <6 months prior to the study
Table 23. Study Criteria for the Randomised ACE/ARB blocker Study in HCM.





N 22 23 21 23
Gender (males) 14 [64] 16 [70] 14 [67 ] 14 [61]
Age (years) 34±9 38±8 3419 37111
NHYA 1.7 ±0.5 1.710.5 1.610.5 1.810.4
Symptoms
nil 2 [9] 5 [22] 2 [10] 4 [17]
angina 9 [41] 8 [35] 5 [24] 9 [39]
dyspnoea 14 [63] 12 [52] 14 [67] 15 [65]
presyncope/lightheaded 7 [32] 7 [30] 8 [38] 11 [48]
syncope 1 [5] 5 [22] 3 [14] 4 [17]
palpitation 14 [64] 12 [52] 8 [38] 12 [52]
fatigue 3 [14] 2 [9] 3 [14] 7 [301
Echocardiogram
LV wall thickness (mm) 27±7 2416 2516 2316
septum (mm) 17±4 1715 1715 1715
posterior wall (mm) 10±4 912 911 911
LV IDd (mm) 44±5 4814 4515 4416
LV IDs (mm) 25±4 2713 2615 2514
left atrium (mm) 37±6 4416 4416 4117
Table 24. Randomised ACE and ARB Inhibition: Baseline Clinical Characteristics.
[], per cent; IDd, internal diastolic dimension; IDs, internal systolic dimension.
4.2.1.4 Results
ACE Genotype, Circulating RAS hormones, and Cardiac Hypertrophy in HCM: ACE levels varied
markedly in the study patients - from 2 to 85 U/L (laboratory normal range, 6.1 to 21.1 U/L).
Prior to therapy, the DD genotype was associated with higher serum ACE levels than either ID
or II genotypes (PRA, plasma Ang-I, and Ang-ll levels were similar, Figure 44 ). However, neither
LV mass nor maximum LV wall thickness was different between ACE genotypes (Figure 45). In
addition, circulating hormone concentrations (ACE, PRA, and Ang-ll) showed no discernable
relationship with either LV mass or maximum LV wall thickness (Figure 46).
Changes Following Inhibition of RAS: Several parameters were measured prior to, and
following treatment.
Hormone activity: Enalapril, alone or in combination with losartan, reduced plasma ACE and
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Figure 44. ACE Polymorphisms and Serum ACE Concentrations.
Angiotensin converting enzyme (ACE) I/O gene polymorphisms are associated with different serum concentrations of
the components of the renin-angiotensin system.
Figure 45. ACE Polymorphisms Do Not Correlate with LV mass.
LV mass was not significantly greater in the patients with the DD genotype compared to that in patients with the ID
and the II genotypes.
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ACE Levels Plasma Renin Activity
Figure 46. Effect of RAAS Inhibition on Component Species.
Significant reductions in plasma angiotensin converting enzyme (ACE) and increases in plasma renin activity (PRA) in
the enalapril plus losartan and enalapril study arms.
p = 0.82; r = 0.02
Ang-l
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Figure 47. Absence of Correlation Between LV Mass and Plasma ACE Concentration.
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Regression of LV mass: LV mass decreased significantly in the enalapril (p<0.0005), and
enalapril plus losartan arms (p<0.005) arms, compared with no change in the placebo arm. LV
regression in the enaiapril and combination therapy groups was significant compared to
placebo (Table 25). LV diastolic, systolic and stroke volumes were unaffected in any of the
treatment groups.
I nalapiil
Placebo Enalapril l.osjrtan plus Losartan
MRI
LV end-diastolic volume (ml) -5.3115.3 6.4117.9 2.5124.3 -2.o±i3.2
LV end-systolic volume (ml) -o.6±9-3 -o.8±8.2 o.5±i8.4 -0.71111
LV stroke volume (ml) -4.7112.8 -5.6115.8 2.3113.7 -1.3113.5
LV mass (gm) -1.3128.1 -16.5117.5* -6.7119.9 -18.2126.0*
Exercise test
maximum heart rate (bpm) o±n
maximum systolic blood pressure -2130







basal ejection fraction (%) -1.217.6
exercise ejection fraction (%) -6.515.4
TPFR 3.1142.4














heart rate (bpm) -1112 1112 1114 -2111
right atrial pressure 013 013 o±3 i±3
right ventricular diastolic pressure +10 014 °±3 014
pulmonary artery systolic pressure i±7 014 ~2±5 4±5
pulmonary artery mean pressure 015 014 -1+5 2+4
PCWP 015 014 -114 114
cardiac index (1/min/m2) -0.110.4 0.110.5 -0.310.4 010.5
aortic systolic pressure 2+13 7114 15112** 17120**
aortic diastolic pressure -1110 5+n 4110 8±8***
aortic mean pressure -1111 4+13 4110* 14114***
LV systolic pressure 1116 1019* 9114 19114***
LV end-diastolic pressure 019 118 017 5+6
basal LV outflow gradient -2HO 118 "3±7 3±9
Table 25. Therapeutic Effects: Changes in Cardiovascular Indices.
Data represent mean + 1 SD changes in the indices: baseline minus follow-up values (positive values: indicate
reduction and negative values an increase); pressures in mm Hg, volumes in ml and mass in gm; TPFR, time to peak
filling rate; PCWP, pulmonary capillary artery wedge pressure *, p<0.05; **, p<0.01; ***p<0.001; and ****p<0.0001
compared to placebo.
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Symptoms: The NYHA functional class improved significantly only in the enalapril plus losartan
arm of the study (1.8 ± 0.4 to 1.5 ± 0.5, p=0.015). Individual symptoms were unchanged.
Heart rate and blood pressure: No significant changes between baseline and study exit in heart
rate and blood pressure responses to exercise and exercise duration or metabolic parameters
were noted in any of the study-arms (Table 25). Similarly, were not altered by any therapy.
Radionuclide Parameters of LVfunction: There were no changes in radionuclide indices of LV
systolic and diastolic function at rest or exercise in any of the study arms.
Hemodynamic changes: Enalapril reduced resting LV systolic pressure by about 10 mmHg. The
haemodynamic effects of losartan alone, and enalapril plus losartan were also modest. ACE
inhibition did not increase LV outflow tract gradients. There was no correlation between
changes in arterial pressures and LV mass regression. Cardiac output and LV filling pressures
(LV end-diastolic pressure and pulmonary arterial capillary wedge pressure) were unchanged in
the placebo group over the six month period, and did not change significantly in the three
treatment groups compared to placebo.
4.2.1.5 Complications
The study was terminated due to light-headedness or hypotension during the first three
trial days of therapy in 9 subjects. The drugs were terminated after 1.3 to 4.2 months of
therapy in a further 7 patients due to side effects (Table 26).
All
Patients Placebo Enalapril Losartan
Enalapril
plus Losartan
Hypotension 5 0 1 1 3
Light-headedness 5 0 1 1 3
Fatigue 3 0 1 0 2
Cough 1 0 1 0 0
Tachycardia 1 0 0 0 1
Hearing loss 1 1 0 0 0
Total 16 1 4 2 9
Table 26. Adverse Events in the Treatment and Placebo Arms of the Study.
170
4.2.1.6 Discussion
This study of a randomised placebo-controlled study of the effects of RAAS inhibition in human
HCM reports regression of LV mass in patients treated with ACE inhibition (with enalapril)
alone, or with ACE inhibition plus ARB (with losartan). A non-significant trend towards LV
regression was found in patients receiving losartan alone. Enalapril is safe and well-tolerated in
HCM patients without resting or provoked LVOTO, and therapy for 6 months results in LV mass
regression (about 5%). Combination enalapril plus losartan therapy resulted in a similar
reduction (about 11%), but was associated with a higher incidence of hypotensive side effects.
The effect of 50 mg of losartan alone on LV mass was statistically insignificant, but a larger
study may have detected significance in the trend towards a smaller effect on mass regression.
Role of RAS in the Cardiac Hypertrophy of HCM: This study's results strongly support the
hypothesis that RAS activity contributes to the cardiac hypertrophy of HCM. Many studies
examining the role of RAS inhibition in patients with LV hypertrophy resulting from essential
hypertension have demonstrated the effectiveness of ACE-inhibitors, ATI receptor blockers
and aldosterone inhibitors at reducing LV mass independently of blood pressure reduction.
Similarly, our study suggests that the LV hypertrophy of HCM is subject to modulating
influences by RAS activity that are independent of the primary cause (gene mutations) of the
hypertrophy.
As reported by others, we observed an increase in plasma ACE hormone levels associated with
the ACE gene deletion (D) allele. This study does not, however, support previous reports that
commonly occurring ACE gene polymorphisms influence the magnitude of LV hypertrophy in
HCM.447 Neither the ACE genotype nor indices of plasma RAS activity correlated with LV mass.
This difference in findings may be attributed to the greater 'noise' resulting from the varied
genetic causes of HCM in subjects in our study compared to studies examining for ACE
polymorphism effects in single large pedigrees.447 Nonetheless, our findings suggest that any
affect of ACE polymorphisms and circulating RAS activity on the magnitude of LV hypertrophy is
small and that alterations in tissue RAS activity are central to the treatment effect.
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As ATI receptors are believed to mediate most of the adverse effects of RAS and receptor
blockade has reduces LV mass in hypertensive LV hypertrophy and in various animal models,
the absence of an effect the ATI receptor blocker losartan in contrast to the efficacy of ACE
inhibition was an unexpected finding. Several explanations could account for this. An effect on
LV hypertrophy smaller than that of enalapril may be detectable by a larger study. Similarly, the
use of larger doses of losartan may have had efficacy. However, the losartan dose used here is
comparable to those used in similar studies of hypertensive LV hypertrophy, and the
hypotensive effects of losartan were similar to those of enalapril in this study. The differences
in LV mass regression may therefore represent a divergence of the anti-hypertensive and anti-
hypertrophic effects of the two drugs. As ACE inhibition interrupts the RAS cascade more
proximally, the effects of enalapril on downstream RAS targets other that the ATI receptor may
be responsible for these differences.
The proportional reduction in cardiac mass is modest, representing a 7-8% reduction in total
cardiac weight. Significant cardiac hypertrophy remains; optimising RAAS antagonism with
prolonged therapy and/or combinations with aldosterone antagonists may improve mass
reduction, but it is likely that trophic signals other than those generated through RAS are also
important.
Role of RAS in the Cardiac Fibrosis of HCM: Although conditions causing pathologic LVH also
result in fibrosis, the development and regression of the two pathologic entities demonstrates
temporal divergence and appear to be mechanistically distinct.428,430,433'434,454 459 In doses too
small to cause regression of LVH, the angiotensin converting enzyme (ACE) inhibitor lisinopril
reduces fibrosis and normalizes myocardial stiffness in rats with spontaneous hypertension.
Sub-antihypertensive doses of the aldosterone antagonist spironolactone prevent LV fibrosis
but not LVH in rats with hyperaldosteronism.430,454 Similarly, in hypertensive patients,
angiotensin (AT) receptor blockade with losartan reduces myocardial fibrosis and chamber
stiffness as measured by the Doppler transmural deceleration time.457 In contrast, reduction in
both blood pressure and LVH with the beta-blocker labetalol is not accompanied by reduction
in collagen content or myocardial stiffness. Finally, there is temporal discordance in the
regression of LVH and myocardial fibrosis following successful surgical treatment of aortic
stenosis and regurgitation.458 These findings all suggest that reverse remodeling of the collagen
172
matrix may be possible by interventions aimed directly at the fibrotic process such as
modulation of the renin-angiotensin-aldosterone system (RAAS).
The effects of RAAS inhibition in animal models of HCM includes a regression in interstitial
fibrosis.452 The extent of collagen accumulation in human HCM hearts has been correlated with
NYHA class, exercise limitation in HCM patients and with pulmonary arterial wedge pressure
during exercise.156,445,460 Notably, there was a significant improvement in well-being as assessed
by NYHA status in the enalapril plus losartan arm of the study.
Serum markers of myocardial collagen metabolism451,452 and CMR imaging with delayed
gadolinium enhancement 463 464 were not included in this study as the study began before these
techniques were described. Future studies of RAAS inhibition will need to include such
assessments with he hypothesis that microscopic (interstitial) and macroscopic fibrosis are
important therapeutic targets and that reduction in fibrosis is associated with symptom
improvement.
Clinical Implications for the Management of HCM: Therapy reducing LV mass is only of benefit
if also associated with an improvement in symptoms and/or prognostic benefit. In this respect,
several clinically important issues are not resolved by our study. Considerations for patient
safety included the selection of relatively asymptomatic study subjects in whom a treatment
effect on functional status will be minimal. The study reports a reduced NYHA score in one of
the three treatment arms, but we must remain cautious about interpreting these results.
Similarly, the short duration of therapy and the low event rate do not allow assessment of
prognostic effect. Our results also cannot be extended to obstructive HCM as patients with
resting or provokable LV outflow obstruction were excluded because the vasodilator effects of
enalapril and losartan may worsen obstruction and associated symptoms. Additionally, in
obstructive HCM as in hypertension and aortic stenosis, the elevated LV systolic pressure may
itself contribute to cardiac hypertrophy144, and effects of reduced blood pressure on LV mass
cannot be discounted. Finally, it is not determined whether reductions in mass are sustained
after cessation of therapy, or even with continuation of therapy beyond six months.
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HCM patients often develop symptoms and signs of heart failure due to either LV diastolic or
systolic dysfunction. Cardiac hypertrophy is an independent predictor of a poor prognosis in
HCM375 and in other cardiac diseases where regression is associated with an improved
outcome.465 468 As ACE inhibition is safe and well tolerated in non obstructive HCM, improves LV
diastolic dysfunction and ameliorates heart failure in several other cardiac disease states, it is
reasonable to treat heart failure symptoms associated with impaired or preserved LV systolic
function in patients with non-obstructive HCM with ACE inhibitors.
Further studies are necessary to confirm our findings and to determine the long-term
consequences of LV mass regression.
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4.2.2 Relief of Drug-Refractory Symptoms Associated with Dynamic Left
Ventricular Outflow Tract Obstruction: Randomised Comparison of
Pacemaker Therapyand Alcohol Septal Ablation.
The three principal invasive modalities for the therapy of refractory symptoms associated with
LVOTO have vocal detractors and enthusiasts. For example, LVM is held by some as the 'Gold
Standard' treatment by virtue of its status as the first, and therefore most enduring, apparently
efficacious treatment. If numbers of procedures or patient years following intervention are the
parameters used to select a gold standard, then LVM would be replaced by ASA as the
preferred treatment. Relative benefits or each modality cannot be compared without a trial
randomising patients to the best practitioners of each treatment.
A fundamental problem with LVM is patient reluctance to undergo cardiac surgery; patient
preference has promoted the less invasive therapies of ASA and DDD. Furthermore, the
modern trend within cardiology away from physician referrers (to cardiac surgeons) towards
cardiologists completing both assessment and treatment has not been confined to treatment
of coronary disease; proponents of ASA have been invasive cardiologists with an additional
interest in HCM. Similarly, the most ardent supporters of DDD pacing have been
electrophysiologists.
The relationship between advocate, stake-holder, HCM physicians referring patients to
themselves for their preferred treatment clearly represents a conflict of interest. However,
these advocates probably deliver the best expressions of the particular therapy. The DDD trials
included lead investigators with little or no pacing expertise, some of whom were clearly
supporters of other treatments before the trials were completed.
The DDD trials, at best, identified pacing as a therapy with a neutral outcome. At worst, they
deny patients a minimally invasive and efficacious treatment with that does not preclude an
escalation to other therapies. On the contrary, DDD pacing neutralises risks from iatrogenic AV
block following ASA or LVM, and the combination of DDD with ICD function negates concerns
regarding the pro-arrhythmic potential of ASA. Finally, the evolution of safer pacer-defibrillator
(ICD) therapy introduces the prospect of an a priori treatment with pacer-ICDs of symptomatic
HCM patients with obstruction that have additional indications for ICD implantation.
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Despite the fact that LVM was developed at NIH by Andrew Morrow in the 1960's, HCM
physicians at NIH have been proponents of pacing. We compared DDD pacing with ASA in a
randomised trial that assessed changes in LV outflow tract gradients as the primary outcome;
cohort data had indicated ASA was more effective at reducing LVOT gradients. The initial and
final assessments of patients including clinic reviews, echocardiography, CMR and cardiac
catheterisation were completed at NHLBI. Patients randomised to pacing received device
implantation and pacer management at NHLBI, and ASA was performed by interventional
cardiologists at nearby but independent institutions (Fayaz Shawl at the Washington Adventist
Hospital and Kenneth Kent at Georgetown University Hospital. CMR was performed on all ASA
patients at baseline and 6 months following treatment (Andrew Arai, NHLBI).
4.2.2.1 Abstract
Background: ASA and DDD pacing are alternative therapies to cardiac surgery in symptomatic
obstructive HCM.
Methods and Results: We performed a prospective randomised comparison of ASA and DDD
pacing in 70 consecutive obstructive HCM patients with drug-refractory symptoms. The study
arms were matched well for age, gender and disease severity. LV outflow gradient was reduced
from 99 ± 40 mm Hg to 32 ± 33 mm Hg (68% reduction, P<0.0001) in the ASA arm of the study,
and from 91 ± 46 mm Hg to 43 ± 39 mm Hg (48% reduction, P<0.0001) in the DDD arm of the
study. The 19 mm Hg greater reduction in LV outflow gradient following ASA was significantly
greater than after DDD (P=0.038). After ASA, 3 patients (9%) required DDD pacing for heart
block and 1 died three weeks following ASA. Both treatments resulted in similar symptomatic
improvement, health-related quality of life, and exercise performance. As assessed by CMR, LV
mass decreased from 278 ± 85 gm to 261 ± 88 gm, (17 gm or 6%; P<0.001) following ASA. ASA
was not associated with changes in LV ejection fraction, LV volumes or occurrence of
spontaneous arrhythmia.
Conclusions: In patients with symptomatic obstructive HCM, both ASA and DDD pacing reduce
LV outflow gradients. ASA is more effective at reducing gradients, but both therapies were
associated with similar improvements in symptoms. Because of risk of complications, a
reasonable approach may be to consider DDD (iimplantable defibrillator) first. ASA or cardiac
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surgery may then be reserved for patients with persistent symptoms and residual LV outflow
obstruction.
4.2.2.2 Introduction
Pharmacological therapy often fails to control symptoms adequately in obstructive HCM, or is
associated with intolerable side effects.1 LVM was adopted (and subsequently refined) as the
first effective treatment for the relief of such symptoms;119139 DDD pacing127,130,469 and
ASA45,117,118 are performed as alternative less invasive therapeutic options. None of these
therapies have been compared in prospective trials.
The primary aim of this prospective randomised study was to determine whether ASA results in
greater reduction in LV outflow gradients than DDD therapy in obstructive HCM associated with
severe drug-refractory symptoms. The secondary aims of the study were to characterize the
effects of the two therapies on (1) symptoms, patient satisfaction, and exercise tolerance; (2)
LV remodelling; (3) LV function; and (4) arrhythmia propensity.
4.2.2.3 Methods
Study Design: The study was performed after informed consent according to a protocol
approved by the Intramural Research Board of National Heart, Lung, and Blood Institute,
National Institutes of Health. Obstructive HCM was defined as LV hypertrophy in the absence of
another cause for the increased cardiac mass, and basal LV outflow gradient >30 mm Hg or >50
mm Hg following isoproterenol infusion at cardiac catheterisation. Inclusion criteria included;
septal thickness of >16 mm (comparable to patients undergoing surgical LV myectomy or
LVMM); patients age >18 years; and New York Heart Association functional class lll/IV despite
conventional drug therapy. Exclusion criteria included significant coronary artery disease and
chronic atrial fibrillation.
Eighty-seven consecutive patients with obstructive HCM were screened between September
1999 and July 2001. All patients were offered LVMM as an alternative to participating in the
trial; 8 declined participation in the study (1 underwent LVMM), and 9 did not meet entry
criteria. Seventy patients were assigned to the two arms of the study using the method of
randomly permuted blocks. The arms of the study matched well with regards to age, gender,
symptoms, LV outflow obstruction and cardiac indices (
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Table 27 and Table 28).
In-patient evaluations at baseline and 6-months after therapy were completed after the
withdrawal of all cardiovascular drugs: (1) assessment of symptoms; (2) echocardiography; (3)
treadmill and bicycle exercise tests; (4) radionuclide angiography (RNA); (5) cardiac
catheterisation and angiography; (7) 24-48-hour ambulatory electrocardiography (ECG)
monitoring; and (8) electrophysiology (EP) studies.470 Patients were also evaluated (symptoms
and echocardiography) at a 3-month out-patient visit. A Health Related Quality of Life (HRQL)
questionnaire was administered prior to randomisation, and at 3 months and 6-months. HRQL
was assessed using physical and mental component summary scores derived from the Short
Form 36 Health Survey (SF-36) Version l.O.471
ASA (n=35) DDD (n=35) p value
Gender (male) 15 [43] 14 [40] ns
Age (years)
mean 49 ±14 47 ±17 ns
range 20-82 20-76
NYHA functional class 3.4 ± 0.5 3.3 ±0.6 ns
Symptoms
angina 29 [83] 29 [83] ns
dyspnoea 33 [94] 34 [97] ns
presyncope 28 [80] 21 [60] ns
syncope 14 [40] 10 [30] ns
palpitations 25 [71] 28 [80] ns
fatigue 30 [86] 32 [91] ns
Prior therapy
beta blocker 35 [100] 34 [97] ns
verapamil 31 [89] 27 [77] ns
diuretic 13 [37] 4 [11] 0.05
disopyramide 9 [26] 9 [26] ns
amiodarone 2 [6] 0 [0] ns
LVMM 1 [3] 0 [0] ns
coronary angioplasty 3 [9] 1 [3] ns
Abnormal BP at exercise* 5 [14] 8 [24] ns
LV wall thickness >30 mm 2 [6] 1 [3] ns
Table 27. Comparison of the Patients' Baseline Clinical Characteristics in the DDD Vs. ASA Study.
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[], per cent; BP, blood pressure; *, <10 mm Hg Increase in systolic BP with exercise.
ASA DDD
Baseline 3-months 6-months Baseline 3-months 6-months
Symptoms
angina 26 [84] 15 [48]**** 11 [35]**** 29 [83] 14 [40]**** 13 [37] * * * *
dyspnoea 29[94] 21 [68]** 24 [77] 34 [97] 27 [77]** 28 [80]**
presyncope 24 [77] 7 £23]**** 3 [10]**** 21 [60] 4 [-Q]**** 3 £0J****
palpitations 22 [71] 17 [55] 19 [61] 28 [80] 19 [54]** 14 [40]***
fatigue 26 [84] 20 [65] 21 [68] 32 [91] 22 [63]** 4 [69]**
SF 36 Indices
Physical Score (normal=50) 31 + 10 40 ±10*** 40 + 12*** 37 ±7 39 ±11*** 39±11***
Mental Score (normal=50) 44 ± 13 53±10*** 49 ± 14 39 ±13 48 ± 11*** 47 ± 10**
Echocardiographic findings
septum (mm) 22 ±6 + 4**** 21 + 4 21 + 4
posterior wall (mm) 12 ±2 11 ± 3 12 ±2 12 ± 3
LVIDD (mm) 41 ±4 43 ±5 42 ±6 41 ±7
LVIDS (mm) 22 ± 4 26 ±5* 22 ±5 23 ±5
LA dimension (mm) 47 ±6 45 ± 8 46 ±7 46 ±7
LV ejection fraction (%)
rest 79 [10] 83 [9] 77 [11] 71 [13]*
exercise 76 [11] 78 [10] 80 [9] 72 [13]**
Cardiac catheterisation
heart rate (per minute) 79 ±19 80 ± 17 80 ± 14 76 ±12
PAP (mm Hg) 18 ±9 19 ± 10 20 ±6 20 ±7
PAWP (mm Hg) 13 ±8 10 ±6 12 ±5 12 ±5
CO (litres/minute) 4.9 + 1.1 4.9 ± 1.1 5.2 ± 1.1 5.0 ± 1.1
Ao pulse pressure (mm Hg) 47 ± 16 58 ± 17* 52 ±24 52 ±20
Ao systolic pressure (mm Hg) 110 ± 18 124 ±22** 113 ± 29 119 ± 20
LV systolic pressure (mm Hg) 209 + 39 158 ±36**** 201 ±43 160 ± 35****
LV pressure change (mm Hg) -53 ± 28 [25] -39 ± 32 [19]
LVEDP (mm Hg) 20 ±8 17 ± 11 16 ±7 16 ±8
LV OT gradient (mm Hg) 99 ±40 32 ±33**** 91 ±46 43 ± 39****
LVOT reduction (mm Hg) 67 ± 40 [68] 48 ±35 [52]+
Table 28. Clinical Outcomes for Patients Following Randomisation to DDD or ASA.
[], per cent; *, p<0.05; **, p<0.01; ***p<0.001; and ****p<0.0001 versus baseline; +, p=0.038 versus ASA.
Magnetic resonance imaging (MRI) studies were performed at baseline and repeated within a
week and 6-months following ASA. End expiratory cine MRI was performed on a 1.5T cardiac
MRI scanner using a four-element cardiac phased array coil. Computer assisted planimetry was
used to quantify myocardial dimensions, volumes, ejection fraction and mass. In water-filled
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phantoms, measured volumes correlated with known volumes (range, 7.5 to 465 ml, MRI =
1.00 x Volume, R2=0.9998, P<0.0001).
ASA: A septal branch was occluded proximally with a 1-2 mm angioplasty 'over-the-wire'
balloon catheter (Figure 48). Angiographic dye verified absence of dye-reflux into the LAD, and
excluded abnormal arterial connections. Echo contrast agent (Optison) was injected beyond
the inflated balloon catheter to ensure the opacified myocardium was adjacent to the area of
maximum LV outflow acceleration. Alcohol was injected over 5-10 minutes. Balloon inflation
was maintained for 10 minutes to allow diffusion of alcohol into the myocardium and to
prevent reflux into the main artery. If >30 mm Hg basal LV gradient continued to be present
another septal artery was ablated. LV outflow gradient was monitored using a pigtail catheter
in the LV and the femoral sheath. Coronary angiography verified occlusion of the target vessel.
Patients were discharged 3-5 days later. A second ASA was recommended if patients had
residual significant symptoms associated with significant LV outflow obstruction within the first
3-months following the initial procedure.
DDD: Device implantation and programming has been described previously.127 Patients with
significant symptoms and residual obstruction at 3-months were offered ASA or cardiac
surgery.
Statistics: Data are presented as mean (± SD). Differences from mean values were compared by
Student's t-test. Pearson's correlation coefficient was used to evaluate the correlation between
variables. A two-tailed P value of <0.05 following Bonferroni correction was considered
significant.
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Figure 48. Illustration Describing the ASA Procedure.
Left upper panel. Coronary angiogram illustrating targeted septal artery (shown by arrows). Right upper panel.
Occlusion of septal artery after ASA. Left lower panel. Diagram of obstructive hypertrophic cardiomyopathy; Right
lower panel. Diagram of myectomy following ASA with relief of left ventricular outflow obstruction.
4.2.2.4 Results
Procedure Details and Adverse Outcomes
ASA: ASA was not technically feasible in 1 patient, 2 patients declined the procedure, and 1
patient died during follow-up. ASA was repeated in 5 patients. Only 1 artery was ablated in 24
patients, 2 arteries in 5 patients, and 3 arteries in 3 patients. Basal LV outflow gradient was
reduced to <20 mm Hg in all patients (provoked LV gradient of <60 mm Hg was used as a guide
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to success of the procedure in 3 patients without rest gradient). An average of 3.0 ± 1.7 ml of
alcohol, range, 0.9 to 7.0 ml, was injected per procedure. Cardiac enzymes increased in all
patients (creatinine kinase, 1170 ± 555 U/l, range, 384-2454 U/l (normal, 38-252 U/l);
creatinine kinase-MB, 154 ± 69 ng/ml, range, 23-355 ng/ml (normal, 0-5.0 ng/ml); and troponin
I, 400 ± 297 ng/ml, range, 52-1055 ng/ml (normal, 0-2.0 ng/ml).
Heart block occurred in 6 of the 32 patients who underwent successful ASA: 3 were temporary,
but 3 required permanent DDD pacing (one of whom died one month after ASA). Three
patients with initially negative EP study received ICD-DDD devices for sustained VT induced at
the 6-month follow up study.
DDD pacemaker therapy: Satisfactory DDD pacing was achieved in all 35 patients in the
pacemaker arm of the study. DDD therapy was complicated by 3 lead displacements and 1
pneumothorax. One patient received an upgrade to a DDD-ICD device for sustained VT induced
at the end of study.
Hemodynamic Changes: LV outflow gradients were reduced by 68% and 48% following ASA
and DDD respectively, an average of 19 mm Hg (P=0.038) greater reduction in the ASA arm
(Table 28). Aortic pressures increased significantly following ASA but were unchanged in the
DDD arm. Cardiac filling pressures were unchanged in both arms of the study. There was a
small but significant decrease in resting ejection fraction in the DDD arm but no change was
observed in the ASA arm.
Symptoms, Functional Class, and HRQL: Both therapies significantly improved symptoms,
notably, angina and light-headedness, (Table 28). Changes in symptoms were not significantly
different between the two study arms. Similarly, both therapies were associated with similar
improvement in functional class status, (Figure 49). There was no further symptomatic
improvement in the ASA study arm between the 3-months and 6-months evaluations. In
































Figure 49. Changes in Functional Class Following ASA and DDD.
For the patients with complete HRQL data (ASA, n=29; DDD, n=32) changes in LV outflow
gradient changes were comparable to the overall cohort. There was no relation between
reduction in LV gradients and changes in HRQL in patients undergoing either ASA or DDD. Both
ASA and DDD were associated with equivalent HRQL benefits at 3-months that persisted to 6-
months (Table 28).
Exercise Performance: Treadmill exercise duration increased in both arms of the study: ASA
(n=26), from 275 ± 203 sec. to 384 ± 212 sec., an increase of 98 ± 150 sec., or 36 %; P=0.001;
and DDD (n=28) from 297 ± 184 sec. to 357 ± 154 sec., an increase of 60 ± 133 sec., or 20%;
P=0.02. The difference in exercise duration between the two study arms was non-significant.
Bicycle exercise duration increased from 295 ± 206 sec. to 342 ± 176 sec., a change of 47 ± 136
sec., or 16%, in the ASA arm (n=27), P=0.10; and from 328 ± 152 sec. to 348 ± 161 sec., a
change of 20 ± 99 sec., or 6%, in the DDD arm (n=33) of the study. P=0.24. The difference in
exercise duration between the two study arms was not significant.
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Maximum exercise [Oxygen] consumption did not improve significantly with ASA (14 ± 5 l/min
at baseline versus 15 ± 5 l/min at 6-month) or with DDD pacing (14.0 ± 5 l/min at baseline
versus 14.0 ± 6 l/min at 6-months).
LV Function: Neither therapy was associated with further elevation in LV end diastolic or
pulmonary wedge pressures (Table 28) indicating ASA and DDD do not contribute to
deterioration of LV diastolic dysfunction. Rest and exercise RNA-derived LV ejection fractions
were unchanged following ASA (Table 28). DDD pacing, however, was associated with a small
but significant decrease in LV ejection fraction.
Cardiac Remodelling Following ASA: LV outflow tract obstruction was markedly improved
in patients who underwent MRI studies (n=26). LV masses measured before and within one
week of ASA were similar (Table 29). However, LV mass decreased significantly by an average of
17 gm or 8% at 6-months. LV diastolic and systolic volumes were unchanged. However, LV





LV mass (gm) 264 ± 66 278 ± 85 280 ± 88 261 ± 88** +++
LVEDV (ml) 123 ± 29 119 ±23 112 ±23 115 ±22
LVESV (ml) 33 ± 12 29 ± 10 29 ±8 31 ±9
LV SV (ml) 91 ±22 90 ±21 83 ± 20* 85 ±19
LV EF (%) 74 ±6 76(7) 74 ±7 73 ±7
Table 29. LV remodelling following ASA: MRI findings.
*=p<0.05; **=p<0.01, ****=p<0.00001 versus baseline; and +++= p<0.001 compared to 1 week.
ECG Changes and Arrhythmia Following ASA: The ECG was unchanged from baseline in 15
patients (45%) at 6 months following ASA. Right bundle branch (RBBB) developed acutely in 16
patients or 48%, and persisted in 10 patients or 30%. RBBB was associated with left posterior
hemiblock in 3 patients, anterior hemiblock in 2 patients, and first degree AV block in 1 patient.
Left bundle branch block developed acutely in 3 patients but resolved by 6-months.
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There were no significant differences in the prevalence of either spontaneous atrial or
ventricular arrhythmias (data not shown). At the 6-month EP study, sustained polymorphic VT
was induced 2 ASA and 1 DDD patient in whom baseline studies were negative. All three
patients received implantable pacemaker-defibrillators.
4.2.2.5 Discussion
This is the first prospective randomised comparison of two therapies for symptomatic
obstructive HCM. Both ASA and DDD therapies significantly reduced LV outflow gradients. ASA
resulted in a slightly greater reduction (19 mm Hg) in LV outflow gradient. However, the
improvement in symptoms, functional class, HRQL indices, and exercise performance were
similar in the two study arms.
Although the results of LVMM have improved recently, few centres have experience
with this procedure and it may be associated with significant short-term and long-term adverse
outcomes.472'475 Although some authorities consider LVMM as the 'gold standard' in
management of drug refractory obstructive HCM, this derives mainly from the length of
experience (now more than 40 years) with the operation. The strong incentive to identify less
invasive and safer alternative therapies has lead to the development of ASA and DDD pacing5,14
30 117,118,127,130,469 Bot^ therapies have merits and potential problems.
Several studies127,128,130,131,417,418,469,476 479 have demonstrated DDD pacing significantly
reduces LV outflow obstruction and improves drug-refractory symptoms. However, some
investigators have reported that DDD pacing may be associated with LV diastolic dysfunction.133
Others have cautioned that the associated symptomatic improvement may in part be due to a
placebo-effect23.129,480 It is important to recognize that this may also apply to the other two
therapeutic options. Importantly, the design of the studies that report a placebo effect do not
account for the fact that the chronic effects of DDD pacing are greater than its acute
effects477,478, and there may also have been a carry-over effect of DDD pacing in the placebo
arm. Assessment of subjective improvement in one of these studies was very likely influenced
by unusually high complication rates of pacemaker implantation.129 The best results have been
reported when attention has been paid to lead placement, and pacemakers are programmed
appropriately to achieve maximum ventricular pre-excitation without interference with left
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atrial emptying.128 The present study demonstrates that DDD pacing is safe in obstructive HCM,
and confirms that it significantly reduces LV outflow gradients as measured by cardiac
catheterisation, and improves symptoms as assessed by several means.
Several studies have also reported on the ability of ASA to relieve LV outflow
obstruction and symptoms in obstructive HCM.134 As ASA is associated with heart block
necessitating permanent DDD pacing in 10-20% of patients, it is not clear how much of any
treatment effect is attributable to ASA and how much to DDD therapy.
We achieved reduction of LV outflow gradient and symptomatic improvement with
only about 10% of patients requiring DDD devices. In our study, ASA was associated with a 17
gm reduction in LV mass. As this is similar to the amount of myocardium removed at LVMM481
it may reflect the direct effects of alcohol on the myocardium rather than regression of
hypertrophy following reduction in LV systolic pressure. ASA did not significantly impair LV
function. Spontaneous arrhythmia and late conduction abnormalities were not significantly
increased.
Therapeutic Recommendations: A reasonable therapeutic algorithm in obstructive HCM
complicated by severe drug-refractory symptoms is to consider DDD pacemaker therapy (± ICD)
first, followed by ASA after about six months of pacing if significant symptoms and significant
LV outflow obstruction remain. LVMM may then be considered if ASA is not feasible or also fails
to relieve symptoms and LV outflow obstruction. This algorithm is based on the following
observations: (i) The current study shows similar symptomatic benefit from the minimally
invasive DDD and ASA; (ii) DDD therapy is less invasive and safer than either ASA or LVMM (iii)
DDD/ASA therapies are effective in many patients and do not preclude LVMM; (iv) Pacemaker-
defibrillator devices are being increasingly used for HCM and the algorithm offers an
opportunity to address risks of sudden death as well as symptom improvement103,105; (v) As
frequent adverse effect of both ASA and LVMM is heart block, prior DDD therapy may increase
the safety of the other procedures. This algorithm advocates a conservative initial approach,
with an emphasis on risk as well as symptom reduction.
Limitations of the Study: Our patients had more LV outflow obstruction than those included in
many reports. The LV outflow gradients were however, of similar magnitude to those reported
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by some authors who have reported satisfactory results with DDD pacing. Longer follow up
studies may increase our understanding of the relative efficacies of the two therapies.
However, previous experience indicates that six months is adequate to examine the results of
therapy in obstructive HCM, and there were few additional changes noted in the present study
between the 3-month and 6-month evaluations in the ASA arm of the study.
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5 Concluding Remarks
5.1.1 Appraisal of Clinical Relevance
My approach to each patient in the clinic is to (1) address the certainty of the clinical
diagnosis of cardiomyopathy, (2) assess symptoms and indications for invasive or
pharmacological therapy, (3) perform estimates of risk from SD, heart failure and stroke,
and (4) undertake genetic counselling including initiating genetic testing and family
screening. The research presented in this thesis was designed to improve our ability to
manage patients. This has been through clinical studies; examining new and established
therapies, evaluating new prognostic measures, developing methods to assess diastole and
using basic science; hoping to provide insights into mechanisms of disease.
A prosaic, but objective, assessment of impact can be made by counting citations, by other
articles, of my published work. From searches on Google Scholar
(http://scholar.Roogle.co.uk), there have been more than 600 citations to articles I have co-
authored, of which 110 citations are to first author papers.
Citation counting may assess a research profile; an objective assessment of clinical impact is
more difficult to make. My clinical practice in heart muscle disease is derived from and
encourages my research activities. I have had the learning opportunities afforded by
working in two of the world's largest centres for Cardiomyopathy research and patient
management (NIH and at the Heart hospital, London). It is in this context that we have
established (along with Dr PG Mills) the Heart Muscle Disease (HMD) clinic at the London
Chest hospital. This service is designed to provide state-of-the art cardiomyopathy services
and to develop a research infrastructure. Access to CMR, with a dedicated scanner, is an
important feature. The current research interests of the HMD clinic include:
(1) Ethnic differences in HCM phenotypes. We have described striking differences in the
prevalence of apical HCM between Caucasian and South East Asian populations. We are
currently seeking to determine if single-gene mutations account for the differences in
disease type, or if other hereditary or environmental factors are accountable.
(2) Symptomatology in apical HCM. This form of HCM is often associated with refractory
symptoms. Symptoms, which include frequent presentations with acute chest pain, are not
well managed or understood.
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(3) Expanding and examining the clinical utility of CMR in heart muscle diseases. The
contributions made to prognosis by magnitude of LVH and by impaired systolic function are
increasingly understood. The diagnostic, symptomatic and prognostic importance of
myocardial scarring (tissue characterisation with late gadolinium enhancement) and
perfusion defects are not established.
5.1.2 Future Directions
Some of the major HCM research frontiers are described below. It is also a belief that future
HCM research can now begin to make important contributions to the understanding of
more common cardiac diseases.
(1) Molecular mechanisms leading from mutant to LVH. As discussed in the introduction
section of this thesis, the molecular basis for the manifold relationships between
hypertrophic stimuli and cardiac phenotype is poorly understood (Figure 3). Determining
the causes of phenotypic variability (these 'modifying factors' may include environmental
states as well as common genetic polymorphisms) resulting from identical or similar
sarcomeric mutations may identify novel modifying treatments. Equally importantly, this
may provide an understanding of why much more common causes of cardiac injury also
manifest variably - for example from hypertension, valve disease, myocardial infarction.
(2) Importance of LV diastole and atrial function. Better methods for assessing atrio¬
ventricular coupling during LV diastole are needed.23 The basis for many symptoms and
exertional limitation in HCM are attributed to diastolic failure, but these are currently
poorly assessed or understood. The complexity of LV filling, dependant as it is on both
variable and constant properties of the LV, the atria and loading conditions means that our
concepts of diastole need considerable development. A single parameter (for example
E/E'200,482) wj|| not suffice, and we need to develop tools assessing LV relaxation, LV
compliance, atrial capacitance, atrial elastance and so on. In its role as a 'supermodel' of
diastolic failure, HCM has facilitated the development of some of these tools,200 and will
continue to do so. Clearly, success in this area of HCM research will be relevant to the
'epidemic' of diastolic heart failure in the general population.483
(3) Improved prognostic stratification. The indications and efficacy of ICD therapy to
prevent arrhythmic death, of warfarin to prevent stroke and heart failure medication to
improve symptoms and longevity will need to be established in HCM. Sudden death is
predicted poorly103 using current schemes98, which also do not reliably differentiate
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between SD from arrhythmia, stroke or heart failure. Future prognostic stratification is
likely to use a combination of current and new risk factors and will aim to independently
consider risks of arrhythmia, stroke and heart failure.
(4) Outflow Tract Obstruction. The HCM community have not completed randomised trials
of septal ablation (ASA) and myectomy (LVM) to the detriment of patient care. A resurgent
interest DDD pacing for outflow obstruction is supported by the increasing use of ICDs and
the incidence of heart block complicating ASA and LVM. An example of a prospective trial is
shown in Figure 50.
Symptomatic LVOTO
NYHA 3-4 symptoms refractory to therapy









Figure 50. Trial Evaluating ASA, LVM and DDD therapy in Obstructive HCM.
The primary objective is to compare the efficacy of LVM and ASA on symptom status. Evaluating a strategy of
prior pacer-ICD in those with indications for ICD for the prevention of sudden death (SD) is a secondary aim.
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